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 Diabetes mellitus is a common disease in cats. Most diabetic cats depend on 
insulin therapy to survive but traditional insulin formulations are associated with adverse 
effects and poor compliance. Novel insulin analogs and incretin-based therapies are more 
effective and have fewer side effects than traditional therapies.  
We studied some of these novel therapies in healthy cats. We used the 
isoglycemic clamp method to compare the pharmacodynamics of the synthetic insulin 
analogs, insulin detemir and insulin glargine. An analog-sensitive insulin ELISA was 
used at the same time to measure exogenous insulin concentrations. We also used the 
isoglycemic clamp method to study the pharmacodynamics of the GLP-1 mimetic, 
exenatide. An exenatide-specific ELISA was used for evaluation of exenatide 
pharmacokinetics. Finally, we studied the incretin effect in cats and compared the effect 
of glucose, lipids or amino acids on secretion of the incretin hormones glucose-dependent 
insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1). The isoglycemic 
clamp method was used to compare the effects of the 3 treatments on insulin secretion.  
We found that insulin detemir and insulin glargine have similar 
pharmacodynamics in healthy cats. With durations of actions of approximately 12 hours 
and significant variability in their time-action profiles, their efficacy and safety as once-a-
day drugs is questionable. We found that exenatide stimulates insulin secretion in cats in 
a glucose-dependent manner, but it did not increase glucose tolerability. Its absorption 
after subcutaneous injection was rapid, but so was its clearance from the blood. 
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Therefore, the use of exenatide, in its current formulation for treatment of diabetes in 
cats, is questionable.  
Finally, we found that a glucose-stimulated incretin effect does occur in cats, it is 
probably mediated by GLP-1, and its magnitude is lower than reported in other species. 
This small incretin effect is probably related to the fact that GIP secretion was not 
stimulated by oral glucose. GIP secretion was strongly stimulated by oral amino acids 
and even more so, by oral lipids. GLP-1 secretion was stimulated to a similar degree by 
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Diabetes mellitus is common in cats. Although diet change and oral medications 
can help initially, most diabetic cats depend on insulin therapy to survive. There are 
some significant problems associated with insulin therapy. Owner compliance is a major 
problem because twice-a-day injections are required with most commonly used insulin 
preparations. Weight gain may indicate a good response to therapy initially but can 
eventually become a problem. Hypoglycemia is a common complication of insulin 
therapy and can be life-threatening. These side effects have been significantly reduced in 
human medicine with the introduction of novel treatments for diabetes such as the 
insulin analogs detemir and glargine, and incretin-based treatments such as exenatide. 
Insulin detemir and insulin glargine are long-acting insulin analogs. In people, insulin 
glargine is longer acting than previously used insulin preparations, and is relatively 
peakless in its effect, whereas insulin detemir has significantly less within-patient 
variability from day to day. Insulin detemir is also associated with less undesired weight 
gain and decreased frequency of hypoglycemic events. Because of the smaller risk of 
side effects associated with insulin analogs compared with insulin formulations that are 
based on native insulin, insulin analogs can be used to achieve tighter glycemic control. 
Over time, tight glycemic control is associated with decreased risk of diabetes-related 
complications. Insulin therapy, however, does not treat the primary defect that causes the 
disease – it does not directly affect beta cell function. 
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In contrast to insulin therapy, incretin-based treatments have the potential to 
reverse the course of the disease. Incretins not only augment insulin secretion but they 
increase the proliferation and survival of pancreatic beta cells and decrease the rate of 
programmed cell death that is caused by the disease. There are multiple treatment 
strategies that take advantage of incretin hormone physiology. Long-acting synthetic 
GLP-1 mimetics are peptides that must be injected subcutaneously. Oral drugs that 
prolong the half-life of incretin hormones by inhibiting the enzymes that degrade them 
are also available. Other oral drugs can stimulate the secretion of incretins by activating 
specific sensors in incretin-secreting cells of the intestines. These sensors normally 
respond to specific nutrients in the lumen of the intestine, and the degree of response to 
different nutrients varies between areas of the gut and between species. Accurate 
knowledge of the degree of stimulation of incretin secretion by specific nutrients might 
be exploited for designing novel diets that enhance incretin hormone secretion. 
The objective of this research was to study novel treatments for feline diabetes. In 
particular we studied the synthetic insulin analogs, insulin detemir and insulin glargine, 
and the GLP-1 mimetic exenatide. We also compared the effect of glucose, amino acids, 
or lipids on the secretion of incretins and insulin. This information might allow devising 
dietary manipulations that would increase endogenous incretin secretion and help in the 






Diabetes mellitus in cats 
Diabetes mellitus (DM) is a disease of glucose homeostasis. In health, glucose 
homeostasis is achieved through interaction between the pancreas, liver, adipose tissue, 
muscles and the gastrointestinal tract. The interactions between these organs are 
orchestrated by nutritional, endocrine and the nervous signals (Shulman et al., 2003). 
Although complex, abnormal glucose homeostasis (i.e. DM) is usually a result of 
abnormal function of the pancreatic beta cells and impaired insulin secretion. 
Abnormalities in other components of glucose homeostasis (e.g. insulin resistance in 
muscles, obesity, impaired secretion of gastrointestinal hormones, etc.) do not cause 
diabetes directly, but can aggravate it or unmask a mildly impaired function of pancreatic 
beta cells. If beta cell function is normal, the capacity to secrete insulin will increase and 
compensate for the defects in the other components (Ahren and Taborsky, 2003). 
Treatment of diabetes, therefore, can be directed at any one of the organs that participate 
in glucose homeostasis, but ultimately, there can be no cure for diabetes unless the 
dysfunction of beta cells is corrected. The causes of diabetes are multifactorial, complex 
and not well-understood. There is currently no known cure for any type of diabetes, in 
cats or in other species. Choosing treatments to manage the disease depends on its type 
and severity, as well as on cost and convenience.  
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Classification of diabetes 
Diabetes mellitus is a general name for a myriad of syndromes and multiple 
disease etiologies that are usually classified into a few disease types. In the past, DM was 
classified into insulin-dependent DM (IDDM) and non-insulin-dependent DM 
(NIDDM). These were later on replaced by type 1 and type 2 DM respectively. It is now 
well-recognized, however, that while the etiologies and other key features of type 1 and 
type 2 DM are different, both can be manifested (at least transiently) as insulin-
dependent or non-insulin-dependent (Inzucchi, 2003). The classifications IDDM and 
NIDDM have also been used in veterinary medicine, and both have been described in 
cats (Nelson, 2005).  Type 1 DM (also called juvenile DM) is an auto-immune disease 
caused by improper antigen presentation on pancreatic beta cells. Because type 1 DM 
used to be synonymous with IDDM, and because many diabetic cats are diagnosed as 
insulin-dependent, it was believed that many cats suffer from type 1 DM. Currently, 
however, there is no evidence that cats develop type 1 DM except for the rare pathologic 
description of islet lymphocytic infiltration (Nakayama et al., 1990; Nelson, 2005). 
Type 2 DM is a form of diabetes in people that is usually diagnosed at middle-
age or older, that is strongly associated with obesity and insulin resistance, and is 
characterized pathologically by the finding of amyloid deposits in the islet of 
Langerhans. Genetic predisposition is also a characteristic of type 2 DM (Kahn and 
Porte, 2003). Another key feature of type 2 DM is impaired beta cell function with 
residual but declining insulin secretion. This means that while the disease slowly 
progresses, a decline in insulin sensitivity or in other components of glucose homeostasis 
can lead to worsening of the overall condition (although not necessarily affecting the 
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capacity of pancreatic beta cells to secrete insulin). On the other hand, improving insulin 
sensitivity or any other component of glucose homeostasis can lead to significant 
improvement in the overall condition, while disease progression is unaltered (Kahn and 
Porte, 2003). This explains why patients with type 2 DM can often revert from IDDM to 
NIDDM and back multiple times, especially under circumstances of changes in diet, 
medications and superimposed illnesses.  
Based on the above characteristics of human type 2 DM, and on the 
characteristics of the disease in cats as described below, diabetes can be classified as type 
2 in about 80 – 95% of cats (Rand et al., 2004). Other types, accounting together for only 
5 – 20%, are either secondary to diseases causing severe insulin resistance (such as 
acromegaly and hypercortisolism) or secondary to diseases of the exocrine pancreas 
(such as pancreatitis and pancreatic adenocarcinoma). Because of the relative rarity of 
these other DM types, and because they are fundamentally different from type 2 DM in 
etiology as well as treatment, from here on I will refer to diabetes in cats only in the 
context of type 2 DM.  
Amyloid deposition 
Amylin is a peptide hormone that is synthesized in pancreatic beta cells and is 
secreted together with insulin through the same secretory machinery (Ahren and 
Taborsky, 2003). Amylin has complementary actions to insulin in controlling glucose 
homeostasis. In people and in cats, the amino acid sequence of amylin contains a region 
that makes it prone to polymerization and formation of amyloid. Amyloid is an 
extracellular, proteinaceous, insoluble deposit exhibiting a fibrilar, beta pleated sheet 
structure. Amyloid deposits have been shown to have toxic effects on pancreatic beta 
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cells, and it is suspected that amyloid deposition is one of the factors that leads to 
progression of type 2 DM, or maybe even causes it. Amyloid deposition is a unique 
feature of type 2 diabetes and it occurs naturally only in cats and primates. It occurs in 
more than 90% of human and feline diabetic patients, and it is fairly infrequent in non-
diabetics (Henson and O'Brien, 2006). 
Epidemiology 
Diabetes is most common in domestic long- and short-hair cats. Burmese cats are 
overrepresented, and many other pure breeds are underrepresented, compared to the 
incidence in domestic cats (Prahl et al., 2007; Lederer et al., 2009). Increasing age is a 
risk factor for type 2 diabetes, and most cats are > 8 years of age with a peak incidence 
between 10 and 13 years of age (Rand et al., 2004; Prahl et al., 2007). In one study, 
increasing age was the single most important risk factor for diabetes in cats (Panciera et 
al., 1990). Neutered male cats are at greater risk of developing diabetes than neutered 
female cats, even when controlled for body weight (Panciera et al., 1990; Prahl et al., 
2007). Human diabetes does not have a sex predilection. In a recent study, indoor 
confinement and low physical activity were identified as independent risk factors for 
diabetes in cats. This study did not find that diet was an independent risk factor 
(Slingerland et al., 2009). 
Obesity causes insulin resistance; it interferes with glycemic control and confers 
a high risk of DM in cats (Nelson et al., 1990; Panciera et al., 1990; Biourge et al., 1997; 
Scarlett and Dononghue, 1998; Appleton et al., 2001; Hoenig et al., 2002; Prahl et al., 
2007). Obesity is becoming increasingly prevalent in cats. Based on body condition 
scoring (BCS), between 25 – 35 % of domestic cats are reported to be overweight or 
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obese in the United States (Scarlett et al., 1994; Scarlett and Dononghue 1998; Lund et 
al., 2005). Similar to the obesity epidemic in the human population, environmental 
factors (e.g. living indoors, diet) predispose cats to obesity (Scarlett et al., 1994; Lund et 
al., 2005). Importantly, the risk of obesity is highest among middle-aged neutered male 
cats – the same population group that is at risk of diabetes (Scarlett et al., 1994; Scarlett 
and Dononghue 1998; Lund et al., 2006). 
Insulin sensitivity is defined as the decrease in blood glucose (BG) concentration 
for a given amount of insulin. Insulin resistance refers to markedly decreased insulin 
sensitivity. The ability of insulin-resistant individuals to compensate for reduced insulin 
sensitivity by increasing insulin secretion largely determines the degree to which their 
glucose tolerance can be prevented from deteriorating (Kahn and Porte, 2003). In 
individuals in which this balance cannot be maintained, impaired glucose tolerance and 
overt diabetes ensue. 
The frequency of diabetes in cats ranges from 0.5 – 2%, depending on the 
population studied (Panciera et al., 1990; Rand et al., 2004). Recent evidence suggests 
that the prevalence is increasing because of an increase in the frequency of predisposing 
factors such as obesity and physical inactivity (Prahl et al., 2007). Obesity and physical 
inactivity are also implicated as the causes of increasing frequency of diabetes in people, 
however, the overall frequency of the disease in people is much higher than in cats 
(7.8%, http://diabetes.niddk.nih.gov/DM/PUBS/statistics/#allages). It is hypothesized 
that, at least in part, this lower frequency of diabetes in cats is related to different criteria 
for diagnosis. In people, diagnosis of diabetes is based on fasting hyperglycemia (blood 
glucose > 130 mg/dl), whereas in cats, it is usually diagnosed once blood glucose has 
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exceeded the threshold for renal tubular glucose recovery (blood glucose > 290 mg/dl), 
and when overt clinical signs are evident (Rand et al., 2004). Because type 2 DM is a 
slowly progressing disease, and because normal fasting blood glucose in people and in 
cats is essentially the same, it is hypothesized that DM in cats is diagnosed later in the 
disease process. This explains why most cats are insulin-dependent at the time of 
diagnosis and why treatments such as diet change and oral hypoglycemic drugs are 
typically not sufficient to control diabetes in cats (Nelson, 2005). 
 
Pharmacokinetics and pharmacodynamics of insulin and the isoglycemic clamp 
method 
In veterinary medicine, blood glucose curves have been used traditionally to 
study the pharmacodynamics of exogenous insulin. These curves, however, reflect not 
only the effect of exogenous insulin but also the effect of endogenous insulin and stress 
hormones. Because of this major flaw, this method is not used in people. In contrast, the 
isoglycemic clamp is the gold standard for the study of pharmacodynamics of insulin in 
people (Heinemann and Anderson, 2004; Heise and Pieber, 2007). With this method, 
blood glucose concentrations are “clamped” at euglycemia or at sub-euglycemic 
concentrations by infusing glucose at a changing rate. This allows the study of the effect 
of injected insulin in a healthy subject with minimum interference from confounding 
factors such as hypoglycemia, stress hormones, and endogenous insulin secretion 
(Heinemann and Anderson, 2004; Heise and Pieber, 2007). The clamp method, however, 
is both labor intensive and expensive. 
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In healthy or type 2 diabetic subjects, an important component of clamp quality 
assessment is measurement of C-peptide. C-peptide is the inert cleavage product of 
proinsulin to insulin. This cleavage occurs inside the secretory vesicles in the pancreatic 
beta cells, and C-peptide and insulin are secreted in equimolar amounts (Ahren and 
Taborsky, 2003). Because a variable fraction of insulin is cleared by the liver before the 
insulin reaches the systemic circulation (and this fraction has a crucial role in glucose 
homeostasis), the systemic concentrations of insulin are not an accurate measure of 
secreted insulin. In contrast, C-peptide is not cleared by the liver and can be used as a 
surrogate measurement of insulin secretion. C-peptide is measured during isoglycemic 
clamps to verify that endogenous insulin secretion is suppressed to a minimum 
(Heinemann and Anderson, 2004). The sequence of C-peptide is highly variable between 
species and a feline-specific C-peptide assay is not available (Hoenig et al., 2006).  
In healthy subjects and in type 2 diabetics, endogenous insulin secretion is 
minimized during the clamp experiment but it is not completely suppressed. This might 
lead to over-estimation of exogenous insulin action. Ideally, pharmacodynamics of 
subcutaneously injected insulin should be studied in type 1 diabetics. Because of 
practical reasons, it is still recommended to perform preliminary pharmacodynamic 
studies in healthy subjects. In this case, there are a few strategies to cope with the 
potential of endogenous insulin secretion. First, BG can be clamped at sub-euglycemic 
concentrations. Depending on clamp quality, this method increases the potential for 
stress-hormone activation and endogenous glucose production, thus causing an under-
estimation of the effect of exogenous insulin. Second, intravenous infusion of regular 
insulin can be applied, but this might lead to an over estimation of exogenous insulin 
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action. In both methods, it has been shown in human subjects that complete suppression 
of endogenous insulin secretion (as reflected by C-peptide measurements) is difficult to 
achieve (Swinnen et al., 2008). In hyperinsulinemic-euglycemic clamp experiments 
insulin sensitivity is studied during an intravenous insulin infusion and insulin absorption 
is, therefore, not a consideration. In hyperinsulinemic-euglycemic clamp experiments a 
third strategy is used: infusion of somatostatin. This is not a valid strategy for the study 
of pharmacodynamics of subcutaneously injected insulin because somatostatin alters 
blood flow, thus affecting absorption of insulin from the subcutaneous depot (Ipp et al., 
1987).  
Glucose concentrations in venous blood are influenced by local conditions and do 
not reflect accurately the systemically relevant glucose concentrations. In an ideal 
isoglycemic clamp, blood glucose concentrations should be measured in arterial blood to 
reflect the sum of systemic glucose utilization and hepatic glucose output. In clamp 
experiments in people, blood glucose is measured in “arterialized” venous blood. 
Arterialization is achieved by continuous warming of the sampled vein by putting the 
person’s hand in a “hot box” which is kept at 55oC. The warming of the hand causes 
arteriovenous anastomoses to open, leading to flow of part of the arterial blood directly 
into the venous system (Heinemann and Anderson, 2004). Sampling of arterialized blood 
increases the accuracy of the isoglycemic clamp. This method of venous arterialization is 
clearly not possible in an awake cat. Similarly, direct catheterization of an artery for the 
purpose of prolonged sampling is not feasible in an awake cat. 
Clamp quality in a given experiment can be evaluated by calculating the 
coefficient of variation of BG during the entire clamp and by calculating the deviation of 
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target BG from measured BG for each time point in each subject. It is important to note 
that the BG results themselves are meaningless and should not be used to assess insulin 
action in the clamp method (Heinemann and Anderson, 2004; Swinnen et al., 2008). This 
is because the BG at each time point is affected by the action of insulin in the previous 
20 – 30 minutes combined with the most recent rate of glucose infusion (which is 
operator-dependent).   
The pharmacokinetics of insulin analogs can be studied in conjunction with the 
isoglycemic clamp. Specific assays that discriminate circulating exogenous insulin from 
circulating endogenous insulin and its precursors are required, especially if C-peptide is 
not measured. If available, the molar concentration of C-peptide can be deducted from 
the molar concentration of the total measured insulin, thus giving an indirect 
quantification of exogenous insulin concentration.  
Pharmacokinetic data is of limited use if pharmacodynamic data is available. This 
is because the plasma concentration of insulin is only one of many factors that determine 
its action. Insulin action also depends on transport and diffusion of insulin through the 
endothelium and extracellular fluid, and its degradation in the target tissue. Finally, 
insulin action can vary greatly depending on the sensitivity of the target tissue 
(Heinemann and Anderson, 2004). All of these factors can vary between different target 
tissues. In fact, it has been shown that interstitial insulin concentrations, but not plasma 
insulin concentrations, correlate with glucose-lowering effect of the insulin (Hamilton-
Wessler et al., 1999). Transendothelial transport and interstitial insulin concentrations 
are important factors especially when the pharmacology of albumin-bound insulin 
analogs (such as insulin detemir) is considered (Ellmerer et al., 2003). Only free detemir, 
 12 
and not albumin-bound detemir, is available for transendothelial transport (in most 
tissues) and therefore for action in the tissue. Currently, only total detemir concentrations 
can be measured in blood, resulting in a pharmacokinetic profile that does not 
necessarily reflect the active fraction. When studying pharmacokinetic data of insulin 
detemir and other insulin formulations, it is important to note that because of its low 
affinity for the human insulin receptor, insulin detemir (Levemir®) is supplied in a molar 
concentration 4 times higher than the molar concentration of other insulin formulations 
so that the unit of activity per volume is comparable. Because of the above reasons, it is 
not recommended to compare pharmacokinetic data of insulin detemir to other insulin 
formulations (Klein et al., 2007). 
 
Synthetic insulin analogs and their use in dogs and cats 
Insulin analogs are artificially altered forms of insulin that differ from native 
insulin but retain its physiological effects. Recombinant insulin analogs have 
revolutionized insulin therapy in human diabetes mellitus, and are having an impact on 
diabetes treatment in veterinary patients as well. Understanding the basics of insulin 
pharmacology and physiology is key to understanding the properties of synthetic insulin 
analogs and the rationale for their use.  
Insulin physiology 
Insulin is secreted by the beta cells of the islets of Langerhans in the pancreas.  It 
reaches the liver through the portal circulation and then enters the systemic circulation 
and reaches its other target organs – mainly skeletal muscle and adipose tissue. Insulin 
synthesis and secretion are stimulated predominantly by increases in blood glucose 
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concentrations, but the degree to which beta cells respond to glucose is modified by a 
multitude of other factors including nutrients, hormones and neural input. (Ahren and 
Taborsky, 2003). 
Endogenous insulin secretion can be divided into two phases: the “basal” phase, 
in which insulin is secreted continuously at a relatively constant rate, and the “bolus” 
phase, in which insulin is secreted in response to nutrients (Owens and Bolli, 2008). The 
primary role of basal insulin secretion is to limit lipolysis and hepatic glucose production 
in the fasting state. Post-prandial insulin primarily suppresses hepatic glucose output and 
stimulates glucose utilization by muscle, thus preventing hyperglycemia after meals 
(Owens and Bolli, 2008). Post-prandial blood glucose concentration is also largely 
determined by other factors such as the carbohydrate, fat, and protein content of the 
meal, gastrointestinal transit time, and the effects of glucagon (Owens and Bolli, 2008). 
In health, insulin secretion is constantly adjusted to work in concert with these other 
factors in order to maintain euglycemia. In the war against diabetes, mimicking this 
highly dynamic process with subcutaneous injections of insulin is a battle best fought 
with advanced weapons.  
Pharmacology of insulin analogs 
There is a large body of evidence indicating that tight glycemic control is 
essential to prevent long term complications of human diabetes (Nathan et al., 2005; 
Genuth, 2006; Akalin et al., 2009). Intensive treatment protocols to achieve that goal are 
often associated with side effects such as hypoglycemia and undesired weight gain. The 
ideal insulin therapy should mimic the physiology of insulin secretion as closely as 
possible. In veterinary medicine there is no clearly established benefit of tight control of 
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blood glucose in the normal range, and the standard of care is alleviation of clinical signs 
while minimizing side effects, rather than achieving sustained euglycemia.  
Insulin has a natural tendency to precipitate and crystallize, especially in the 
presence of zinc. In the pancreatic beta cells insulin is stored as hexamers surrounding 
molecules of zinc. Insulin hexamers are slow to penetrate capillaries, but when released 
from the beta cells the zinc is diluted and the hexamers break down to dimers and 
monomers that are absorbed into the blood stream (Havelund et al., 2004).  In older 
insulin formulations, the tendency of insulin to crystallize is enhanced by modifying the 
solution (e.g. adding zinc and/or protamine), thus causing precipitation in the vial and at 
the site of injection (Havelund et al., 2004; Sheldon et al., 2009). Once injected 
subcutaneously, the zinc is slowly diluted (and protamine slowly degraded), thus 
releasing insulin into the blood. This strategy has an obvious disadvantage in that insulin 
has to be re-suspended evenly before being drawn into a syringe, which can lead to 
inaccuracy in dosing (Kohn et al., 2007). A second disadvantage is that the 
deprecipitation in the injection site is highly variable and unpredictable, and that can lead 
to considerable variation in insulin absorption (Havelund et al., 2004; Owens and Bolli, 
2008). Third, the older insulin formulations such as lente and NPH have action profiles 
that are inadequate when trying to mimic normal insulin secretion physiology in human 
diabetics. The onsets of action are too slow and durations of action are too long to mimic 
the “bolus” phase; at the same time, insulin action profiles are often too peaked and 
durations are usually not long enough to mimic “basal” secretion (Havelund et al., 2004; 
Choe and Edelman, 2007; Owens and Bolli, 2008). A similar problem exists in diabetic 
dogs and cats. For the typical diabetic pet, twice daily injections of insulin at mealtime is 
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the standard of care. Using intermediate-acting insulin formulations, this protocol is 
usually geared towards alleviating clinical signs of diabetes. Achieving tight glycemic 
control is difficult and increases the risk of hypoglycemia.   
Another disadvantage of treatment with traditional insulin formulations is loss of 
normal liver:periphery insulin concentration gradients (Hordern et al., 2005; Hermansen 
and Davies, 2007). Inhibition of hepatic glucose output, a major factor in maintaining 
euglycemia, requires high insulin concentrations in the blood, while inhibition of 
lipolysis requires much lower concentrations. More than half of the insulin secreted by 
the pancreas is removed from the bloodstream by the liver before the remainder is 
circulated to other target organs. When insulin is injected subcutaneously, equal 
concentrations are delivered to the liver, muscles, and adipose tissue. This accomplishes 
either appropriate control of hepatic glucose output with inappropriately high 
concentrations of insulin in adipose tissue (promoting weight gain), or insufficient 
control of hepatic glucose output leading to poor glycemic control. A synthetic insulin 
analog that is preferentially targeted to the liver would likely decrease the magnitude of 
this problem. 
 Synthetic insulin analogs were designed to mimic physiologic insulin secretion as 
closely as possible. Intensive insulin therapy protocols in people typically consist of a 
“bolus” insulin with rapid absorption and ultra-short action given at meal time, and a 
“basal” insulin given once daily (Choe and Edelman, 2007). These insulin analogs were 
designed to have more predictable action profiles than older insulin formulations, an 
important feature in prevention of hypoglycemic events. The synthetic insulin analogs 
are based on human-recombinant insulin, and are altered biochemically to change their 
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pharmacological properties. Amino acid substitutions in the B26-B30 region alter the 
tendency of insulin to crystallize while retaining the ability to activate insulin receptors 
(Sheldon et al., 2009). All available insulin analogs are supplied as clear solutions and do 
not need to be re-suspended before use. This reduces inaccuracy in dosing, but insulin 
analogs can still form hexamers at the site of injection, resulting in some degree of 
variability in absorption.   
Insulin has a mitogenic effect in the body. This effect is mediated by the insulin 
receptor as well as the IGF-1 receptor (Smith and Gale, 2009). The mitogenic effect of 
synthetic insulin analogs has been investigated because the modifications to their 
sequence change their affinity for receptors. Changes in the absolute affinity, as well as 
the relative affinity to the insulin receptor compared to the IGF-1 receptor, might 
increase the mitogenicity of a synthetic analog. Few and inconsistent data do exist 
showing increased risk of developing cancer in people treated with insulin glargine 
(Weinstein et al., 2009; Hemkens et al., 2009). Contradictory evidence, however, 
together with obvious benefits of using insulin glargine, have lead to the present 
consensus to support the use of insulin glargine in human diabetic patients (Smith and 
Gale, 2009; Rosenstock et al., 2009; Home and Lagarenne, 2009; Colhoun, 2009). No 
clinical data exist regarding the mitogenicity of insulin detemir but one experimental 
study suggests that it is no more mitogenic than human insulin (Kurtzhals et al., 2000). 
The affinity of insulin for insulin receptors has been reported in cats and in dogs 
(Wolfsheimer and Peterson, 1991; Paxton and Ye, 2000; Tolan et al., 2001). IGF-1 
receptor affinity has been reported in dogs, (Sukegawa et al., 1987) but not in cats. There 
is one report of affinity of an experimental synthetic insulin analog for the insulin 
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receptor in dogs (Kohn et al., 2007) but there are no such reports in cats, nor are there 
reports of receptor binding studies using commercially available insulin analogs in dogs 
or cats. As such, there is no evidence to support a claim that any insulin product (natural 
or synthetic) is safer than another from a mitogenesis standpoint in cats and dogs. 
Rapid-acting insulin analogs: Lispro, aspart and glulisine 
Historically, a combination of regular insulin and an intermediate-acting insulin 
was used to replace postprandial insulin in human diabetic patients. However, the action 
profile of regular insulin after subcutaneous injection may be inadequate for the 
treatment of diabetes because its absorption is relatively slow and the duration of action 
is too long (about 5 – 8 hours in people, about 5 hours in cats and dogs) (Plum et al., 
2000; Gilor et al., 2008; Rave et al., 2009). Insulin lispro was the first rapid-acting 
analog to be approved for use in people (Sheldon et al., 2009). The amino-acid sequence 
of insulin lispro consists of a reversal of proline at the B28 position and lysine at the B29 
position. This small change greatly decreases the tendency for association and enhances 
the rate of absorption. In people, this results in an early onset of action (0.5 - 1 hour) a 
relatively high peak in activity, and a short duration of action (2 – 3 hours). Thus, 
subcutaneous insulin lispro is more suited to mimic post-prandial insulin secretion than 
subcutaneous regular insulin (Sheldon et al., 2009). 
In insulin aspart the proline at B28 is replaced with aspartic acid.  In insulin 
glulisine, lysine at B29 is replaced by glutamic acid and on position B3 asparagine is 
replaced by lysine. Insulin aspart and insulin glulisine have pharmacokinetic and 
pharmacodynamic profiles similar to insulin lispro (Sheldon et al., 2009). All 3 are used 
in type 1 and type 2 diabetic people. In type 1 diabetics these insulin analogs have a clear 
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advantage over regular insulin in reducing the risk of hypoglycemic events (Siebenhofer 
et al., 2006). In type 2 diabetics, when combined with a basal insulin analog, these rapid-
acting insulin analogs provide better glycemic control than regular insulin without 
increasing hypoglycemic episodes (Mannucci et al., 2009). In one study of human 
diabetic patients, similar glycemic control was achieved whether insulin aspart was 
injected 15 minutes before or 15 minutes after initiation of a meal (Brunner et al., 2000). 
In veterinary medicine, because of the inability of pet owners to predict whether their pet 
would eat its meal in full, it is recommended that insulin is injected after the meal. 
Rapid-acting insulin analogs might be of an advantage in this scenario.   
There are currently no reports on the use of rapid-acting analogs in the chronic 
treatment of diabetes in cats and dogs. Insulin lispro has been successfully used in dogs 
to treat DKA (Sears et al., 2009). In this study insulin lispro was administered 
intravenously and had similar efficacy as the traditionally used regular insulin. No 
adverse reactions were seen. There is no clear rationale for preferring insulin lispro over 
regular insulin for use in constant-rate IV insulin infusions. The biochemical alteration in 
insulin lispro confers greater dissociation and faster absorption of insulin injected 
subcutaneously, but both insulin lispro and regular insulin should dissociate immediately 
when delivered intravenously. This has been observed experimentally in human patients 
but not to our knowledge in veterinary patients (Horvath et al., 2008). Insulin lispro has 
also been used experimentally in dogs in one study.  It was injected once subcutaneously 
at a dose of 0.2 U/Kg. Its plasma concentration peaked at 45 minutes and was still high 
at 3 hours (no further measurements were done). Insulin lispro caused a nadir in blood 
glucose 2 hours post-injection, and the duration of action was over 3 hours (Matsuo et 
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al., 2003). Insulin aspart pharmacology has also been studied in dogs, and was reported 
to have more rapid absorption following subcutaneous injection than regular insulin, but 
the pharmacokinetics and pharmacodynamics were largely similar to regular insulin 
(Plum et al., 2000). We are aware of no reports on insulin glulisine in cats or dogs. 
Rapid-acting insulin analogs were designed to replace normal bolus phase insulin 
secretion in people and have a duration of action of 3 hours or less. But what is the 
“normal” postprandial insulin secretion profile in dogs and cats? In 2 studies in non-
diabetic cats, “bolus” phase insulin secretion had a longer duration (over 6 hours in one 
study and over 12 in the other) and a later and lower peak (occurring at 2-6 hours and 
reaching 2 – 3 times baseline concentrations compared to over 5 times baseline 
concentrations in people) compared to the bolus phase in people (Appleton et al., 2001; 
Mori et al., 2009; Sheldon et al., 2009). In both studies cats were fasted (overnight or for 
36 hours) before the meal and were then fed half their daily caloric average over 15-30 
minutes. Overall, cats were fed 4 different diets in those 2 studies. If this reflects normal 
postprandial insulin secretion profile in cats, and if the pharmacologic profile of short-
acting insulin analogs in cats is similar to that in people, there would be no advantage to 
using short-acting insulin analogs in feline diabetes.  
Long-acting basal insulin analogs: Insulin glargine 
Insulin glargine has 2 arginine residues added to the C-terminus of the B chain at 
position 30.  This modification increases the isoelectric pH of the molecule. A second 
modification is the replacement of asparagine in position A21 with glycine. This 
increases the stability of the molecule in acidic pH (Owens and Bolli, 2008). Insulin 
glargine is soluble at pH 4.0 (in which it is supplied) but in neutral pH (such as in 
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subcutaneous tissue) it has a strong tendency to precipitate, thus slowing its absorption 
after injection (Kohn et al., 2007). The precipitation-deprecipitation process, however, 
introduces a component of variability in absorption, rendering insulin glargine relatively 
unpredictable in action (Heise and Pieber, 2007). When determined by isoglycemic 
clamps in people, insulin glargine has a duration of action of over 24 hours and a 
relatively flat time-action profile.  Insulin glargine is commonly used in people as once-
daily basal insulin therapy, often supplemented with ultra short-acting insulin analogs 
given at meal time. Compared to the traditional intermediate-acting formulations, insulin 
glargine offers similar reductions in glycosylated hemoglobin concentration but with 
decreased risk of hypoglycemia and greater convenience (Danne et al., 2008; Fakhoury 
et al., 2008; Monami et al., 2008). 
 In a small experimental study, the pharmacodynamics of insulin glargine have 
been studied in dogs and compared to NPH (Mori et al., 2008). Using the isoglycemic 
clamp technique and with a dose of 0.5 U/kg, insulin glargine had a duration of action of 
about 18-24 hours with a pronounced peak at 7 hours. NPH had a shorter duration of 
action (about 12 hours) and peaked at 5 hours. Unexpectedly and in contrast to reports in 
people, insulin glargine had greater inter-subject variability compared to NPH.  
In one study in newly-diagnosed diabetic cats, 8/8 cats became insulin 
independent when treated with twice-a-day insulin glargine and an ultra-low 
carbohydrate diet (Marshall et al., 2009). This remission rate was higher than the 
remission rate for cats treated with PZI (3/8) and Lente (2/8) in the same study. The 
duration of illness prior to inclusion in the study was not mentioned and the allocation 
into treatment groups was not random. Also, treatment protocols were not identical 
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between groups. Lower remission rates were reported in another study in which the goal 
of treatment was achieving euglycemia (Roomp and Rand, 2009b). In this study 84% of 
cats that were started on the treatment protocol within 6 months of diagnosis achieved 
remission while only 35% of cats that were started on the protocol after more than 6 
months from diagnosis achieved remission. All cats in this study were fed an ultra-low 
carbohydrate diet. These remission rates are similar to the results of another study in 
which cats treated with a variety of insulin formulations other than glargine (mostly PZI) 
had 68% remission rate when fed a low-carbohydrate diet (Bennett et al., 2006). Only 11 
of 31 cats in this study were recently-diagnosed (within 45 days) but there was no 
difference in remission rates between those cats and others that were sick for over 45 
days.  
In a small clinical study in cats, once-a-day insulin glargine was compared to 
twice-a-day Lente in cats fed ultra-low carbohydrate diet (Weaver et al., 2006). In that 
study both treatment groups experienced improvement in serum fructosamine 
concentrations, and 16-hour blood glucose curves were improved. Four of the 13 cats of 
this study experienced remission of diabetes, but only one of these was in the insulin 
glargine-treated group. Disease duration was not clearly presented in this study. The 
same group of investigators reported another study in which cats with diabetes were 
treated with insulin glargine and fed a high-protein / low-carbohydrate diet or a control 
diet (Hall et al., 2009). Both groups had improved glycemic control, but only 2/12 cats, 
one in each group, achieved remission. Taken together, these studies suggest that a low-
carbohydrate diet in combination with glargine or any other insulin formulation is 
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clinically useful in treating diabetes in cats. In newly diagnosed diabetic cats, treatment 
with glargine might be more likely to achieve remission. 
Long-acting basal insulin analogs: Insulin detemir 
In contrast to insulin glargine, pharmacodynamics of insulin detemir are 
considered highly predictable in people, with minimal inter- and intra-subject variability 
(Soran and Younis, 2006; Heise and Pieber, 2007). Insulin detemir has a myristic acid 
residue (14-carbon fatty acid) replacing threonine at position B30. Instead of the natural, 
weaker, ionic interactions between insulin molecules, insulin detemir molecules 
associate through strong hydrophobic interactions between the fatty acids. These fatty 
acids also bind reversibly to albumin which buffers the concentration of insulin detemir 
in the blood and tissues, adding to its protracted and more predictable effect. Predictable 
pharmacodynamics, demonstrated with insulin detemir in human clinical trials, are key 
to minimizing hypoglycemic events (Heise and Pieber, 2007; Danne et al., 2008; 
Fakhoury et al., 2008; Monami et al., 2008). The interaction of insulin detemir with 
albumin also increases the availability of insulin detemir to organs with fenestrated 
capillaries such as the liver. Relatively high concentrations of insulin detemir are 
achieved in the liver compared with other target tissues. Thus insulin detemir inhibits 
hepatic glucose output more effectively, lipogenesis in adipose tissue is decreased, and 
weight gain is minimized ( Hermansen and Davies, 2007; Danne et al., 2008; Fakhoury 
et al., 2008; Monami et al., 2008). Other acylated long-acting insulin analogs have been 
described but are not in clinical use. The peripheral action, but not the subcutaneous 
absorption, of insulin detemir and one other acylated analog (O346) have been studied in 
dogs (Hamilton-Wessler et al., 1999; Ellmerer et al., 2003). In both studies the insulin 
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was administered intravenously and in both studies it was shown that the transendothelial 
transport of the acylated insulin is considerably slower than that of regular insulin. O346 
bound so avidly to albumin that its duration of action was estimated to be 2 days in dogs.  
A thyroxyl-insulin analog that binds to thyroid-hormone binding proteins has also been 
described (Shojaee-Moradie et al., 1998; Shojaee-Moradie et al., 2000). This insulin 
analog was hepato-selective in people and in dogs, but its duration of action in people 
was slightly shorter than the duration of action of NPH insulin.  
When determined by isoglycemic clamps in people, insulin detemir has a 
duration of action of approximately 20 hours (Heise and Pieber, 2007) and it is used 
commonly as a once-daily basal insulin in human diabetic patients. Although seldom 
compared side by side, the clinical outcomes of treatment with insulin detemir or insulin 
glargine are similar. Use of these analogs is associated with similar reductions in 
glycosylated hemoglobin, with decreased numbers of hypoglycemic events. Insulin 
glargine may be slightly more effective in reducing glycosylated hemoglobin, and 
hypoglycemic events may be less common with the use of insulin detemir. Insulin 
detemir, however, is consistently associated with less undesired weight gain in people 
(Danne et al., 2008; Fakhoury et al., 2008; Monami et al., 2008).  
Insulin detemir vs. insulin glargine in cats 
In a study in healthy cats, the duration of action of insulin glargine after a single 
subcutaneous injection at a dose of 0.5 U/kg was found to be 22 ± 1.8 hours (Marshall et 
al., 2008). This was based, however, on the return of blood glucose to baseline 
concentrations during prolonged fasting. While this method of studying insulin 
pharmacokinetics and pharmacodynamics is common in veterinary research, results of 
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such studies may not be completely relevant because they do not take into account 
endogenous insulin and normal physiologic responses to changes in blood glucose. For 
these reasons, studies of insulin pharmacology are better done by “clamping” blood 
glucose concentrations to euglycemia, and measuring other indicators of insulin activity. 
The effects of prolonged fasting were also not taken into account in that study and it is 
possible that the duration of action of insulin glargine was over-estimated. Interestingly, 
in the same study, serum insulin concentrations returned to baseline within 6.7 ± 1.3 
hours (range 0.6 – 13 hours). We have compared the pharmacodynamics of single 0.5 
U/kg injections of insulin detemir and insulin glargine in cats using the isoglycemic 
clamp method. The onset-of-action of insulin detemir was 1.8 ± 0.8 hours, the end-of 
action was reached at 13.5 ± 3.5 hours and there was a significant variation in the time-
action profile between cats. Surprisingly, the duration of action of insulin glargine was 
much shorter than previously reported (11.3 ± 4.5 hours), and like insulin detemir, there 
was a significant variation in the time-action profile between cats, ranging from curves 
that were essentially flat to others that had pronounced peaks (Gilor et al., 2010).  
 Insulin detemir has been compared to insulin glargine in one clinical study in 
which the goal of treatment was tight glycemic control (maintaining euglycemia with 
blood glucose concentrations ranging between 50-100 mg/dl) (Roomp and Rand, 2009a; 
Roomp and Rand, 2009b).  Blood glucose concentrations were monitored by owners at 
home, and the doses of insulin were changed by the owners. All cats in this study were 
fed high-protein / low-carbohydrate canned diets. Over all remission rate in this study 
was 67% for insulin detemir and 64% for insulin glargine. Hypoglycemia was common 
but clinical signs were rarely noticed. Also rare was the occurrence of Somogyi effect. 
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The median maximum insulin glargine dose was 2.5 IU (range 1.0 to 9.0 IU) compared 
with a median insulin detemir dose of 1.75 IU (range 0.5 to 4.0 IU). In this study a twice 
daily regimen of insulin administration was used for both analogs. 
 
Incretin hormones and the incretin effect 
K and L cells are enteroendocrine cells dispersed along the epithelium of intestinal 
tract.  Their physiological role is to sense the type and quantity of digested nutrients in 
the gut. They then secrete incretin hormones as preparatory signals to other remote 
organs (e.g. brain, pancreas etc.). In the pancreas, the incretin signal is translated to 
increased sensitivity to the stimulatory effect of glucose. This effect is responsible for the 
observed difference in insulin secretion between oral and intravenous glucose and is 
defined as the “incretin effect”; oral glucose leads to much greater insulin secretion 
compared to intravenous glucose even when blood glucose concentrations are equal 
(McIntyre et al., 1965; Nauck et al., 1986). Because the stimulatory effect of incretins on 
the pancreas depends on elevations in blood glucose concentrations, an increase in 
incretin blood concentration is unlikely to cause hypoglycemia (Holst et al., 2009). The 
incretin effect is thought to be exclusively mediated by 2 peptide hormones: Glucagon-
like peptide-1 (GLP-1) which is secreted from L cells, and glucose-dependent 
insulinotropic polypeptide (GIP) which is secreted from K cells (Holst et al., 2009). The 
incretin effect is severely reduced or absent in people with type 2 DM, contributing to 
glucose intolerance and post-prandial hyperglycemia. In diabetics, the secretion of GIP is 
normal or slightly reduced but its effect on the pancreas is markedly decreased. In 
contrast, GLP-1 retains its insulinotropic effects in type 2 DM (at least in 
 26 
supraphysiologic concentrations), but its secretion is decreased (Nauck et al., 1993; Toft-
Nielsen et al., 2001a, Toft-Nielsen et al., 2001b; Holst et al., 2009). Very little is known 
about incretin hormones and the incretin effect in cats. In the following sections, unless 
stated otherwise, data from other animal models are reviewed in general. Information 
regarding incretins in cats will be specified.  
Distribution of L and K cells 
L and K cells are interspersed in the epithelium of the gut. They are described as 
open-type cells, reaching the lumen of the gut via a slender apical process. On their basal 
side they are located in close proximity to the vasculature and neurons of the lamina 
propria (Baggio and Drucker, 2007). Quantitative immunohistochemical studies in rats, 
pigs and people have demonstrated that the majority of L cells are located in the ileum 
and colon, with small numbers in the distal jejunum (Kauth and Metz, 1987; Eissele et 
al., 1992). In contrast, K cells are concentrated in the duodenum and proximal jejunum 
(Damholt et al., 1999). A population of K/L cells that contain both GIP and GLP-1 is 
also present in rats, pigs and people (Mortensen et al., 2000; Mortensen et al., 2003; 
Fujita et al., 2008). In the mid-jejunum, about two thirds of K and L cells are actually 
K/L cells. In dogs, the density of L cells increases from the duodenum aborally to the 
ileum as in other species, however, quantitative analysis revealed that over 70% of L 
cells are found in the jejunum. Interestingly, K cells in the dog are also concentrated in 
the jejunum with lesser concentrations in the duodenum. Importantly, over 30% of L 
cells in the jejunum of the dog are found in close proximity to K cells, suggesting the 
existence of a paracrine interaction between the two. K/L cells were not described in 
dogs. For both K and L cells, there is no difference in their density between crypts and 
 27 
villi (Damholt et al., 1999). In cats, enteroendocrine cells with GIP immunoreactivity 
were described in the duodenum and jejunum while enteroendocrine cells with glicentin 
immunoreactivity were described in the ileum and colon (Glicentin or “gut glucagon” is 
a product of the proglucagon gene as will be discussed later; it was previously thought to 
be the main hormone product of L cells). No data are available regarding the relative 
density of K and L cells and their spatial relationship in cats (Larsson and Moody, 1980; 
Vaillant and Lund, 1986). 
Stimulation of secretion of incretin hormones 
The main stimulus for secretion of hormones from K and L cells is the presence of 
nutrients in the lumen of the gut (but not by nutrients in the blood). Hormone secretion 
takes place in the basolateral side (to the blood). The degree of GIP and GLP-1 
stimulation by different nutrients is species-dependent (Deacon, 2005). Fat is more 
potent than carbohydrates in stimulating GIP secretion in people and dogs but the 
opposite is true in rodents and pigs (Baggio and Drucker, 2007). Amino acids are weak 
stimulators of GIP secretion in people but strong stimulators of it in dogs and rats 
(Pederson et al., 1975; Thomas et al., 1978; Elliott et al., 1993; Wolfe et al., 2000). GIP 
secretion depends on the rate of absorption of nutrients and not on their mere presence in 
the lumen of the gut (Baggio and Drucker, 2007). Post-prandial GLP-1 secretion is 
typically biphasic and is stimulated by ingested lipid, carbohydrate and protein (Elliott et 
al., 1993, Herrmann et al., 1995). In dogs and rodents, but not in people, it is also 
stimulated by GIP (Damholt et al., 1999). There are conflicting reports regarding the 
physiological importance of neural regulation of GLP-1 secretion with some evidence 
that it is stimulated by the vagus nerve (Kim and Egan, 2008). Different distributions of 
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GLP-1-secreting cells (L cells and K/L cells) along the intestinal tract in different species 
determine, in part, the importance of different stimuli of GLP-1 secretion (Damholt et 
al., 1999; Kim and Egan, 2008). 
In people, fat-stimulated GLP-1 secretion necessitates hydrolysis into fatty acids 
(Beglinger et al., 2010). Monounsaturated fatty acids stimulate GLP-1 secretion more 
than polyunsaturated fatty acids or saturated fatty acids (Beysen et al., 2002). Fatty acids 
are sensed by specific G protein-coupled receptors (GPR). GPR40 (FFAR1) and 
GPR120 are found in L and K cells and they can be activated by saturated and un-
saturated medium- and long-chain fatty acids (Parker et al., 2009, Miyauchi et al., 2010). 
GPR119 has been described recently in L and K cells, and it is activated by 
phospholipids and fatty acid amides (Overton et al., 2008; Parker et al., 2009). It is likely 
that continued de-orphanization of GPR’s will lead to discovery of other stimulators of 
incretin secretion (Overton et al., 2008).  Drug-delivery systems that target FFA’s to 
GPR120 on colonic L cells and increase GLP-1 secretion have been recently developed 
as potential treatments for diabetes (Adachi et al., 2008; Morishita et al., 2008). Small-
molecule agonists of GPR119 with drug-like properties and oral activity were also 
described (Overton et al., 2008).  
In people and rodents simple sugars are sensed in the luminal surface of the gut via 
a specific G protein-coupled “sweet taste receptor” that belongs to the same family of 
taste receptors in the tongue (Jang et al., 2007). Cats lack this sweet taste receptor and 
they do not seem to sense sweet tastes (Li et al., 2006). Whether or not cats have a 
different G protein-coupled taste receptor or a different mechanism of sensing 
carbohydrates by intestinal enteroendocrine cells is unknown. Some studies questioned 
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the importance of GPR taste receptors in stimulation of secretion from K and L cells 
(Reimann et al., 2008; Parker et al., 2009). In these studies, glucose stimulated GIP and 
GLP-1 secretion via glucose metabolism and KATP channel closure in a mechanism 
similar to stimulation of insulin secretion in pancreatic beta cells. Nonmetabolizable 
sugars were still able to promote GLP-1 release via a sodium-glucose cotransporter-
dependent mechanism (Gribble et al., 2003, Parker et al., 2009).  
Luminal receptors for amino acids have been described, but their presence in K 
cells or L cells has not been established (Rozengurt, 2006). In dogs there is some 
evidence that stimulation of K cells by protein is mediated by pH changes in the 
duodenum that are secondary to protein digestion in the stomach (Deacon, 2005). Amino 
acids can also activate secretion of incretins by inducing sodium-dependent inward 
currents when they enter the cells via specific transporters (Reimann et al., 2004). 
In cats, a rapid increase in GLP-1 plasma concentrations after intra-gastric glucose 
administration has been described (Hoenig et al., 2010). In that study, blood glucose 
concentrations returned to baseline within 2 hours of glucose administration, suggesting 
no significant glucose absorption after that time. Plasma GLP-1 concentrations, however, 
did not return to baseline even after 5 hours in healthy cats, but did return to baseline in 
obese cats. This is an interesting finding because it might suggest that the stimulatory 
effect of glucose on GLP-1 secretion persists for hours after glucose has been completely 
absorbed. Such a prolonged stimulatory effect contradicts the paradigm of incretin 
biology, i.e. enteroendocrine cells are first-line sensors of nutrients, and incretin 
hormones serve as preparatory signals for other organs. Such an interpretation of these 
 30 
data is questionable given the methods used in that study to measure GLP-1 
concentrations (as will be discussed later in “Incretins in diabetes and obesity”).  
As mentioned before, in people, saturated fatty acids are the weakest incretin 
secretagogues compared to monounsaturated and polyunsaturated fatty acids (Beysen et 
al., 2002). Cats are obligate carnivores and, as such, they eat mostly saturated fat. As is 
the case for glucose, this specialized evolutionary need might have led to a different 
sensing mechanism for fatty acids or to an altered incretin effect.  
Products of post-translational processing of the proglucagon and proGIP genes 
The proglucagon gene is expressed in the alpha cells of the endocrine pancreas, 
in the L cells of the intestine, and in neurons in the caudal brainstem and hypothalamus. 
Transcription and translation of the proglucagon gene yield a single 180 amino acid 
precursor protein that is identical in all 3 tissues. Proglucagon undergoes tissue specific 
posttranslational processing to yield tissue specific peptide profiles (Baggio and Drucker, 
2007). In pancreatic alpha cells, proglucagon (PG) is cleaved by prohormone convertase 
2 (PC2) into glicentin-related pancreatic peptide (GRPP, corresponding to PG 1-30), 
glucagon (PG 33-61) and major proglucagon fragment (MPGF, PG 72-158).  MPGF 
contains the sequence of GLP-1 and GLP-2 and it may be cleaved further to generate 
GLP-1 (1-37) (PG 72-108). GLP-1 (1-37) can go further processing into GLP-1 (1-36) 
amide. Glucagon is by far the predominant product in alpha cells but some release of 
GLP-1 (1-37) and (1-36) amide can occur. These latter 2 peptides are biologically 
inactive but they can cross-react with GLP-1 in immunological assays that detect the C-
terminal part of the peptide (Deacon and Holst, 2009).  
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Posttranslational processing of proglucagon in L cells depends on expression of 
the prohormone convertase 1/3 (PC 1/3) (Rouille et al., 1997; Ugleholdt et al., 2006). In 
L cells, processing of proglucagon leaves the N-terminal side of the molecule largely 
intact, forming glicentin (PG 1-69), small amounts of GRPP (PG 1-30) and 
oxyntomodulin (PG 33-69). The C-terminal of proglucagon is cleaved to the 2 major 
products of the L cell: GLP-1 (7-37) (PG 78-108) and GLP-2 (PG 126-158) (Deacon and 
Holst, 2009). GLP-1 (7-37) is then processed into GLP-1 (7-36) amide. Although both 
GLP-1 (7-37) and GLP-1 (7-36) amide are biologically active, immunological assays 
that detect the C-terminus of GLP-1 can detect only one of the two forms (Orskov et al., 
1993; Deacon and Holst, 2009). Although the amino acid sequence of GLP-1 is 100% 
homologous in all mammals in which it has been studied (including rat, hamster, cow, 
Guinea pig, human being, and pig [Bell et al., 1983; Lopez et al., 1983; Heinrich et al., 
1984; Seino et al., 1986; White and Saunders, 1986; Orskov et al., 1989]), the relative 
concentrations of its 2 active forms differ between species (Pridal et al., 1995). In people, 
GLP-1 is mostly processed to the (1-36) amide form whereas in dogs, pigs and rodents 
the 2 forms are secreted in variable ratios (Pridal et al., 1995; Deacon and Holst, 2009). 
Immunological assays that detect a more central region of the molecule will detect both 
active forms, but they also detect the inactive forms that are secreted from the pancreas 
(1-37 and 1-36 amide) as well as active GLP-1 that was degraded to its inactive forms 
GLP-1 (9-37) and GLP-1 (9-36) amide (the latter 2 will be described later).  
Glucagon is the major counterregulatory hormone to insulin. Glucagon regulates 
hepatic glucose production via activation of glycogenolysis and gluconeogenesis and 
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inhibition of glycolysis, and is essential for maintaining glucose homeostasis in the 
fasting state (Baggio and Drucker, 2007).  
The physiologic actions of glicentin are not well-defined. Oxyntomodulin inhibits 
gastrointestinal secretion and motility, stimulates pancreatic enzyme secretion and 
intestinal glucose uptake and promotes satiety. GLP-2 stimulates cell proliferation and 
inhibits apoptosis in the intestinal crypt compartment. It also up-regulates intestinal 
glucose transport, improves intestinal barrier function, and inhibits food intake, gastric 
emptying, and acid secretion (Baggio and Drucker, 2007). 
GIP gene expression has been detected in the stomach and intestinal K cells in 
rodents and humans, as well as in the submandibular salivary gland in rats. The mature 
42-amino acid bioactive form of GIP is released from its 153-amino acid preproGIP 
precursor via PC1/3-dependent posttranslational cleavage. The peptides encoded within 
the GIP N- or C-terminal sequences have no known function. The GIP sequence is 
highly conserved among species with human, mouse, rat, porcine, and bovine GIP 
exhibiting more than 90% amino acid sequence homology (Baggio and Drucker, 2007; 
Deacon and Holst 2009).  
Degradation and elimination of incretin hormones 
Active GIP (1-42) and active GLP-1 (7-37 and 7-36 amide) are degraded by the 
enzyme dipeptidyl peptidase-4 (DPP-4) into inactive forms: GIP (3-42), GLP-1 (9-37) 
and GLP-1 (9-36) amide. DPP-4, also known as CD26, is a serine protease that 
specifically cleaves dipeptides from the amino terminus of oligopeptides or proteins that 
contain an alanine or proline residue in position 2, thereby modifying or inhibiting their 
activity (Baggio and Drucker, 2007). Active GLP-1 (but not active GIP) is also degraded 
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by the enzyme neutral endopeptidase 24.11 (NEP-24.11), a membrane-bound zinc 
metallopeptidase. DPP-4 and NEP are ubiquitous in tissues, and DPP-4 is also present in 
a soluble form in the blood. Notably, DPP-4 is present on the surface of endothelial cells, 
including those lining blood vessels that drain the intestinal mucosa, which are 
positioned directly adjacent to the sites of GIP and  GLP-1 secretion. Consequently, 
more than 75% of the GLP-1 that enters the portal circulation already has been 
inactivated (Hansen et al., 1999). Similarly, about 50% of the remaining active GLP-1 is 
degraded in the liver. Therefore, only 10-15% of secreted GLP-1 reaches the systemic 
circulation in its active form. It is therefore widely accepted that for estimation of GLP-1 
secretion, measuring the active form is inadequate and the total (active and inactive 
forms) should be measured (Larsen and Holst, 2005; Deacon and Holst, 2009). 
Measuring total GLP-1 also better estimates the full effect of the active peptide, 
including its neurally mediated effects within the gut and portal veins, as well as its 
direct effect on the pancreas. For estimation of the action of GLP-1 directly on the 
pancreas, it is accepted that active GLP-1 should be measured (Larsen and Holst, 2005; 
Deacon and Holst, 2009).  
When injected intravenously, active GLP-1 has a half-life of about 1-2 minutes. 
The inactive GLP-1 is quickly cleared by the kidneys and has a half-life of about 4-5 
minutes (Larsen and Holst, 2005). Clearance by the kidneys is not affected by disease 
states such as obesity and diabetes (Vilsboll et al., 2003). The half-life of active GIP in 
the blood is similarly short (about 2 minutes in rodents and about 5 minutes in healthy 
people) (Baggio and Drucker, 2007). As mentioned before, active GIP is not a substrate 
of NEP and its concentrations are therefore exclusively affected by DPP-4 (in contrast to 
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GLP-1). Like GLP-1, GIP is also cleared in the kidneys. In contrast to active GLP-1, the 
kidneys are a major degradation site for active GIP (at least in pigs) and thus, more 
active GIP escapes the portal system and can have systemic effects (Deacon et al., 2001).  
In mice, glucose stimulates secretion of GLP-1 while oleic acid and whey protein 
increase the concentrations of active GLP-1 by inhibiting DPP-4 but not by stimulating 
secretion (Gunnarsson et al., 2006). Such modulation of DPP-4 activity has not been 
described in other species to date. 
As mentioned above, GLP-1 (9-36) amide is considered the inactive degradation 
product of the active GLP-1 (7-36) amide. In a recent study, however, GLP-1 (9-36) 
amide was found to have a marked inhibitory effect on hepatic glucose production and 
some insulinotropic effect. These effects were much more pronounced in obese people 
than in lean (Elahi et al., 2008).  
The activity of DPP-4 in healthy cats has been indirectly demonstrated in a recent 
study. Administration of a DPP-4 inhibitor to healthy cats was associated with increased 
insulin concentrations and decreased glucagon concentrations after an intravenous 
glucose challenge (Furrer et al., 2010). The half-life of active GIP and GLP-1 and the 
relative paracrine vs. endocrine effects they might have are unknown in cats. Also 
unknown is the extent of incomplete post translational processing and release of the 
inactive 1-37 and 1-36 amide peptides in intestinal and pancreatic tissue as well as the 
extent of amidation of GLP-1 (7-37) to GLP-1 (7-36) amide. All these variables need to 
be taken into account when choosing an immunological assay to detect incretin 
hormones. As mentioned before, assays that detect active GLP-1 and active GIP might 
under estimate the extent of their secretion in response to stimuli as well as some of their 
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biological effect. Also, assays that detect active GLP-1 are typically “sandwich” assays 
that use one antibody to detect the intact N-terminal side and a second antibody that 
detects the amidated C-terminal. Because the extent of amidation of GLP-1 in cats is 
unknown, such assays might significantly underestimate the concentrations of GLP-1. 
Assays that use antibodies directed against the middle region of the peptide (“side-
view”) will detect active and inactive forms, including amidated and glycine-extended 
forms. The disadvantage of “side-view” assays is their cross reactivity with the N-
terminal extended GLP-1 (1-37) and (1-36) amide. The plasma concentrations of the 
latter 2 are insignificant in other species but no data exist regarding these issues in cats 
(Deacon and Holst, 2009). 
The effects of incretin hormones in the pancreas 
The primary function of pancreatic beta cells is the secretion of insulin in 
response to changing concentrations of blood glucose. The primary functions of incretin 
hormones are stimulation of insulin biosynthesis, stimulation of glucose-dependent 
insulin secretion and regulation of beta cell mass (Baggio and Drucker, 2007). GIP and 
GLP-1 are ligands of the G protein-coupled receptors GIPR and GLP-1R, respectively. 
Both receptors are present on pancreatic beta cells. The effects of GIP and GLP-1 on the 
beta cell are similar and, for the most part, will be discussed here together. 
Activation of GLP-1R and GIPR leads to activation of adenylate cyclase and 
production of cAMP. Subsequently, cAMP stimulates insulin secretion via PKA-
dependent phosphorylation of downstream targets and PKA-independent activation of 
Epac2. The effects downstream include the following: (1) inhibition of KATP channels, 
which leads to cell membrane depolarization; (2) increases in intracellular calcium 
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caused by influx of extracellular Ca2+ through voltage-gated Ca2+ channels, activation of 
nonselective cation channels, and mobilization of intracellular Ca2+ stores; (3) increases 
in mitochondrial ATP synthesis, which lead to further membrane depolarization; (4) 
closure of voltage-dependent K+ (Kv) channels and consequent reductions in Kv 
currents, thereby preventing cell membrane repolarization; and (5) direct effects on the 
protein machinery of exocytosis (that occur distal to increases in ATP and intracellular 
Ca2+ ), including induction of docking, priming and fusion of vesicles (Baggio and 
Drucker, 2007; Kim and Egan, 2008). These effects are responsible for the potentiation 
of insulin secretion in response to an increase in blood glucose. The cAMP signal 
transduction system is also responsible for 2 other major effects in the beta cell: (1) the 
synergistic effect of incretins with glucose to promote insulin gene transcription, mRNA 
stability, and biosynthesis (2) enhancement of the glucose-sensing apparatus by 
increasing the expression of its components: GLUT-2 and glucokinase. Thus incretins 
have the potential to replenish beta cell insulin stores, prevent exhaustion of beta cell 
reserves and increase the sensitivity of beta cells to glucose (Baggio and Drucker, 2007; 
Kim and Egan, 2008). 
 The effects of GIP and GLP-1 on insulin secretion are similar and (in sub-
maximal concentrations) additive. It is suspected that their final pathway to insulin 
secretion is a common one. On a molar basis, however, GLP-1 is a more potent 
insulinotropic agent than GIP in at least 2 orders of magnitude (Kim and Egan, 2008). 
For the treatment of diabetes, expansion of beta cells mass is probably the most 
unique and exciting effect of incretins. Incretins potentiate glucose induced proliferation 
and differentiation of beta cells by activating the expression of immediate early genes 
 37 
encoding transcription factors that regulate islet cell proliferation and differentiation. 
GLP-1R agonists also promote conversion of pancreatic ductal cells of the exocrine 
pancreas into insulin-secreting, glucose-responsive endocrine-like cells (Hui et al., 
2001).  
Incretins protect beta cells from apoptosis induced by various cytotoxic agents or 
dexamethasone (Baggio and Drucker, 2007; Kim and Egan, 2008). They also prevent 
apoptosis secondary to glucolipotoxicity (Robertson et al., 2004). Interestingly, a 2-week 
infusion of GIP in diabetic rats reduced significantly beta cell apoptosis, despite severe 
down regulation of the GIPR. This might suggest that GIP has GIPR-independent effects 
on beta cells (Kim et al., 2005).  
GIPR and GLP-1R undergo rapid homologous and heterologous desensitization 
and internalization. GLP-1R desensitization has not been observed in vivo, however, 
even after long-term GLP-1R agonist administration.  
Exendin (9-39), an N-terminally truncated peptide derivative of exendin-4 (which 
will be described later), binds the GLP-1R and functions as a specific GLP-1R antagonist 
(Kim and Egan, 2008). 
GIP increases glucagon secretion. GIP receptors have been demonstrated on 
alpha cells and activation of GIPR by GIP has increased intracellular cAMP and Ca2+. 
This effect of GIP on alpha cells is typically masked during hyperglycemia when GIP-
stimulated insulin secretion decreases glucagon secretion (Kim and Egan, 2008). In 
contrast to GIP, GLP-1 inhibits glucagon secretion in a glucose-dependent manner, thus 
reducing hepatic glucose output especially in hyperglycemia. The glucagonostatic effect 
of GLP-1 is lost when blood glucose concentrations decrease below euglycemia, thus 
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minimizing the risk of severe hypoglycemia. There is controversy as to whether the 
action of GLP-1 on alpha cells is direct or indirect. GLP-1 receptors have not been 
demonstrated convincingly on alpha cells (inconsistent data using outdated techniques). 
In a recent study using in-situ hybridization and triple fluorescence in pancreata from 
mice, rats and people, GLP-1R expression was restricted to beta cells and pancreatic 
ductal cells, with no significant expression in alpha cells, delta cells (secreting 
somatostatin) or F cells (secreting pancreatic polypeptide).  Rarely, glucagon, insulin and 
GLP-1R were colocalized to the same cell and in mice only, there was minimal 
colocalization of somatostatin and GLP-1R (Tornehave et al., 2008). This study 
therefore, also calls into question the hypothesis that GLP-1 might be affecting glucagon 
secretion via somatostatin stimulation. More contradictory evidence to the direct 
glucagonostatic effect of GLP-1 in alpha cells was found in studies of a glucagonoma 
cell line transfected with GLP-1R and in isolated alpha cell cultures. In both studies, 
GLP-1 stimulated glucagon secretion mediated by an increase in cAMP, similar to the 
effect of GIP (Ding et al., 1997; Dillon et al., 2005).  
The indirect glucagonostatic effects of GLP-1 are well-established (Baggio and 
Drucker, 2007). This effect is mediated at least in part by activation of secretion from 
beta cells and a paracrine effect of insulin and amylin on glucagon secretion. The 
necessity of mediation by beta cells was recently questioned, however, when GLP-1 led 
to inhibition of glucagon secretion in a group of type 1 diabetic patients that were C-
peptide negative (Asmar et al., 2010). In that report, it was hypothesized that the 
glucagonostatic effect of GLP-1 is mediated by somatostatin, despite the recent evidence 
from Tornehave et al. (2008). 
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Extra-pancreatic effects of incretin hormones 
GIPRs are expressed on adipocytes and GIP seems to play a role as an anabolic 
regulator of fat metabolism. The anabolic effects of GIP in fat include stimulation of 
fatty acid synthesis and re-esterification, enhancement of insulin-stimulated 
incorporation of fatty acids into triglycerides, up-regulation of lipoprotein lipase 
synthesis, and reduction of glucagon-stimulated lipolysis. In rodent models of obesity, 
knockout of GIPR or chronic administration of a GIPR antagonist leads to resistance to 
diet-induced obesity and improved glucose tolerance and insulin sensitivity. In some 
studies, however, blocking GIP action was associated with decreased glucose tolerance 
(Kim and Egan, 2008). GIPR is not present in liver or muscle tissue and thus it is 
hypothesized that by blocking GIPR action, fatty acid uptake and oxidation by these 
tissues is favored, leading to increased energy expenditure and decreased fat storage in 
face of positive energy balance. 
Physiologic concentrations of GIP inhibit gastric acid secretion in dogs but only 
supra-physiologic concentrations achieve a similar response in people. This correlates 
with the fact that GIP secretion is stimulated by acid in the duodenum in dogs but not in 
people as mentioned before. GIP also inhibits GI motility in supra-physiologic 
concentrations but it does not have an effect on the rate of gastric emptying (Baggio and 
Drucker, 2007).  
GIP and its receptor are expressed in other tissues including bones, brain, heart, 
and others. Their effect in those tissues does not seem related to glucose homeostasis or 
diabetes and therefore will not be discussed here (Kim and Egan, 2008). 
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GLP-1 is a regulator of appetite, food intake and body weight. Studies in rodents 
show that GLP-1R agonists reduce short-term food intake when injected peripherally or 
directly into the CNS. Repeated injections inhibit weight gain. These effects are 
observed also in lean, obese, and diabetic people. GLP-1 crosses the blood brain barrier 
and exerts its effect on the CNS directly but it also affects it via stimulation of the vagus 
nerve in the intestines and in the portal system. Interestingly, some of the effects of 
leptin and ghrelin on food intake are believed to be mediated through GLP-1 (Kim and 
Egan, 2008). 
In contrast to GIP, GLP-1 is a potent inhibitor of gastric emptying and gastric acid 
secretion, thus it slows the entry of nutrients into the circulation and improves post-
prandial hyperglycemia in healthy as well as diabetic patients (type 1 and type 2). The 
effect of GLP-1 on the stomach is mostly mediated by the vagus nerve, but some 
evidence exists for a direct effect (Kim and Egan, 2008). 
In some experiments GLP-1 stimulated glucose incorporation into glycogen in 
muscle and liver as well as lipolysis in adipose tissue. Although GLP-1R expression is 
detected in canine muscle and adipose tissues (Sandhu et al., 1999), evidence for the 
presence of GLP-1Rs in human or rodent adipose tissue, liver, or muscle is equivocal. 
Also, the effect of GLP-1 in muscle, adipose and liver tissue is not mediated by cAMP 
generation but rather by inositol phosphoglycan generation. Interestingly, the GLP-1R 
antagonist exendin (9-39) has similar effect to GLP-1 in human and rat myocytes 
(González et al., 2005, Arnés et al., 2008). These data are inconsistent with a GLP-1R-
mediated action in muscle, adipose and liver tissues and it is hypothesized that GLP-1 
might affect these tissues via an unidentified receptor (Baggio and Drucker, 2007).  
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GLP-1 and its receptor are expressed in other tissues including thyroid C cells 
(secreting calcitonin), heart, blood vessels, and others. Their effects in those tissues do 
not seem related to glucose homeostasis or diabetes and therefore will not be discussed 
here.  
The incretin effect in diabetes and obesity 
As mentioned before, the incretin effect is blunted in type 2 DM. The secretion of 
GIP is normal or slightly reduced but its effect on the pancreas is markedly decreased. In 
contrast, GLP-1 retains its insulinotropic effects in type 2 DM (at least in 
supraphysiologic concentrations), but its secretion is decreased (Nauck et al., 1993; Toft-
Nielsen et al., 2001a, Toft-Nielsen et al., 2001b; Holst et al., 2009). Although the blunted 
incretin response clearly contributes to the glucose intolerance in diabetes, it seems to be 
a secondary process caused by diabetes. This is based on a normal incretin effect in 
glucose-tolerant first-degree relatives or twins of patients with type 2 DM on the one 
hand, and a blunted incretin effect in patients with diabetes of other types on the other 
hand (Holst et al., 2009). In disagreement with this notion, there are now data to support 
the idea that intensified treatment of diabetes, resulting in near normal blood glucose 
concentrations, leads to a partial restoration of the incretin effects of GLP-1 and GIP on 
pancreatic beta cells, but it does not restore the normal secretion of incretin hormones in 
response to a meal (Hojberg et al., 2008).  
More evidence for the role of incretins in development of diabetes is the 
involvement of the Wnt signaling pathway in diabetes. Stimulation of beta cell 
proliferation by incretins, as well as the effects of incretins on insulin biosynthesis and 
secretion, is mediated in part by PKA activation of the bipartite transcription factor beta-
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catenin/T cell transcription factor (β-cat/TCF). β-cat/TCF is also crucial in induction of 
GLP-1 biosynthesis. β-cat/TCF is the ultimate effector of the Wnt signaling pathway and 
it is encoded by the TCF7L2 gene (Jin, 2008). Polymorphisms in the TCF7L2 gene are 
strongly associated with reduced incretin action and with a strong risk of type 2 diabetes 
(Lyssenko, 2007, Pilgaard et al., 2009).  
There is some evidence that obesity contributes to attenuation of the incretin effect 
independently of diabetes although the mechanisms of this phenomenon are unknown. In 
a recent study, obesity was associated with decreased incretin effect including decreased 
beta-cell response to GLP-1 but also decreased GLP-1 secretion (Muscelli et al., 2008). 
In some studies, GLP-1 secretion was normal in obese people but GIP secretion was 
increased during fasting and early after a meal (Vilsbøll et al., 2005, Salera et al., 1982). 
In contrast, one study showed decreased GLP-1 secretion in response to oral 
carbohydrate but normal secretion in response to oral fat in obese patients (Ranganath et 
al., 1996). In obese mice, an increased amount of dietary fat not only increased the 
concentration of GIP in plasma and in the intestine but, interestingly, it enhanced 
intestinal K cell density in upper jejunum (Bailey et al., 1986). In another study, insulin 
resistant mice on a high fat diet had an exaggerated response to oral glucose with an 
increased incretin effect. The exaggerated effect was at least partially mediated by an 
increased sensitivity to GLP-1 (Ahren et al., 2008). In contrast, in healthy people, 
feeding a high fat diet increased the GIP response to glucose but the incretin effect on the 
pancreas was not exaggerated (Morgan et al., 1988). 
Insulin resistance in itself, regardless of obesity or diabetes, has been associated 
with abnormal secretion of GIP and GLP-1 (Rask et al., 2001). Increased insulin 
 43 
concentrations in the insulin-resistant subjects might down-regulate incretin secretion 
(Rask et al., 2001). Decreased incretin secretion might be the limiting factor on 
appropriate compensatory responses of pancreatic beta cells to insulin resistance, leading 
to an insufficient increase in insulin secretion and development of glucose intolerance in 
early diabetes. The possibility that abnormalities in GLP-1 and GIP secretion do not 
necessarily result from obesity, but rather contribute to its development, should also be 
considered because of their roles in appetite control (GLP-1) and increasing insulin 
sensitivity in adipose tissue (GIP) (Kieffer, 2003). 
In cats, glucose-stimulated GLP-1 plasma concentrations were higher in lean vs. 
obese cats (Hoenig et al., 2010). After gastric glucose administration, GLP-1 
concentrations did not return to baseline within 5 hours in lean cats but they did return to 
baseline in obese cats within 3 hours. GLP-1 concentrations were also a lot more 
variable in lean compared to obese in that study (Hoenig et al., 2010). These data might 
suggest that in cats, as previously shown in people, GLP-1 secretion is down-regulated 
by insulin resistance. The effect of diet however, was not controlled in that study. Cats 
were maintained on different diet regimens in order to maintain their lean or obese states. 
Also, GLP-1 secretion could not be assessed accurately in that study because a GLP-1 
(7-36) amide ELISA was used. As discussed above, the fraction of GLP-1 (7-36) amide 
out of the total GLP-1 is unknown in cats and its measurement might significantly 
underestimate the total amount of GLP-1 that was secreted. It is also unknown whether 
obesity and/or diet affect the rate of conversion to of GLP-1 (7-37) to GLP-1 (7-36) 
amide or the action of DPP-4 and the rate of degradation to (9-36) amide and (9-37) (as 
described previously in mice). Thus it is possible that the stimulating effects of glucose 
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on GLP-1 secretion in cats are not at all different in obese vs. lean cats and that diet, or 
obesity or a related factor contribute to different processing of GLP-1 in lean vs. obese 
cats. Another limitation of that study was the use of benzamidine as an inhibitor of DPP-
4 in the collected samples. Specific DPP-4 inhibitors are available and are recommended 
by the manufacturer of the ELISA used in that study. Benzamidine is not one of those 
recommended inhibitors and therefore it might not be fully effective. GLP-1 (7-36) 
amide supposedly has a very short half-life in cats (in other species the activity of DPP-4 
in plasma results in a half-life of 1-2 minutes). In the absence of a potent DPP-4 
inhibitor, small variations in sample collection might result in large variations in 
concentrations of the measured peptide (e.g. a sample that was drawn over 10 seconds 
and then placed on ice might have significantly more active GLP-1 than a sample that 
was drawn over 60 seconds and then placed on ice). Such variations in collection times 
are not uncommon when working with cats. 
 
Incretin-based therapies for diabetes 
Treatment strategies using the incretin effect – Exenatide 
The peptide exendin-4 was first isolated from the poisonous venom of the Gila 
Monster (Heloderma suspectum) (Chia and Egan, 2008; Holst et al., 2009). Exendin-4 is 
a 39-amino acid peptide that shares only a 53% sequence homology with GLP-1 but its 
affinity for the GLP-1 receptor is 1000 times greater than the affinity of GLP-1. Unlike 
GLP-1, exendin-4 is not a substrate for DPP-4 and NEP (Chia and Egan, 2008; Holst et 
al., 2009). Exenatide is a synthetic exendin-4. Resistant to degradation, exenatide is 
eliminated by the kidneys and has a half-life of 3-4 hours in people. Its biological effect 
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lasts about 8 hours after subcutaneous injection and it can be detected in the plasma for 
up to 15 hours (Kolterman et al., 2005). Multiple studies, both in vitro and in vivo, have 
shown that, in general, exendin-4 has the same physiologic effects as GLP-1 in the 
pancreas, GI tract, and brain (Kim and Egan, 2008). Exenatide lowers blood glucose 
through multiple mechanisms, including enhancement of glucose-dependent insulin 
secretion, suppression of excess glucagon secretion, reduction of food intake, and 
slowing of gastric emptying. Exenatide is associated with improvement in some of the 
earliest and most fundamental abnormalities of type 2 diabetes: diminished “first-phase 
insulin response” and proinsulin/insulin ratio. Acute administration of exenatide in type 
2 diabetic patients corrects the abnormal insulin secretion pattern after an IV glucose 
bolus (first phase and second phase insulin responses) and restores the ability of beta 
cells to respond to rapid changes in blood glucose concentrations (Fehse et al., 2005). 
Exenatide also improves proinsulin/insulin ratio after 30 weeks of treatment (DeFronzo 
et al., 2005). Exenatide has been shown to be as effective as insulin glargine in the 
treatment of DM but with less side effects (e.g. hypoglycemia and weight gain) (Heine et 
al., 2005; Barnett et al., 2007; Glass et al., 2008). In a 2-year follow-up of patients 
receiving exenatide, patients achieved sustained and significant reductions in 
glycosylated hemoglobin, accompanied by significant weight loss (instead of weight 
gain commonly seen in diabetics receiving insulin) and improvement in serum liver 
enzyme activity and blood pressure. Most importantly, treatment with exenatide 
improved beta cell function as measured by homeostasis model assessment of beta cell 
function (HOMA-B) (Buse et al., 2007). Exenatide has also been used recently to 
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improve the survival and function of transplanted pancreatic islets in type 1 DM 
(Ghofaili et al., 2007). 
Exenatide has minimal side effects in people. It is mostly associated with nausea 
and less frequently with vomiting. Infrequently, it might cause hypoglycemia. Severe 
hypoglycemia (requiring assistance) was reported rarely (only 5 of 2781 patients) and 
only in patients who also received sulfonylurea drugs. The rate of hypoglycemic events 
decreased over time. Interestingly, the risk of hypoglycemia was not different in 
exenatide vs. insulin treatment. Antibodies to exenatide developed in 67% of patients but 
this did not affect outcome and was not associated with side effects (Amori et al., 2007).  
When first discovered, exendin-4 was shown to potentiate amylase release from 
rat acinar pancreatic cells in response to other hormones such as cholecystokinin. This 
was shown ex vivo and in high doses. Although exendin-4 was implicated as a cause of 
pancreatitis in one case report, a cause and effect has not been proven and exenatide is 
still considered a safe drug (Malhotra et al., 1992; Dimarco and Denker, 2006; Amori et 
al., 2007; Holst et al., 2009). 
Recently, a study in rats revealed an unexpected consequence of acute exendin-4 
administration (Perez-Tilve et al., 2010).  Exendin-4, whether administered into the 
circulation or into the CNS, caused stimulation of the sympathetic nervous system, 
leading to hyperglycemia. This effect was independent of the glucose-dependent 
insulinotropic effect of exendin-4 and it waned with more chronic administration (after 6 
days).  
  Exenatide is a peptide and thus it has to be injected to retain efficacy. A long-
acting sustained-release formulation of exenatide has recently been described. It consists 
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of injectable microspheres of exenatide and poly(D,L-lactic-co-glycolic acid), a common 
biodegradable medical polymer with established use in absorbable sutures and extended-
release pharmaceuticals, that allows gradual drug delivery at controlled rates. This drug 
is administered in people subcutaneously once weekly. It has been shown in a recent 
clinical study to be more effective than twice-a-day exenatide in achieving glycemic 
control with no increased risk of hypoglycemia and with similar reductions in body 
weight (Drucker et al., 2008; Buse et al., 2010). If this drug can be used in cats as 
effectively, it will revolutionize the treatment of feline diabetes. Studies of exenatide in 
cats have not been reported to date. 
 
Treatment strategies using the incretin effect – Other GLP-1 analogs, and DPP-4 
inhibitors  
GLP-1 analogs: 
Liraglutide is a human GLP-1 synthetic analog with 2 amino acid substitutions 
and a fatty acid acyl group that enables noncovalent binding to albumin, thereby 
extending the pharmacokinetic profile of the GLP-1 molecule. Liraglutide exhibits a 
prolonged pharmacokinetic profile after a single injection, and exhibits all of the actions 
of native GLP-1 (Baggio and Drucker, 2007). Liraglutide (once-a-day) was recently 
compared to exenatide (twice-a-day). Liraglutide provided significantly greater 
improvements in glycemic control than did exenatide and was generally better tolerated 
(Buse et al., 2009). Liraglutide has been used successfully to treat obesity in non-diabetic 
patients (Astrup et al., 2009). 
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Albugon (Naliglutide) is a recombinant GLP-1-albumin protein that exhibits a 
reduced affinity for the GLP-1R, but displays a broad spectrum of GLP-1R-dependent 
actions in preclinical studies, including inhibition of food intake and gastric emptying 
and reduction of glycemia excursion after meal ingestion (Baggio et al., 2004). 
DPP-4 inhibitors (e.g. sitagliptin, vildagliptin) are administered orally. 
Vildagliptin and sitagliptin are well-tolerated and not associated with hypoglycemia 
when used alone. Both agents increase plasma concentrations of GLP-1 and GIP after 
meal ingestion, enhance glucose-stimulated insulin secretion and reduce ratios of 
proinsulin:insulin, consistent with an improvement in beta cell function. They are, 
however, less potent than other oral hypoglycemic drugs (Baggio and Drucker, 2007). In 
contrast to GLP-1 analogs, DPP-4 inhibitors are not associated with nausea or vomiting 
but they are associated with weight gain. DPP-4 inhibitors are also associated with 
increased risk of nasopharyngitis, urinary tract infections and headaches (Amori et al., 
2007). Increased risk of infections might be related to the action of DPP-4 in T-cells as a 
co-stimulatory molecule (CD26). 
As mentioned before, a DPP-4 inhibitor has been used experimentally in cats and 
was effective in enhancing insulin secretion and inhibiting glucagon secretion after an 
intravenous glucose challenge. Glucagon inhibition was also observed after a meal 
challenge (Furrer et al., 2010). In that study, the drug was administered subcutaneously 
and not orally. 
 
 49 
List of References 
Adachi T, Yanaka H, Kanai H, et al. Administration of perilla oil coated with Calshell 
increases glucagon-like peptide secretion. Biol Pharm Bull. 2008;31:1021-3. 
 
Ahren B, Taborsky GJ. Beta-Cell Function and Insulin Secretion. In:  Porte DJ, Sherwin 
RS, Baron A, eds. Ellenberg & Rifkin’s Diabetis Mellitus., 6 ed, The McGrew-Hill 
Companies Inc.; 2003. pp.43-66. 
 
Ahrén B, Winzell MS, Pacini G. The augmenting effect on insulin secretion by oral 
versus intravenous glucose is exaggerated by high-fat diet in mice. J Endocrinol. 
2008;197:181-7. 
 
Akalin S, Berntorp K, Ceriello A, et al. Intensive glucose therapy and clinical 
implications of recent data: a consensus statement from the Global Task Force on 
Glycaemic Control. Int J Clin Pract. 2009;63:1421-5. 
 
Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: 
systematic review and meta-analysis. J Am Med Assoc. 2007;298:194-206. 
 
Appleton DJ, Rand JS, Sunvold GD. Insulin sensitivity decreases with obesity, and lean 
cats with low insulin sensitivity are at greatest risk of glucose intolerance with weight 
gain. J Feline Med Surg. 2001;3:211-28. 
 
 50 
Arnés L, González N, Tornero-Esteban P, et al. Characteristics of GLP-1 and exendins 
action upon glucose transport and metabolism in type 2 diabetic rat skeletal muscle. Int J 
Mol Med. 2008;22:127-32 
 
Asmar M, Bache M, Knop FK, et al. Do the Actions of Glucagon-Like Peptide-1 on 
Gastric Emptying, Appetite, and Food Intake Involve Release of Amylin in Humans? J 
Clin Endocrinol Metab. 2010 Mar 1. [Epub ahead of print] 
 
Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: 
a randomised, double-blind, placebo-controlled study. Lancet. 2009;374:1606-16. 
 
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 
2007;132:2131-57.  
 
Baggio LL, Huang Q, Brown TJ, et al. A recombinant human glucagon-like peptide 
(GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-
dependent pathways coupled with satiety, gastrointestinal motility, and glucose 
homeostasis. Diabetes. 2004;53:2492–500. 
 
Bailey CJ, Flatt PR, Kwasowski P, et al. Immunoreactive gastric inhibitory polypeptide 
and K cell hyperplasia in obese hyperglycaemic (ob/ob) mice fed high fat and high 
carbohydrate cafeteria diets. Acta Endocrinol (Copenh). 1986;112:224-9. 
 
 51 
Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated 
insulin glargine in adult patients with type 2 diabetes previously uncontrolled with 
metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, 
crossover noninferiority trial. Clin Ther. 2007;29:2333-48. 
 
Beglinger S, Drewe J, Schirra J, et al. Role of fat hydrolysis in regulating glucagon-like 
Peptide-1 secretion. J Clin Endocrinol Metab. 2010;95:879-86. 
 
Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of 
glucagon and two related peptides. Nature. 1983;302:716-8. 
 
Bennett N, Greco DS, Peterson ME, et al. Comparison of a low carbohydrate-low fiber 
diet and a moderate carbohydrate-high fiber diet in the management of feline diabetes 
mellitus. J Feline Med Surg. 2006;8:73-84. 
 
Beysen C, Karpe F, Fielding BA, et al. Interaction between specific fatty acids, GLP-1 
and insulin secretion in humans. Diabetologia. 2002;45:1533-41. 
 
Biourge V, Nelson RW, Feldman EC, et al. Effect of weight gain and subsequent weight 
loss on glucose tolerance and insulin response in healthy cats. J Vet Intern Med. 
1997;11:86-91 
 52 
Brunner GA, Hirschberger S, Sendlhofer G, et al. Post-prandial administration of the 
insulin analogue insulin aspart in patients with Type 1 diabetes mellitus. Diabet Med. 
2000;17:371-5. 
 
Buse JB, Drucker DJ, Taylor KL, et al. DURATION-1: Exenatide Once Weekly 
Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks. Diabetes Care. 
2010 Mar 9 [epub ahead of print]. 
 
Buse JB, Klonoff DC, Nielsen LL, et al. Effects of two years of exenatide treatment on 
diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim 
analysis of data from the open-label, uncontrolled extension of three double-blind, 
placebo-controlled trials. Clin Ther. 2007;29:139-53. 
 
Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a 
day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label 
trial (LEAD-6). Lancet. 2009;374:39-47. 
 
Chia CW, Egan JM. Incretin-based therapies in type 2 diabetes mellitus. J Clin 
Endocrinol Metab. 2008;93:3703-16. 
 
Choe C, Edelman S. New therapeutic options for treating type-2 diabetes: a review of 
insulin analogs and premixed insulin analogs. J Natl Med Assoc. 2007;99:357-60, 363-7. 
 
 53 
Colhoun HM. Use of insulin glargine and cancer incidence in Scotland: a study from the 
Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009;52:1755-
65. 
 
Damholt AB, Kofod H, Buchan AM. Immunocytochemical evidence for a paracrine 
interaction between GIP and GLP-1-producing cells in canine small intestine. Cell 
Tissue Res. 1999;298:287-93. 
 
Danne T, Datz N, Endahl L, et al. Insulin detemir is characterized by a more 
reproducible pharmacokinetic profile than insulin glargine in children and adolescents 
with type 1 diabetes: results from a randomized, double-blind, controlled trial. Pediatr 
Diabetes. 2008;9:554-60. 
 
Deacon CF. What do we know about the secretion and degradation of incretin 
hormones? Regul Pept. 2005;128:117-24. 
 
Deacon CF, Danielsen P, Klarskov L, et al. Dipeptidyl peptidase IV inhibition reduces 
the degradation and clearance of GIP and potentiates its insulinotropic and 
antihyperglycemic effects in anesthetized pigs. Diabetes. 2001;50:1588–97. 
 
Deacon CF, Holst JJ. Immunoassays for the incretin hormones GIP and GLP-1. Best 
Pract Res Clin Endocrinol Metab. 2009;23:425-32 
 
 54 
DeFronzo RA, Ratner RE, Han J et al. Effects of exenatide (exendin-4) on glycemic 
control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. 
Diabetes Care. 2005;28:1092-100. 
 
Dillon JS, Lu M, Bowen S, et al. The recombinant rat glucagon-like peptide-1 receptor, 
expressed in an alpha cell line, is coupled to adenylyl cyclase activation and intracellular 
calcium release. Exp Clin Endocrinol Diabetes. 2005;113:182-9. 
 
Dimarco PE. Denker PS. Exenatide (exendin-4)-induced pancreatitis: a case report. 
Diabetes Care. 2006;29:471. 
 
Ding WG, Renstrom E, Rorsman P, et al. Glucagon-like peptide I and glucose-dependent 
insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a 
protein kinase A-mediated mechanism. Diabetes. 1997;46:792–800. 
 
Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the 
treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet. 
2008; 372:1240–50. 
 
Eissele R, Göke R, Willemer S, et al. Glucagon-like peptide-1 cells in the 




Elahi D, Egan JM, Shannon RP, et al. GLP-1 (9-36) amide, cleavage product of GLP-1 
(7-36) amide, is a glucoregulatory peptide. Obesity (Silver Spring). 2008;16:1501-9.  
 
Elliott RM, Morgan LM, Tredger JA, et al. Glucagon-like peptide-1 (7-36)amide and 
glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion 
in man: acute post-prandial and 24-h secretion patterns. J Endocrinol. 1993;138:159-66. 
 
Ellmerer M, Hamilton-Wessler M, Kim SP, et al. Mechanism of action in dogs of slow-
acting insulin analog O346. J Clin Endocrinol Metab. 2003;88:2256-62. 
Fakhoury W, Lockhart I, Kotchie RW, et al. Indirect comparison of once daily insulin 
detemir and glargine in reducing weight gain and hypoglycaemic episodes when 
administered in addition to conventional oral anti-diabetic therapy in patients with type-2 
diabetes. Pharmacology. 2008;82:156-163. 
 
Fehse F, Trautmann M, Holst JJ. Exenatide augments first- and second-phase insulin 
secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin 
Endocrinol Metab. 2005;90:5991-7.  
 
Fujita Y, Chui JW, King DS et al. Pax6 and Pdx1 are required for production of glucose-
dependent insulinotropic polypeptide in proglucagon-expressing L cells. Am J Physiol 
Endocrinol Metab. 2008;295:E648-57.  
 
 56 
Furrer D, Kaufmann K, Tschuor F, et al. The dipeptidyl peptidase IV inhibitor NVP-
DPP728 reduces plasma glucagon concentration in cats. Vet J. 2010;183:355-7. 
 
Genuth S. Insights from the diabetes control and complications trial/epidemiology of 
diabetes interventions and complications study on the use of intensive glycemic 
treatment to reduce the risk of complications of type 1 diabetes. Endocr Pract. 2006;12 
Suppl 1:34-41. 
 
Ghofaili KA, Fung M, Ao Z, et al. Effect of exenatide on beta cell function after islet 
transplantation in type 1 diabetes. Transplantation. 2007;83:24-8. 
 
Gilor C, Keel T, Attermeier KJ, et al. Hyperinsulinemic-euglycemic clamps using insulin 
detemir and insulin glargine in healthy cats (Abstract). J Vet Intern Med. 2008;22:729. 
 
Gilor C, Ridge TK, Attermeier KJ, et al. Pharmacodynamics of insulin detemir and 
insulin glargine assessed using an isoglycemic clamp method in healthy cats. J Vet Intern 
Med. 2010. In press. 
 
Glass LC, Qu Y, Lenox S, et al. Effects of exenatide versus insulin analogues on weight 




González N, Acitores A, Sancho V, et al. Effect of GLP-1 on glucose transport and its 
cell signalling in human myocytes. Regul Pept. 2005;126:203-11 
 
Gribble FM, Williams L, Simpson AK, et al. A novel glucose-sensing mechanism 
contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes. 
2003;52:1147-54. 
 
Gunnarsson PT, Winzell MS, Deacon CF, et al. Glucose-induced incretin hormone 
release and inactivation are differently modulated by oral fat and protein in mice. 
Endocrinology. 2006;147:3173-80. 
Hall TD, Mahony O, Rozanski EA, et al. Effects of diet on glucose control in cats with 
diabetes mellitus treated with twice daily insulin glargine. J Feline Med Surg. 
2009;11:125-30. 
 
Hamilton-Wessler M, Ader M, Dea M, et al. Mechanism of protracted metabolic effects 
of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin. 
Diabetologia. 1999;42:1254-63. 
 
Hansen L, Deacon CF, Orskov C, et al. Glucagon-like peptide-1-(7-36)amide is 
transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the 




Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin detemir, a 
long-acting, acylated analog of human insulin. Pharm Res. 2004;21:1498-1504. 
 
Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with 
suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 
2005;143:559-69.  
 
Heinemann L, Anderson JH, Jr. Measurement of insulin absorption and insulin action. 
Diabetes Technol Ther. 2004;6:698-718. 
 
Heinrich G, Gros P, Lund PK, et al. Pre-proglucagon messenger ribonucleic acid: 
nucleotide and encoded amino acid sequences of the rat pancreatic complementary 
deoxyribonucleic acid. Endocrinology. 1984;115:2176-81. 
 
Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An 
assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes 
Metab. 2007;9:648-59. 
 
Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes 




Henson MS, O'Brien TD. Feline models of type 2 diabetes mellitus. ILAR J. 
2006;47:234-42. 
 
Herrmann C, Göke R, Richter G, et al. Glucagon-like peptide-1 and glucose-dependent 
insulin-releasing polypeptide plasma levels in response to nutrients. Digestion. 
1995;56:117-26. 
 
Hermansen K, Davies M. Does insulin detemir have a role in reducing risk of insulin-
associated weight gain? Diabetes Obes Metab. 2007;9:209-17. 
 
Hoenig M, Alexander S, Holson J, et al. Influence of glucose dosage on interpretation of 
intravenous glucose tolerance tests in lean and obese cats. J Vet Intern Med 
2002;16:529-32. 
 
Hoenig M, Caffall ZF, McGraw RA, et al. Cloning, expression and purification of feline 
proinsulin. Domest Anim Endocrinol. 2006;30:28-37. 
 
Hoenig M, Jordan ET, Ferguson DC, et al. Oral glucose leads to a differential response 
in glucose, insulin, and GLP-1 in lean versus obese cats. Domest Anim Endocrinol. 
2010;38:95-102. 
 
Højberg PV, Vilsbøll T, Zander M, et al. Four weeks of near-normalization of blood 
glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic 
 60 
B-cell responsiveness to a meal in patients with Type 2 diabetes. Diabet Med. 
2008;25:1268-75. 
 
Holst JJ, Vilsbøll T, Deacon CF. The incretin system and its role in type 2 diabetes 
mellitus. Mol Cell Endocrinol. 2009;297:127-36. 
 
Home PD, Lagarenne P. Combined randomised controlled trial experience of 
malignancies in studies using insulin glargine. Diabetologia. 2009;52:2499-506. 
 
Hordern SV, Wright JE, Umpleby AM, et al. Comparison of the effects on glucose and 
lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h 
euglycaemic clamp. Diabetologia. 2005;48:420-6. 
 
Horvath K, Bock G, Regittnig W, et al. Insulin glulisine, insulin lispro and regular 
human insulin show comparable end-organ metabolic effects: an exploratory study. 
Diabetes Obes Metab. 2008;10:484-91. 
 
http://diabetes.niddk.nih.gov/DM/PUBS/statistics/#allages (accessed March 20, 2010). 
 
Hui H, Wright C, Perfetti R. Glucagon-like peptide 1 induces differentiation of islet 




Inzucchi SE. Classification and Diagnosis of Diabetes Mellitus. In:  Porte DJ, Sherwin 
RS, Baron A, eds. Ellenberg & Rifkin’s Diabetis Mellitus., 6 ed, The McGrew-Hill 
Companies Inc.; 2003. pp. 265-76. 
 
Ipp E, Sinai Y, Bar-Oz B, et al. Somatostatin impairs clearance of exogenous insulin in 
humans. Diabetes. 1987;36:673-7. 
 
Jang HJ, Kokrashvili Z, Theodorakis MJ, et al. Gut-expressed gustducin and taste 
receptors regulate secretion of glucagon-like peptide-1. Proc Natl Acad Sci U S A. 
2007;104:15069-74.  
 
Jin T. The WNT signalling pathway and diabetes mellitus Diabetologia. 2008;51:1771-
80 
 
Kahn SE and Porte DJ. The Pathophysiology and Genetics of Type 2 Diabetes Mellitus. 
In:  Porte DJ, Sherwin RS, Baron A, eds. Ellenberg & Rifkin’s Diabetis Mellitus., 6 ed, 
The McGrew-Hill Companies Inc.; 2003. pp. 331-67. 
 
Kauth T, Metz J. Immunohistochemical localization of glucagon-like peptide 1. Use of 
poly- and monoclonal antibodies. Histochemistry. 1987;86:509-15. 
 
Kieffer TJ. GIP or not GIP? That is the question. Trends Pharmacol Sci. 2003;24:110-2.  
 
 62 
Kim SJ, Winter K, Nian C, et al. Glucose-dependent insulinotropic polypeptide (GIP) 
stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-
kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead 
transcription factor Foxo1, and down-regulation of bax expression. J Biol Chem. 
2005;280:22297-307.  
 
Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. 
Pharmacol Rev. 2008;60:470-512.  
Klein O, Lynge J, Endahl L, et al. Albumin-bound basal insulin analogues (insulin 
detemir and NN344): comparable time-action profiles but less variability than insulin 
glargine in type 2 diabetes. Diabetes Obes Metab. 2007;9:290-9. 
 
Kley S, Caffall Z, Tittle E, et al. Development of a feline proinsulin immunoradiometric 
assay and a feline proinsulin enzyme-linked immunosorbent assay (ELISA): a novel 
application to examine beta cell function in cats. Domest Anim Endocrinol. 
2008;34:311-8. 
 
Kohn WD, Micanovic R, Myers SL, et al. pI-shifted insulin analogs with extended in 
vivo time action and favorable receptor selectivity. Peptides. 2007;28:935-48. 
 
Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and 
safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 
2005;62:173-81. 
 63 
Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of receptor binding and 
metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 
2000;49:999-1005. 
 
Larsen PJ, Holst JJ. Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. 
Regul Pept. 2005;128:97-107. 
 
Larsson LI, Moody AJ. Glicentin and gastric inhibitory polypeptide immunoreactivity in 
endocrine cells of the gut and pancreas. J Histochem Cytochem. 1980;28:925-33. 
 
Lederer R, Rand JS, Jonsson NN, et al. Frequency of feline diabetes mellitus and breed 
predisposition in domestic cats in Australia. Vet J. 2009;179:254-8. 
 
Li X, Li W, Wang H, et al. Cats lack a sweet taste receptor. J Nutr. 2006;136:1932S-34S.  
 
Lopez LC, Frazier ML, Su CJ, et al. Mammalian pancreatic preproglucagon contains 
three glucagon-related peptides. Proc Natl Acad Sci U S A. 1983;80:5485-9. 
 
Lund EM, Armstrong PJ, Kirk CA, et al. Prevalence and Risk Factors for Obesity in 




Lyssenko V. The transcription factor 7-like 2 gene and increased risk of type 2 diabetes: 
an update. Curr Opin Clin Nutr Metab Care. 2008;11:385-92. 
 
Malhotra R, Singh L, Eng J, et al. Exendin-4, a new peptide from Heloderma suspectum 
venom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini. 
Regul Pept. 1992;41:149-56. 
 
Marshall RD, Rand JS, Morton JM. Glargine and protamine zinc insulin have a longer 
duration of action and result in lower mean daily glucose concentrations than lente 
insulin in healthy cats. J Vet Pharmacol Ther. 2008;31:205-212. 
 
Marshall RD, Rand JS, Morton JM. Treatment of newly diagnosed diabetic cats with 
glargine insulin improves glycaemic control and results in higher probability of 
remission than protamine zinc and lente insulins. J Feline Med Surg. 2009;11:683-91. 
 
Mannucci E, Monami M, Marchionni N. Short-acting insulin analogues vs. regular 
human insulin in type 2 diabetes: a meta-analysis. Diabetes Obes Metab. 2009;11:53-59. 
 
Matsuo Y, Shimoda S, Sakakida M, et al. Strict glycemic control in diabetic dogs with 
closed-loop intraperitoneal insulin infusion algorithm designed for an artificial endocrine 
pancreas. J Artif Organs. 2003;6:55-63. 
 
 65 
McIntyre N, Holdsworth CD, Turner DS. Intestinal factors in the control of insulin 
secretion. J Clin Endocrinol Metab. 1965;25:1317-24. 
 
Miyauchi S, Hirasawa A, Ichimura A, et al. New frontiers in gut nutrient sensor research: 
free fatty acid sensing in the gastrointestinal tract. J Pharmacol Sci. 2010;112:19-24. 
 
Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH 
human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2008;81:184-
189. 
 
Morgan LM, Hampton SM, Tredger JA, et al. Modifications of gastric inhibitory 
polypeptide (GIP) secretion in man by a high-fat diet. Br J Nutr. 1988;59:373-80. 
 
Mori A, Sako T, Lee P, et al. Comparison of time-action profiles of insulin glargine and 
NPH insulin in normal and diabetic dogs. Vet Res Commun. 2008;32:563-73. 
 
Mori A, Sako T, Lee P, et al. Comparison of three commercially available prescription 
diet regimens on short-term post-prandial serum glucose and insulin concentrations in 
healthy cats. Vet Res Commun. 2009;33:669-80. 
 
Morishita M, Tanaka T, Shida T, et al. Usefulness of colon targeted DHA and EPA as 
novel diabetes medications that promote intrinsic GLP-1 secretion. J Control Release. 
2008;132:99-104. 
 66 
Mortensen K, Christensen LL, Holst JJ, et al. GLP-1 and GIP are colocalized in a subset 
of endocrine cells in the small intestine. Regul Pept. 2003;114:189–196. 
 
Mortensen K, Petersen LL, Orskov C. Colocalization of GLP-1 and GIP in human and 
porcine intestine. Ann NY Acad Sci. 2000;921:469–72. 
Muscelli, E., Mari, A., Casolaro, A, et al. Separate impact of obesity and glucose 
tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 
2008;57:1340-8. 
 
Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like 
peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in 
patients with type-2 diabetes mellitus. J Clin Invest. 1993;91:301-7. 
 
Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads 
in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol 
Metab. 1986;63:492-8. 
 
Nakayama H, Uchida K, Ono K, et al. Pathological observation of six cases of feline 
diabetes mellitus. Nippon Juigaku Zasshi. 1990;52:819-22.  
 
Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and 
cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-
53. 
 67 
Nelson RW. Diabetes Mellitus. In:  Ettinger SJ, Feldman EC, eds. Textbook of 
Veterinary Internal Medicine - Diseases of the Dog and Cat, 6 ed. Philadelphia: WB 
Saunders Co. 2005. pp. 1563-91. 
 
Nelson RW, Himsel CA, Feldman EC, et al. Glucose tolerance and insulin response in 
normal-weight and obese cats. Am J Vet Res. 1990;51:1357-62. 
 
Orskov C, Bersani M, Johnsen AH, et al. Complete sequences of glucagon-like peptide-1 
from human and pig small intestine. J Biol Chem. 1989;264:12826-9. 
 
Orskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of glucagonlike 
peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are 
indistinguishable. Diabetes. 1993;42:658-61. 
 
Overton HA, Fyfe MC, Reynet C. GPR119, a novel G protein-coupled receptor target for 
the treatment of type 2 diabetes and obesity. Br J Pharmacol. 2008;153:S76-81. 
 
Owens DR, Bolli GB. Beyond the era of NPH insulin--long-acting insulin analogs: 
chemistry, comparative pharmacology, and clinical application. Diabetes Technol Ther. 
2008;10:333-49. 
 
Panciera DL, Thomas CB, Eicker SW, et al. Epizootiologic patterns of diabetes mellitus 
in cats: 333 cases (1980-1986). J Am Vet Med Assoc. 1990;197:1504-8. 
 68 
Parker HE, Habib AM, Rogers GJ, et al. Nutrient-dependent secretion of glucose-
dependent insulinotropic polypeptide from primary murine K cells. 
Diabetologia. 2009;52:289-98. 
 
Paxton R, Ye LX. Purification and characterization of a feline hepatic insulin receptor. 
Am J Vet Res. 2000;61:1625-32. 
 
Pederson RA, Schubert HE, Brown JC. Gastric inhibitory polypeptide. Its physiologic 
release and insulinotropic action in the dog. Diabetes. 1975;24:1050-6. 
 
Perez-Tilve D, González-Matías LC, Aulinger BA, et al. Exendin-4 increases blood 
glucose levels acutely in rats by activation of the sympathetic nervous system. Am J 
Physiol Endocrinol Metab. 2010 Mar 2. [Epub ahead of print] 
 
Pilgaard K, Jensen CB, Schou JH, et al. The T allele of rs7903146 TCF7L2 is associated 
with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of 
plasma insulin and glucagon, and increased hepatic glucose production in young healthy 
men. Diabetologia. 2009;52:1298-307.  
 
Plum A, Agerso H, Andersen L. Pharmacokinetics of the rapid-acting insulin analog, 
insulin aspart, in rats, dogs, and pigs, and pharmacodynamics of insulin aspart in pigs. 
Drug Metab Dispos. 2000;28:155-60. 
 
 69 
Prahl A, Guptill L, Glickman NW, et al. Time trends and risk factors for diabetes 
mellitus in cats presented to veterinary teaching hospitals. J Feline Med Surg. 
2007;9:351-8.  
 
Pridal L, Ingwersen SH, Larsen FS, et al. Comparison of sandwich enzyme-linked 
immunoadsorbent assay and radioimmunoassay for determination of exogenous 
glucagon-like peptide-1(7-36)amide in plasma. J Pharm Biomed Anal. 1995;13:841-50. 
 
Rand JS, Fleeman LM, Farrow HA, et al. Canine and feline diabetes mellitus: nature or 
nurture? J Nutr. 2004;134:2072S-80S. 
 
Ranganath LR, Beety JM, Morgan LM, et al. Attenuated GLP-1 secretion in obesity: 
cause or consequence? Gut. 1996;38:916-19. 
 
Rask E, Olsson T, Soderberg S, et al. Impaired incretin response after a mixed meal is 
associated with insulin resistance in nondiabetic men. Diabetes Care. 2001;24:1640-5. 
 
Rave K, Potocka E, Boss AH, et al. Pharmacokinetics and linear exposure of AFRESA 
compared with the subcutaneous injection of regular human insulin. Diabetes Obes 
Metab. 2009;11:715-20. 
 
Reimann F, Habib AM, Tolhurst G, et al. Glucose sensing in L cells: a primary cell 
study. Cell Metab. 2008;8:532-9. 
 70 
Reimann F, Williams L, da Silva Xavier et al. Glutamine potently stimulates glucagon-
like peptide-1 secretion from GLUTag cells. Diabetologia. 2004;47:1592–601. 
 
Robertson RP, Harmon J, Tran PO, et al. Beta-cell glucose toxicity, lipotoxicity, and 
chronic oxidative stress in type 2 diabetes. Diabetes. 2004;53:S119-24. 
 
Roomp K, Rand JS. Evaluation of detemir in diabetic cats managed with a protocol for 
intensive blood glucose control (Abstract). J Vet Intern Med. 2009;23:697. 
 
Roomp K, Rand JS. Intensive blood glucose control is safe and effective in diabetic cats 
using home monitoring and treatment with glargine. J Feline Med Surg. 2009;11:668-82. 
 
Rosenstock J, Fonseca V, McGill JB, et al. Similar risk of malignancy with insulin 
glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: 
findings from a 5 year randomised, open-label study. Diabetologia. 2009;52:1971-73. 
 
Rozengurt E. Taste receptors in the gastrointestinal tract. I. Bitter taste receptors and 
alpha-gustducin in the mammalian gut. Am J Physiol Gastrointest Liver Physiol. 
2006;291:G171-7. 
 
Rouille Y, Kantengwa S, Irminger JC, et al. Role of the prohormone convertase PC3 in 
the processing of proglucagon to glucagon-like peptide 1. J Biol Chem. 1997;272:32810-
6. 
 71 
Salera M, Giacomoni P, Cornia G, et al. Gastric inhibitory polypeptide release after oral 
glucose: relationship to glucose intolerance, diabetes mellitus, and obesity. J Clin 
Endocrinol Metab. 1982;55:329-36. 
 
Sandhu H, Wiesenthal SR, MacDonald PE, et al. Glucagon-like peptide 1 increases 
insulin sensitivity in depancreatized dogs. Diabetes. 1999;48:1045-53. 
 
Scarlett JM, Donoghue S. Associations between body condition and disease in cats. J 
Am Vet Med Assoc. 1998;212:1725-31. 
 
Scarlett JM, Donoghue S, Saidla J, et al. Overweight cats: prevalence and risk factors. 
Int J Obes Relat Metab Disord. 1994;18:S22-8. 
 
Sears KW, Drobatz KJ, Hess RS. Use of lispro insulin for treatment of dogs with 
diabetic ketoacidosis (Abstract). J Vet Intern Med. 2009;23:696. 
 
Seino S, Welsh M, Bell GI, et al. Mutations in the guinea pig preproglucagon gene are 
restricted to a specific portion of the prohormone sequence. FEBS Lett. 1986;14;203:25-
30. 
 
Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular 
human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 
2006:CD003287. 
 72 
Sheldon B, Russell-Jones D, Wright J. Insulin analogues: an example of applied medical 
science. Diabetes Obes Metab. 2009;11:5-19. 
 
Shojaee-Moradie F, Eckey H, Jackson NC, et al. Novel hepatoselective insulin 
analogues: studies with covalently linked thyroxyl-insulin complexes. Diabet Med. 
1998;15:928-36. 
 
Shojaee-Moradie F, Powrie JK, Sundermann E, et al. Novel hepatoselective insulin 
analog: studies with a covalently linked thyroxyl-insulin complex in humans. Diabetes 
Care. 2000;23:1124-9. 
 
Shulman GI, Barrett EJ, Sherwin RS. Integrated Fuel Metabolism. In:  Porte DJ, Sherwin 
RS, Baron A, eds. Ellenberg & Rifkin’s Diabetis Mellitus., 6 ed, The McGrew-Hill 
Companies Inc.; 2003. pp. 1-14. 
 
Slingerland LI, Fazilova VV, Plantinga EA, et al. Indoor confinement and physical 
inactivity rather than the proportion of dry food are risk factors in the development of 
feline type 2 diabetes mellitus. Vet J. 2009;179:247-53. 
 




Soran H, Younis N. Insulin detemir: a new basal insulin analogue. Diabetes Obes Metab. 
2006;8:26-30. 
 
Sukegawa I, Hizuka N, Takano K, et al. Characterization of insulin-like growth factor I 
receptors on Madin-Darby canine kidney (MDCK) cell line. Endocrinol Jpn. 
1987;34:339-46. 
 
Swinnen SG, Holleman F, DeVries JH. The interpretation of glucose clamp studies of 
long-acting insulin analogues: from physiology to marketing and back. Diabetologia. 
2008;51:1790-5. 
 
Thomas FB, Sinar D, Mazzaferri EL et al. Selective release of gastric inhibitory 
polypeptide by intraduodenal amino acid perfusion in man. Gastroenterology. 
1978;74:1261-5. 
 
Toft-Nielsen MB, Damholt MB, Madsbad S, et al., Determinants of the impaired 
secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 
2001;86:3717-23. 
 
Toft-Nielsen MB, Madsbad S, Holst JJ. Determinants of the effectiveness of glucagon-
like peptide-1 in type 2 diabetes. J Clin Endocrinol Metab. 2001;86:3853-60. 
 
 74 
Tolan I, Ragoobirsingh D, Morrison EY. The effect of capsaicin on blood glucose, 
plasma insulin levels and insulin binding in dog models. Phytother Res. 2001;15:391-4. 
 
Tornehave D, Kristensen P, Rømer J, et al. Expression of the GLP-1 receptor in mouse, 
rat, and human pancreas. J Histochem Cytochem. 2008;56:841-51. 
 
Ugleholdt R, Poulsen ML, Holst PJ, et al. Prohormone convertase 1/3 is essential for 
processing of the glucosedependent insulinotropic polypeptide precursor. J Biol Chem. 
2006;281:11050-7. 
 
Vaillant CR, Lund PK. Distribution of glucagon-like peptide I in canine and feline 
pancreas and gastrointestinal tract. J Histochem Cytochem. 1986;34:1117-21. 
 
Vilsboll T, Agerso H, Krarup T, et al. Similar elimination rates of glucagon-like peptide-
1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab. 
2003;88:220-4. 
 
Vilsboll T, Krarup J, Sonne S, et al: Incretin secretion in relation to meal size and body 
weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin 
Endocrinol Metab. 2005;88:2706-13. 
 
Weaver KE, Rozanski EA, Mahony OM, et al. Use of glargine and lente insulins in cats 
with diabetes mellitus. J Vet Intern Med. 2006;20:234-8. 
 75 
Weinstein D, Simon M, Yehezkel E, et al. Insulin analogues display IGF-I-like 
mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev. 
2009;25:41-9. 
 
White JW, Saunders GF. Structure of the human glucagon gene. Nucleic Acids Res. 
1986;14:4719-30. 
 
Wolfe MM, Zhao KB, Glazier KD, et al. Regulation of glucose-dependent insulinotropic 
polypeptide release by protein in the rat. Am J Physiol Gastrointest Liver Physiol. 
2000;279:G561-6. 
 
Wolfsheimer KJ, Peterson ME. Erythrocyte insulin receptors in dogs with spontaneous 




PHARMACODYNAMICS OF INSULIN DETEMIR AND INSULIN  
GLARGINE ASSESSED USING AN ISOGLYCEMIC CLAMP METHOD  
IN HEALTHY CATS 
 
Abstract  
Background: Insulin detemir and insulin glargine are synthetic long-acting insulin 
analogs. In people, insulin glargine is longer acting and relatively peakless, while insulin 
detemir has significantly less within-subject variability. Insulin detemir is also associated 
with less undesired weight gain and decreased frequency of hypoglycemic events. 
Objectives: To compare the duration of action of insulin detemir and insulin glargine in 
healthy cats. 
Animals: Ten young, healthy, neutered, purpose-bred cats 
Methods: Randomized, cross-over design. Pharmacodynamics of insulin detemir and 
insulin glargine were determined using the isoglycemic clamp method following a 0.5 
U/kg subcutaneous injection.  
Results: There were no significant differences in the pharmacodynamics of insulin 
detemir and insulin glargine except for onset of action (mean onset ± SD of insulin 
detemir 1.8 ± 0.8 hours, mean onset of insulin glargine 1.3 ± 0.5 hours, P = 0.03). End of 
action of insulin detemir was reached at 13.5 ± 3.5 hours and for insulin glargine at 11.3 
± 4.5 hours. Time to peak action of insulin detemir was reached at 6.9 ± 3.1 hours and 
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for insulin glargine at 5.3 ± 3.8 hours. The time-action curves of both insulin analogs 
varied between relatively peakless curves in some cats and peaked curves in others.  
Conclusion and clinical importance: Insulin detemir and insulin glargine have shorter 
durations of action than previously reported in people when using the clamp method, but 
in some cats these insulin analogs may be useful as once-a-day drugs. Peak effects of 
both insulin analogs are pronounced in some cats.  
 
Introduction 
Type 2 diabetes mellitus is common in cats. Although diet change and oral 
medications may help initially, most diabetic cats depend on insulin therapy to survive 
(Nelson, 2005; Marshall et al., 2008a). There are some significant problems associated 
with insulin therapy. Owner compliance is a major problem because twice-a-day 
injections are required with most commonly used insulin preparations. Weight gain may 
indicate good response to therapy initially but can eventually become a problem. 
Hypoglycemia is a common complication of insulin therapy and can be life-threatening 
(Nelson, 2005). These side effects have been significantly reduced in human medicine 
with the introduction of newer insulin analogs such as insulin detemir and insulin 
glargine (Danne et al., 2008; Fakhoury et al., 2008; Monami et al., 2008). These are 
synthetic human insulin analogs that have been modified chemically to improve their 
pharmacological profiles. Insulin glargine has 2 arginine residues added to the C-
terminus of the B chain at position 30. This modification increases the tendency of the 
insulin molecules to precipitate in neutral pH, thus slowing its absorption after 
subcutaneous injection. The precipitation-deprecipitation process, however, introduces a 
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component of variability in absorption, rendering glargine relatively unpredictable in 
action (Heise and Pieber, 2007). In contrast, pharmacodynamics of insulin detemir are 
considered highly predictable in people, with minimal inter- and intra-subject variability 
(Soran and Younis, 2006; Heise and Pieber, 2007). Insulin detemir has a myristic acid 
residue (14-carbon fatty acid) replacing threonine at position B30. The protracted 
absorption after injection is caused by hydrophobic interactions between the fatty acids 
(Havelund et al., 2004). Those fatty acids also bind reversibly to albumin which buffers 
the concentration of insulin detemir in the blood and tissues, adding to its predictable 
effect. Predictable pharmacodynamics, demonstrated with insulin detemir in human 
clinical trials, are key to minimizing hypoglycemic events (Heise and Pieber, 2007; 
Danne et al., 2008; Fakhoury et al., 2008; Monami et al., 2008). The interaction of 
insulin detemir with albumin also increases the availability of insulin detemir to organs 
with fenestrated capillaries (i.e. liver), thus mimicking a more physiologic state 
compared to other subcutaneously injected insulin preperations (Hermansen and Davies, 
2007). This helps minimize undesired weight gain in diabetic people (Danne et al., 2008; 
Fakhoury et al., 2008; Monami et al., 2008). When determined by isoglycemic clamps in 
people, insulin glargine has a duration of action of over 24 hours and insulin detemir has 
a duration of action of approximately 20 hours (Heise and Pieber, 2007). Both are used 
effectively as once-daily basal insulin therapy, and are often supplemented with ultra 
short-acting insulin analogs given at meal time (Danne et al., 2008; Fakhoury et al., 
2008; Monami et al., 2008).  
In veterinary medicine, blood glucose curves have been used traditionally to study 
the pharmacodynamics of exogenous insulin. These curves, however, reflect not only the 
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effect of exogenous insulin but also the effect of endogenous insulin and stress 
hormones. Because of this major flaw, this method is not used in people. In contrast, the 
isoglycemic clamp is the gold standard for the study of pharmacodynamics of insulin in 
people (Heinemann and Anderson, 2004; Heise and Pieber, 2007). With this method, 
blood glucose concentrations are “clamped” at euglycemia or at sub-euglycemic 
concentrations by infusing glucose at a changing rate. This allows the study of the effect 
of injected insulin in a healthy subject with minimum interference of confounding factors 
such as hypoglycemia, stress hormones and endogenous insulin secretion (Heinemann 
and Anderson, 2004; Heise and Pieber, 2007). The clamp method, however, is labor 
intensive and expensive. Based on blood glucose curves, it has been reported that the 
duration of action of insulin glargine is 24 hours in some cats, but twice-a-day 
administration has been recommended because of better clinical response (Marshall et 
al., 2008a; Marshall et al., 2008b). The same studies also demonstrated large variation 
between cats in response to insulin glargine. The pharmacodynamics of insulin detemir 
are not reported in cats. The goal of our study was to compare the pharmacodynamics of 
insulin detemir and insulin glargine in healthy cats, with emphasis on end of action.  
 
Materials and Methods 
Animals: Ten young, healthy, purpose-bred cats were used in this study (6 spayed 
females and 4 neutered males). Cats were group-housed and experiments were 
performed in AAALAC-accredited facilities and all animal use was approved by the 
University of Illinois Institutional Animal Care and Use Committee. All cats were 
acclimatized and socialized for 8 weeks prior to the start of experiments, and extensive 
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environmental enrichment was provided.  This included spending at least 3 hours daily in 
a 100 sq ft play area with climbing apparatus, elevated perches, and various toys, and 2 - 
3 hours daily of interaction with people. Cats were fed commercial cat fooda and 
monitored daily by physical exams. Body weight was measured weekly. Routine 
laboratory tests (including CBC, serum chemistry panels, total T4, coagulation panels 
and urinalysis) were performed at first arrival and just prior to the first clamp experiment 
in each cat.  PCV, total solids and CBC’s were repeated prior to the second clamp 
experiment in each cat. Experiments were performed in ambient temperatures between 
19 and 22oC.  
Study design: A randomized crossover study design was used. Each cat received 2 
subcutaneous injections of 0.5 U/kg of insulin, once with insulin detemirb and once with 
insulin glarginec, on 2 different days, at least 1 week apart (and no more than 4 weeks 
apart) in random order. To maximize dosing accuracy, 0.3 ml (100 U) insulin syringes 
were used. The dose was rounded up to the nearest half unit. Insulin was injected on the 
back, midway between the scapulas. Experiments were always started between 8:00 and 
10:00 a.m. on a given day. Cats were fasted overnight for 16 hours prior to each 
experiment and remained fasted during the experiment.  
Blood samples were collected through indwelling jugular cathetersd placed under 
sedation with dexmedetomidine (0.009 mg/kg), butorphanol (0.22 mg/kg), and atropine 
(0.022mg/kg), at least one day prior to the experiment. These catheters were maintained 
by flushing heparinized saline daily.  Cephalic catheterse were placed the day before each 
experiment and removed at the end of it. These catheters were used exclusively for 
glucose infusion. For glucose infusion, a 50% dextrose solutionf was diluted with saline 
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to a 20% solution. Infusion rate was set on a syringe pump. Blood glucose concentrations 
(BG) were measured with a hand-held point-of-care glucose meter g that was validated 
for use in cats in our laboratory (range: 20 – 600 mg/dl, intra-assay CV = 2.46%, 
correlation with standard hexokinase method: r = 0.984, P < 0.0001). 
Isoglycemic clamp method: Following insulin injection, BG was maintained 
(“clamped”) at a target isoglycemic concentration for the duration of the experiment by 
infusing glucose. BG was measured every 5 minutes and then the glucose infusion rate 
(GIR) was adjusted to achieve the target BG. Baseline BG was determined by averaging 
3 - 4 BG measurements taken every 15 - 20 minutes prior to insulin injection. The target 
BG was defined as 0.9 x baseline BG. Glucose infusions were started when BG reached 
the target BG. GIR was recorded manually every 5 minutes. The insulin time-action 
curve was defined as the GIR over time. The onset of action was defined as the time 
from insulin injection (time zero) until the target BG was first reached (or first increase 
in GIR). The end of action was defined as the time from insulin injection until GIR 
stabilized back at zero. The duration of action was defined as [end of action – onset of 
action].  The graph from each clamp experiment was smoothed using computer softwarei 
[which calculates a local polynomial regression (in this case of the 4th order) on a series 
of values (in this case the adjacent 9 neighbors) to determine the smoothed value for 
each point]. The peak insulin action was defined as the highest GIR of the smoothed 
data. Time to peak was defined as the time elapsed from insulin injection until peak 
insulin action. The average time action curves for insulin detemir and insulin glargine 
were calculated from the raw data and then smoothed. The total metabolic effect was 
defined as the total amount of glucose infused throughout the clamp.  
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Statistical analysis: Statistical analysis was performed using computer software h.  
Data are reported for the entire group (N = 10) as mean ± SD unless specified otherwise. 
The Shapiro-Wilk test was used to assess deviance from normal distribution of data. The 
coefficient of variation (CV) was calculated for each parameter for each insulin group by 
dividing the standard deviation with the group mean. Homogeneity of variance was 
compared between groups using F tests. Differences in ages and body weights of males 
and females were analyzed using the Mann-Whitney test. 
Clamp quality was evaluated by calculating the coefficient of variation of BG 
during the entire clamp and by calculating the deviation of target BG from measured BG 
for each time point in all cats. The significance of the deviation from zero was assessed 
using a one-sample t-test. Pharmacodynamic parameters in the entire study population 
were normally distributed. Paired t-tests were used to compare means between treatment 
groups. For each cat, differences between detemir and glargine of a pharmacodynamic 
parameter were calculated as Xdetemir – Xglargine. Pearson’s r correlation and linear 
regression were used to assess the association between differences (in individual cats) of 
onset of action, duration of action and end of action. The Wilcoxon matched pairs test 
was used to compare means between treatment groups when the data was analyzed 
separately for males and females.  All statistical tests were performed as two-tailed tests 
and a P value < 0.05 was considered significant.  
 
Results 
There were 6 spayed females and 4 neutered males in this study. The mean age for 
the entire study population (n = 10) was 3.4 ± 0.7 years (range 1.5 – 4.5 years), mean 
 83 
BW was 5.3 ± 0.95 kg (range 3.7 – 6.9), and the median BCS was 5/9 (range 4/9 – 7/9) 
with no significant difference between males and females.  
After an over-night fast, baseline BG ranged between 67 – 97 mg/dl (mean 77.4 ± 
8.0). Target BG ranged between 60 – 79 mg/dl (mean 70.9 ± 7.0). In one cat, the baseline 
of BG of 97 mg/dl was inconsistent with previous fasting BG and the target was set at 77 
mg/dl. Mean CV of BG for the 20 clamps was 15% ± 4. There was no significant 
difference in CV of BG between insulin detemir and insulin glargine clamps (P = 0.17). 
The mean deviation of target BG from actual mean BG was 0.12 ± 3.09 mg/dl and this 
deviation did not differ significantly from zero (P = 0.85). There was no significant 
difference between insulin detemir and insulin glargine clamps in the absolute deviation 
of target BG from actual mean BG (P = 0.48). 
No side effects were seen in the injection site or systemically after any of the clamp 
experiments.  
Summary statistics of pharmacodynamic parameters are presented in table 3.1. 
There were no significant differences in the pharmacodynamic parameters of insulin 
detemir and insulin glargine between males and females and therefore the results are 
presented for the entire study population. There were no significant differences in the 
pharmacodynamic parameters of insulin detemir and insulin glargine except for onset of 
action (mean onset of insulin detemir 1.8 ± 0.8 hours, mean onset of insulin glargine 1.3 
± 0.5 hours, P = 0.03). The difference in onset of action between insulin detemir and 
insulin glargine in individual cats ranged from -0.25 to 1.4 hours. In 7 cats the onset of 
action of detemir was later than the onset of action glargine but in only 2 of them the 
difference was greater than one hour (1.3 and 1.4 hours). End of action of insulin detemir 
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was reached at 13.5 ± 3.5 hours (CV = 26.4%) and for insulin glargine at 11.3 ± 4.5 
hours (CV = 40.2%). The difference in end of action between detemir and glargine in 
individual cats ranged from -4.4 hours to 9.8 hours. In 6 cats the end of action of insulin 
detemir was longer than that of insulin glargine; those differences were 0.3, 0.5, 3.4, 7.7, 
8.4 and 9.8 hours. The differences in end of action were not related to delayed onset of 
action: The differences in duration of action were similar to the differences in end of 
action in each cat and there was no significant correlation between onset of action 
difference and end of action difference (r = - 0.22, P = 0.53) and between onset of action 
difference and duration of action difference (r = -0.34, P = 0.33). In contrast, there was a 
strong association between duration of action difference and end of action difference [r = 
0.99 (95% CI 0.97 – 1.0), R2 = 0.98, P < 0.0001, slope = 1.03 (95% CI = 0.93 – 1.13)].  
Time to peak action of insulin detemir was reached at 6.9 ± 3.1 hours (CV = 
45.3%) and for insulin glargine at 5.3 ± 3.8 hours (CV = 72.9%) (Table 3.1). The total 
metabolic effect of insulin glargine was positively correlated with duration of action [r = 
0.64 (95% CI 0.02 – 0.90), P = 0.046] with a similar trend in correlation with end of 
action [r = 0.57 (95% CI -0.09 – 0.88), P = 0.024]. The total metabolic effect of insulin 
glargine was negatively correlated with onset of action [r = - 0.80 (95% CI - 0.95 – 
-0.36), P < 0.005] but did not correlate with peak action [r = 0.26 (95% CI - 0.45 – 0.76), 
P = 0.47]. These results were consistent with an overall trend towards a peakless time-
action profile. In contrast, the total metabolic effect of insulin detemir did not correlate 
with any of these parameters. For both insulin analogs, however, the individual time-
action curves (Figure 3.1) varied between flat and peaked and the shape of the curve did 
not seem to be insulin dependent or cat dependent.   
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Discussion 
 Long-acting basal insulin analogs are designed to approximate the relatively 
constant secretion of insulin from the pancreas between meals. Physiologically, the main 
function of this basal secretion is to curb hepatic glucose output. The ideal basal insulin 
analog should replace this basal secretion but should not exceed it so that hypoglycemia 
is avoided. This hypothetical ideal insulin analog cannot be studied in healthy subjects 
by using the isoglycemic clamp method because if hypoglycemia is not induced, GIR is 
maintained at zero, and no meaningful data can be generated (Swinnen et al., 2008). This 
illustrates one limitation of the isoglycemic clamp method: Its sensitivity is determined 
by the target BG. In this study we chose a target BG that is lower than euglycemia 
because we aimed to decrease bias towards artificial prolongation of perceived insulin 
action. This artificial prolongation is a potential problem in subjects capable of 
endogenous insulin secretion (i.e. healthy and type 2 diabetics) because small deviations 
in BG towards the hyperglycemic range can induce secretion of insulin and prompt a 
further increase in GIR. When euglycemic clamps are performed to study insulin 
sensitivity, endogenous insulin secretion is suppressed by administrating somatostatin 
and insulin intravenously. Somatostatin should not be used for the study of 
pharmacodynamic parameters following subcutaneous insulin administration because it 
affects subcutaneous blood flow and insulin clearance (Ipp et al., 1987; Swinnen et al., 
2008). Artificially long duration of action is also a potential problem considering the 
effects of fasting on insulin sensitivity and BG concentration. In people, prolonged 
fasting (24 hours) causes increased insulin sensitivity and decreased BG concentration 
(Swinnen et al., 2008). This occurs even under euglycemic clamp conditions in which 
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glucose is infused over 24 hours in patients receiving placebo instead of insulin 
(Heinemann et al., 2000; Heise and Pieber, 2007; Swinnen et al., 2008). In a recent study 
in healthy cats, the duration of action of insulin glargine after a single subcutaneous 
injection at a dose of 0.5 U/kg was found to be 22 ± 1.8 hours (Marshall et al., 2008a). 
This was based, however, on the return of BG to baseline concentrations during 
prolonged fasting and without infusing glucose. The effects of prolonged fasting were 
not taken into account in that study and it is possible that the duration of action of insulin 
glargine was over-estimated. Interestingly, in the same study, insulin concentrations 
returned to baseline within 6.7 ± 1.3 hours (range 0.6 – 13 hours), suggesting either a 
prolonged after-effect of insulin, difficulty measuring insulin glargine, or an over-
estimation of the duration of action. These pharmacokinetics data are more consistent 
with our results of duration of action of insulin glargine (Table 3.1).  
 Insulin detemir and insulin glargine are used extensively in people as once-a-
day basal insulin replacement. Although insulin glargine is longer-acting in people, it is 
not clinically superior to insulin detemir (Heise and Pieber, 2007; Fakhoury et al., 2008; 
Monami et al., 2008). Insulin detemir has the advantage of decreased day-to-day 
variability within subjects (Heise and Pieber, 2007; Klein et al., 2007; Danne et al., 
2008). We found no significant differences between insulin detemir and insulin glargine 
except for longer onset of action of insulin detemir (indicating a more protracted 
absorption). The difference in onset of action was small and it did not affect the duration 
of action. In 3 of 10 cats the end of action of insulin detemir was longer by over 7 hours 
than the end of action of insulin glargine. This may suggest that, in some cats, there 
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might be a clinically relevant difference between the 2 analogs, but this is only true if the 
day-to-day effect is fairly constant. 
 Based on our results, both analogs could be useful as once-a-day drugs in some 
cats, given a median end of action of over 12 hours (Table 3.1). The combination of 
positive correlation between total metabolic effect and duration of action, together with 
lack of correlation between total metabolic effect and peak action suggests that insulin 
glargine is relatively peakless in cats. The average time-action curve (Figure 3.1K) 
suggests that both analogs are relatively peakless. Considering the individual time action 
curves, however, it is clearly not safe to assume that either insulin detemir or insulin 
glargine are long-acting and peakless in any given patient (Figure 3.1A – 3.1J). Further 
investigation of the pharmacodynamic characteristics of both analogs is needed with 
emphasis on within-subject variability.  
 Translation of the results of clamp studies in healthy subjects to diabetic 
patients is limited by 3 factors. First, as discussed before, prolonged fasting increases 
insulin sensitivity even when glucose is infused, and therefore, clamp studies might 
overestimate the duration of action of the insulin studied. Second, a single-injection 
experiment might not reflect accurately the time-action curve of a long-acting insulin 
under steady-state conditions. This is true, however, only if the time interval between 
injections is short enough to allow overlap. Given the durations of insulin glargine and 
insulin detemir in our study, they are unlikely to have much overlap in most patients, 
even if administered twice daily. Third, clamp studies are usually performed on a 
relatively small number of subjects, and they might not reflect the full range of responses 
to the studied insulin in the target population. In people, it was found that even when 
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performed in diabetic patients, clamp studies do not fully reflect the potential range of 
clinical outcomes (Swinnen et al., 2008). For example, better glycemic control was 
achieved when insulin glargine was administered twice daily compared to once daily in 
type 1 diabetics despite its reported duration of action of over 24 hours. Insulin glargine 
was also associated with more hypoglycemic events than expected from its reported 
“flat” time-action curve (for further review see Swinnen et al., 2008). Because the 
clinical usefulness of each insulin is dependent upon its within-subject variability, large 
clinical trials in diabetic patients are necessary.  In one small clinical study, once-a-day 
insulin glargine was comparable to twice-a-day NPH in controlling clinical signs and 
improving glycemic control in diabetic cats (Weaver et al., 2006). No data are available 
regarding clinical efficacy of insulin detemir.  
 In conclusion, insulin detemir and insulin glargine have shorter duration of 
action in cats than in people. Their time-action profiles seem less flat and more variable 
than in people and their peaks can be pronounced in some cats. In some cats, however, 
these insulin analogs might be useful as once-a-day drugs if their day-to-day variability 
is low. This, however, needs to be investigated further.  
 
Footnotes 
a Purina DM, Nestlé Purina PetCare Company  
b
 Levemir®, Novo Nordisk Inc. Princeton, NJ USA 
c
 Lantus®, Sanofi-Aventis U.S. LLC, Bridgewater, NJ USA 
dV-Cath®, 3.0F, NeoMedical, Inc, Fremont, CA  USA 
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eBD Angiocath AutoGuard®, Becton Dickinson Infusion Therapy Systems, Inc., Sand, 
UT  USA 
f 50% Dextrose USP. Hospira Inc. Lakeforest, IL USA. 
g
 OneTouch Ultra, LifeScan Inc., Milpitas CA USA. 
h
 GraphPad Prism, GraphPad Software Inc., CA, USA.  
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Tables and figures 







n = 10 
Glargine 
n = 10 
 
P value 
mean ± SD  
(95% CI) 
1.8 ± 0.8 
(1.1 – 2.3) 
1.3 ± 0.5 















mean ± SD  
(95% CI) 
13.5 ± 3.5  
(11.0 – 16.0) 
11.3 ± 4.5 















mean ± SD  
(95% CI) 
11.7 ± 3.6 
(9.1 – 14.0) 
10.0 ± 4.7 

















Table 3.1 (continued) 
  Detemir 
n = 10 
Glargine 
n = 10 
 
P value 
mean ± SD  
(95% CI) 
5.3 ± 2.9 
(3.2 – 7.4) 
5.0 ± 2.3 















mean ± SD  
(95% CI) 
6.9 ± 3.1 
(4.7 – 9.2) 
5.3 ± 3.8 















mean ± SD  
(95% CI) 
2.06 ± 1.2 
(1.18 – 2.95) 
1.67 ± 1.1 
















Figure 3.1 Insulin detemir (solid line) and insulin glargine (dashed line) time action 
curves. Panels A – J represent data from individual cats. The average curve is depicted in 























PHARMACOKINETICS OF INSULIN DETEMIR AND INSULIN GLARGINE 
IN HEALTHY CATS 
 
Abstract 
Background: The synthetic insulin analogs, insulin glargine and insulin detemir are 
comparable in their clinical use. Their chemical structure and hence their 
pharmacological properties are very different.   
Objectives: To evaluate the pharmacokinetics of insulin detemir and insulin glargine in 
healthy cats. 
Animals: Five young, healthy, neutered, purpose-bred cats 
Methods: Randomized, cross-over design. Pharmacokinetics of insulin detemir and 
insulin glargine were determined during an isoglycemic clamp following a 0.5 U/kg 
subcutaneous injection. A sensitive insulin-analog ELISA was used to measure serum 
insulin. 
Results: The pharmacokinetic profile of each analog correlated well with its 
pharmacodynamic profile. Insulin concentrations increased from pre-injection values 
within one hour in 9 of 10 experiments. Insulin concentrations returned to zero in the last 
measurement point in only one experiment. The difference in timing of last sampling 
was not significant but the insulin concentrations of the last sampling point tended to be 
higher in the insulin detemir experiments compared to the insulin glargine experiments.  
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Conclusion and clinical importance: With both analogs, insulin was still detectable in 
serum when the glucose-lowering effect (measured as an increase in glucose infusion 
rate during an isoglycemic clamp) was no longer detectable. Therefore, a threshold 
concentration for insulin action might be determined. This threshold could be used 




 Studying the pharmacokinetics of an insulin formulation requires a sensitive and 
specific assay for the measurement of the insulin. The synthetic insulin analogs are based 
on human-recombinant insulin, and are altered biochemically to change their 
pharmacological properties. Amino-acid substitutions in the B26-B30 region alter the 
tendency of insulin to crystallize while retaining the ability to activate insulin receptors 
(Sheldon et al., 2009). Insulin analogs are mostly modified in this region. As a 
consequence of the alterations made in their sequences, insulin analogs are also 
immunologically different than native mammalian insulin. Thus, specific antibodies can 
be developed and used in antibody-based assays to differentiate native insulin from 
synthetic insulin. Feline insulin differs from human insulin in 4 amino acids, and from 
bovine insulin in only 1 amino acid (Hoenig et al., 2006). Thus, it is generally assumed 
that the immunogenicity of feline and bovine insulin is similar.  
Insulin detemir has low affinity to the insulin receptor. Commercially, insulin 
detemir (Levemir®) is supplied in a molar concentration that is 4 times higher than the 
molar concentration of other insulin formulation so that the unit of activity per volume 
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would be comparable. Insulin detemir has a strong affinity to human albumin and it 
binds to it reversibly. Most circulating detemir is bound but only the un-bound fraction is 
free to cross endothelium and react with the insulin receptor. Thus, the pharmacokinetic 
data of insulin detemir cannot be directly compared with those of insulin glargine (or 
with the pharmacokinetic data of any other non-acylated insulin).  
 
Materials and Methods 
Blood samples for analysis of insulin analog concentration were collected in 5 of 
the 10 cats of the previously described experiment (Chapter 3). Samples were collected 
immediately prior to injection of insulin (time zero) and then every hour on the hour 
until the end of the isoglycemic clamp. The last sample was collected within half an hour 
of discontinuation of glucose infusion. Blood samples were collected through indwelling 
jugular cathetersa placed under sedation as described before. Blood samples for insulin 
measurement were collected at time zero and then every hour until the end of the 
isoglycemic clamp. Whole blood was collected in glass tubes and kept on ice a 
maximum of 12 hours. The blood was then centrifuged, and serum was harvested and 
frozen at -20º Celsius. Insulin concentrations were analyzed at the end of the study in one 
batch. Serum insulin detemirb and serum insulin glarginec concentrations were measured 
with the Iso-Insulin ELISA kitd that was designed to react with recombinant insulin 
analogs. According to the manufacturer the assay is calibrated with human insulin (cross 
reactivity = 100%) and has a detection range of 3 – 100 mU/L with a sensitivity of 1 
mU/L for human insulin. Cross reactivity is lower for insulin glargine (44%) and insulin 
detemir (22%). The lowest detectable concentrations of insulin glargine and insulin 
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detemir are ≥ 8 mU/L and ≥ 16 mU/L respectively. This cross reactivity for insulin 
analogs is much higher than in other insulin assays. For example, in an ultrasensitive 
insulin ELISA (from the same manufacturer), the cross reactivity with insulin glargine 
and insulin detemir is 9.9% and zero, respectively.  Assay cross reactivity is reported by 
the manufacturer as 58% for bovine insulin which should be similar to feline insulin (so 
that the threshold for feline insulin should be 3/0.58 mU/L = 5.2 mU/L, or 178 ng/L). 
To validate the use of the Iso-Insulin assay for use in cats, fifteen feline serum 
samples were ran first in the Feline Insulin ELISAe. These were banked samples that 
were collected in previous experiments after fasting and during various hyperglycemic 
conditions. These samples were free of any exogenous insulin. Insulin concentration in 
those samples ranged between 43.2 – 612.0 ng/L. A second set of aliquots of the same 
samples was then run in the Iso-Insulin ELISA. All samples were below detection range 
of the assay. In a separate study we measured fasting serum insulin with the Feline 
Insulin ELISAe in the 5 cats of this study and in 5 others. The mean ± SEM insulin 
concentration of the 5 cats of this study was 298.3 ± 22.5 ng/L in 25 measurements and 
for the 10 cats together it was 290.6 ± 20.9 ng/L in 45 measurements. These results 
indicated that fasted concentrations of feline insulin are unlikely to be detected by the 
Iso-Insulin kit.  
For graphic representation, the serum insulin concentrations were adjusted based 
on the assay cross reactivity for the given insulin by dividing the measured concentration 
by a factor of 0.44 and 0.22 (the assay cross reactivity for insulin glargine and insulin 
detemir respectively). Concentrations that exceeded the assay range (100 mU/L) were 
designated a value of 100mU/L.  
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Statistical analysis was performed using computer software f.  Data are reported for 
the entire group (N = 5) as median (range). The Wilcoxon matched pairs test was used to 
compare medians between treatment groups.  Statistical tests were performed as two-
tailed tests and a P value < 0.05 was considered significant.  
 
Results 
Summary statistics of pharmacodynamic parameters were presented before in 
chapter 3, table 3.1. Adjusted insulin concentrations over time with their respective 
smoothed GIR over time in the 5 detemir clamps are presented in figures 4.1 F1-J1 (K1 
is their mean). Adjusted insulin concentrations over time and smoothed GIR over time in 
the 5 glargine clamps are presented in figures 4.1 F2-J2 (K2 is their mean). 
Pre-injection insulin concentrations in the Iso-Insulin assay were zero except on 2 
occasions (unadjusted concentrations: 23.3 mU/L [figure 4.1 H1] and 20.5 mU/L [figure 
4.1 J1]). Insulin concentrations increased from pre-injection values within one hour in 9 
of 10 experiments. In the tenth it increased only in the second hour and this increase 
correlated with the increase in GIR. Visual inspection of general trends in figures 4.1 F-
K reveals that changes in insulin concentrations correlated with changes in GIR.  
Insulin concentrations returned to zero in the last measurement point in only one 
experiment. Excluding this one experiment, the last measured concentration in the 4 
insulin glargine clamps (unadjusted to cross-reactivity) was (median, range) 5.7 (3.6 – 
15.3) mU/L. The last measured concentration in the 5 insulin detemir clamps (unadjusted 
to cross-reactivity) was (median, range) 19.3 (18.5 – 24.3) mU/L. In the 5 cats, the 
median difference between the 2 clamps in the last insulin concentrations measurement 
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was 17.4 mU/L (3.2 – 20.7). The difference was not significant but with obvious trend 
towards higher concentrations in the insulin detemir clamps compared to the insulin 
glargine clamps (P = 0.0625).  The difference in timing of last sampling was not 
significant (30 minutes [-240 – 640 minutes], P = 1.0). 
 
Discussion 
 In this study we found good agreement between pharmacokinetic and 
pharmacodynamic data of each of the insulin analogs. An increase in concentration of 
insulin was detected within one hour in all clamps except for one glargine clamp in 
which it was detected after 2 hours and correlated with the increase in GIR. Shapes of 
insulin curves resembled the GIR curves. This is despite the fact that on many occasions 
the concentrations exceeded the assay range. Because sampling was limited to once 
every hour, assessing time of appearance and duration of stay is inaccurate. 
 It is unclear why 2 of the pre-injection samples had a false positive reading of 
insulin detemir. We have shown that serum samples from fasted cats as well as serum 
samples from glucose-stimulated cats do not normally contain sufficient concentrations 
of feline insulin to cross react with the Iso-Insulin ELISA. It is possible that the fasted 
concentrations of insulin in these 2 cats were high enough to exceed the threshold of the 
Iso-Insulin assay for feline insulin. In a separate study (incretin study, chapters 5 and 6), 
fasted serum samples from these 2 cats were tested on multiple occasions and the results 
were variable but not high enough to be detected in the Iso-Insulin assay (median 204 
ng/L, [range 151-428] in one cat and 346 ng/L, [range 309-383] in the other). It is also 
possible that the false positive reading was caused by some non-specific matrix 
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interference but this was not repeatable in these 2 cats. Ideally, insulin concentrations 
should have been analyzed in all samples using the Feline Insulin ELISA in parallel to 
the Iso-Insulin assay. These might have explained the aberrant reading in the 2 cats in 
time zero and also shed light on the results of the last measurement in each clamp. 
Insulin concentration did not decrease to zero at the end of the clamp in 9 of 10 
experiments. This could be because the endogenous insulin was high enough to be 
measured by the ELISA.  
 Alternatively, it is possible that the low insulin concentrations at the end of 
each clamp represent mostly exogenous insulin and that these low concentration resulted 
in metabolic activity that was low enough to allow a decrease in GIR to zero without 
appreciable decrease in BG. This second alternative seems more likely because of three 
reasons. First, the isoglycemic clamps were performed at sub-euglycemic blood glucose 
concentrations to avoid artificial prolongation of duration of action (discussed previously 
in Chapter 3). In this scenario, it is possible that the remaining circulating insulin at the 
end of the clamp was not enough to lower the BG below our chosen threshold but was 
still present and may even had some metabolic activity. Second, the unadjusted insulin 
concentration tended to be higher at the end of the detemir clamps compared to the end 
concentration at the end of the glargine clamp. This difference is most likely related to a 
difference between treatments because all other factors were controlled as this was a 
repeated measures experiment. The different treatments could have led to different 
metabolic effects and to a change in insulin sensitivity for example, that might be 
reflected by a difference in endogenous insulin once the experiment is over. This is 
unlikely, however, because the end of action was not significantly different between the 
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2 clamps in each cat. Third, endogenous insulin is expected to be low at the end of the 
clamp because of prolonged fasting. As mentioned before, the mean fasting endogenous 
insulin concentrations in these 5 cats in a different study was 298.3 ± 22.5 ng/L. Even if 
all the insulin that was measured at the end of each clamp was endogenous insulin and if 
feline insulin has across-reactivity similar to bovine insulin in this assay then the 
measured concentrations at the end of these detemir clamps represent a value of 619 – 
838 ng/L. This is very unlikely to be the concentration of endogenous insulin in these 5 
cats after over 24 hours of fasting (prolonged fasting increases insulin sensitivity and 
decreases endogenous insulin secretion).  
 If the measured insulin at the end of each clamp represents the remaining 
exogenous insulin and not endogenous insulin, insulin detemir at an adjusted 
concentration of 84 – 110 mU/L (2900 – 3800 ng/L) was associated with a return of GIR 
to zero. This might be important clinically. If measured after an over night fast, one 
single measurement of serum insulin concentration in the Iso-Insulin ELISA can indicate 
whether insulin detemir is still present in concentrations that should have a glucose 
lowering effect and give an indication of its duration of action. If the concentration is 
lower than 110 mU/L it is unlikely to still have a metabolic effect. It is important to note 
that insulin concentrations in this range were measured in cats after a meal rich in protein 
and fat, although insulin was measured in a different assays (Appleton et al., 2001; Mori 
et al., 2009). In other studies we have stimulated insulin secretion in healthy cats with IV 
glucose, oral glucose, lipids or amino acids. Insulin concentrations were measured with 
Feline Insulin ELISA and rarely exceeded 60 mU/L (2000 ng/L) except after oral 
administration of amino acids. It should be even less likely to measure such high 
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concentrations of insulin in a diabetic cat, unless it has circulating exogenous insulin. It 
is important to remember that such high concentrations of insulin detemir are necessary 
for a metabolic effect because of its low affinity to the insulin receptor and because it is 
mostly albumin-bound and not available for action.  
The Iso-Insulin ELISA is calibrated with human insulin standards and its results 
are presented as units of activity per liter. This means that for detemir the results should 
be divided by an unknown factor because the affinity of insulin detemir for the feline 
insulin receptor is unknown. 
Footnotes 
a V-Cath®, 3.0F, NeoMedical, Inc, Fremont, CA  USA. 
b
 Levemir®, Novo Nordisk Inc. Princeton, NJ USA. 
c
 Lantus®, Sanofi-Aventis U.S. LLC, Bridgewater, NJ USA. 
d
 Iso-Insulin ELISA, Mercodia AB, Uppsala, Sweden 
e
 Feline Insulin ELISA, Mercodia AB, Uppsala, Sweden 
h
 GraphPad Prism, GraphPad Software Inc., CA, USA.  
 
List of References 
Appleton DJ, Rand JS, Sunvold GD. Insulin sensitivity decreases with obesity, and lean 
cats with low insulin sensitivity are at greatest risk of glucose intolerance with weight 
gain. J Feline Med Surg. 2001;3:211-28. 
 
Hoenig M, Caffall ZF, McGraw RA, et al. Cloning, expression and purification of feline 
proinsulin. Domest Anim Endocrinol. 2006;30:28-37. 
 107 
Mori A, Sako T, Lee P, et al. Comparison of three commercially available prescription 
diet regimens on short-term post-prandial serum glucose and insulin concentrations in 
healthy cats. Vet Res Commun. 2009;33:669-80. 
 
Sheldon B, Russell-Jones D, Wright J. Insulin analogues: an example of applied medical 
science. Diabetes Obes Metab. 2009;11:5-19. 
 108 
Figures 
Figures 4.1 GIR (solid line) and insulin concentration (dashed line) during insulin 
detemir isoglycemic clamps (F1 – K1) and insulin glargine isoglycemic clamps (F2-K2). 
Panels F1 – J1 and F2 – J2 represent data from individual cats and correspond to panels 
F – J in figure 3.1. The average curves for the 5 cats are depicted in panels K1 and K2.  
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THE INCRETIN EFFECT IN CATS:  
COMPARISON BETWEEN ORAL GLUCOSE, LIPIDS, AND AMINO ACIDS 
 
Abstract 
Background: Naturally occurring type 2 diabetes mellitus (DM) is common in domestic 
cats, and is a compelling model for the disease in people. Little is known about incretin 
hormones in cats. 
Objectives: To study the incretin effect in cats and compare the effect of oral glucose, 
lipids or amino acids on serum concentrations of insulin, total GIP and total GLP-1. 
Methods: Randomized, cross-over design. Ten healthy cats. Glucose, lipid or mixed 
amino acids were administered through nasoesophageal tubes on separate study days. 
Blood glucose concentrations (BG) were matched between experiments by measuring 
BG every 5 minutes and infusing glucose intravenously at a changing rate (isoglycemic 
clamp). Intravenous glucose infusion (IV glucose) with no prior treatment served as 
control. Insulin concentrations were measured with a feline insulin ELISA. Total GIP 
and total GLP-1 concentrations were measured with human ELISA’s that were validated 
for use in cats. The incretin effect was estimated as the difference in insulin area under 
the curve (AUC) after oral compared to IV glucose.  Total glucose infused (TGI), and 
area under the insulin, GIP and GLP-1 curves were compared between different 
treatments. 
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Results: On average, 0.49 g/kg of glucose administered IV resulted in slightly higher 
BG compared to 1 g/kg oral glucose. Insulin concentrations were not significantly 
different. BG and TGI were not significantly different in the three oral challenges. 
Insulin AUC after amino acids was 5.46 ± 1.33 fold higher than insulin AUC after lipids 
and 2.2 ± 0.3 fold higher than insulin AUC after oral glucose. Total GIP concentrations 
increased significantly after lipids (32 fold, range 10 – 137) and amino acids (12 fold, 
range 2 – 35) but not after oral glucose. Total GLP-1 concentrations increased 
significantly after all 3 oral stimulations to a similar degree (after glucose 1.6 fold [1.2 – 
2.9], lipids 1.5 fold [1.2 – 3.9], and amino acids 1.7 fold [1.4 – 2.5]).  
Conclusion and clinical importance: Potentiation of insulin secretion after oral 
ingestion of glucose is minimal in cats and is not mediated by GIP. Lipids are more 
potent GIP secretagogues compared to amino acids, but both cause rapid and pronounced 
increases in serum GIP concentrations. GLP-1 secretion is stimulated equally by glucose, 
lipids or amino acids. 
 
Introduction 
Stimulation of insulin secretion by glucose ingestion is partly due to direct action 
of glucose on the pancreatic beta cells. In addition, the entero-insular axis enhances the 
total amount of insulin released. The incretin effect is the difference between insulin 
secretion after glucose ingestion and that after an isoglycemic intravenous glucose 
infusion (Nauck et al., 1986). In people, the incretin effect accounts for about 80% of 
insulin secreted after glucose ingestion (Nauck et al., 1986). Incretin hormones potentiate 
insulin secretion, resulting in increased insulin secretion at any given concentration of 
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blood glucose. Incretins also participate in regulation of pancreatic beta-cell 
differentiation, proliferation and survival; they affect glucagon secretion, slow the rate of 
gastric emptying and increase satiety. Thus, incretins play a major role in glucose 
homeostasis (Kim and Egan, 2008). 
The domestic cat is a compelling animal model of diabetes because it 
spontaneously develops a form of the disease that closely resembles human type 2 
diabetes. Cats, humans and macaques are the only species that spontaneously develop 
islet amyloid deposits (Henson and O'Brien, 2006). Other similarities include onset at 
middle age or older, a genetic predisposition, association with obesity as a major risk 
factor, and impaired beta cell function with residual but declining insulin secretion. In 
contrast to other models of type 2 diabetes, cats are obligate carnivores. As such, their 
natural diet is based mostly on fat and protein and contains less carbohydrate. Sugar-
sensing in taste buds is therefore unnecessary to the cat, and indeed cats lack the T1R2 
sweet-taste receptor (Li et al., 2006). Sugar-sensing, however, is also an important 
function of enteroendocrine cells that secrete incretin hormones. Glucose is sensed in 
enteroendocrine cells by T1R2 sweet-taste receptors, but also by mechanisms similar to 
its sensing in pancreatic beta cells (involving its entry through SGLT1/GLUT-2, its 
metabolism through glucokinase and than closure of KATP channels) (Jang et al, 2007; 
Kim and Egan, 2008; Reimann et al., 2008; Parker et al., 2009). Because cats lack the 
T1R2 sweet-taste receptor, and because they are obligate carnivores, it is likely that their 
enteroendocrine response to glucose and other nutrients would be different than in other 
species.  
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Two hormones account fully for the incretin effect in people: Glucose-dependent 
Insulinotropic Peptide (GIP) and Glucagon-Like Peptide -1 (GLP-1). The degree of GIP 
and GLP-1 stimulation by different nutrients is species-dependent. Fat is more potent 
than carbohydrates in stimulating GIP secretion in people but the opposite is true in pigs. 
Amino acids are weak stimulators of GIP secretion in people but strong stimulators of it 
in dogs and rats (Deacon, 2005; Kim and Egan, 2008). GLP-1 secretion is stimulated by 
ingested lipid, carbohydrate and protein as well as by GIP (Damholt et al., 1998; 
Gunnarsson et al., 2006; Kim and Egan, 2008).  Different distributions of GLP-1-
secreting cells (L cells and K/L cells) along the intestinal tract in different species 
determine, in part, the importance of different stimuli of GLP-1 secretion (Damholt et 
al., 1999; Kim and Egan, 2008). 
Based on the view of the domestic cat as an obligate carnivore, we hypothesized 
that the glucose-induced incretin effect in cats would be less than is observed in other 
species. We also explored the differential effects of glucose, lipid and amino acids on 
secretion of incretin hormones.  
 
Materials and Methods 
Animals: Ten young, healthy, purpose-bred cats were used in this study (4 spayed 
females and 6 neutered males, median age 48 months [range 36 – 58 months], mean BW 
was 4.8 ± 0.68 kg, with no significant difference between males and females). Cats were 
group-housed in AAALAC-accredited facilities and all animal use was approved by the 
University of Illinois Institutional Animal Care and Use Committee. All cats were 
acclimatized and socialized for at least 4 weeks prior to the start of experiments, and 
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extensive environmental enrichment was provided. Cats were fed commercial cat fooda 
and monitored daily by physical exams. Body weight was measured weekly. Routine 
laboratory tests (including CBC, serum chemistry panels, total T4, coagulation panels 
and urinalysis) were performed at first arrival and just prior to the first part of the 
experiment in each cat.  PCV, total solids and CBC’s were repeated prior to each part of 
the experiment in each cat.  
Study design: A repeated measures study design was used. The experiment was 
divided to 4 parts: Oral glucose tolerance test (OGTT), isoglycemic clamp (IGC), lipid 
challenge with an isoglycemic clamp (LIGC) and amino acids challenge with an 
isoglycemic clamp (AAIGC). First, an OGTT was performed and blood glucose 
concentrations (BG) were measured every 5 minutes until euglycemia was restored. In 
the second part, IGC was performed 2-3 days after the OGTT. During the IGC, BG was 
measured every 5 minutes and glucose was infused IV at a changing rate. The rate of 
infusion was adjusted to match or exceed the BG that was recorded during the OGTT at 
the next time point by no more than 10%. The third and fourth parts of the experiment 
were done four weeks later: LIGC and AAIGC were performed 3 days apart, in random 
order. In these clamps the target BG was 0-10% less than the BG recorded during the 
IGC.  
On the day of each experiment, BG was measured twice between 8 and 9 a.m. If 
hyperglycemia was detected, the experiment was postponed until the next day. At 9 a.m. 
a sample was obtained for hormone measurement and then a solution of glucoseb (2 
ml/kg), lipidsc (1.7 ml/kg) or amino acidsd (8.5 ml/kg) was administered through a 
nasoesophageal tube. The 3 solutions were calorically equivalent (3.4 Kcal/kg) and the 
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volumes were matched by flushing the tubes with water to reach a total volume of 9 
ml/kg. All 3 solutions (water flush included) were administered over 4 minutes. Time 
zero was defined as the end of glucose and amino acid administration in the OGTT and 
AAIGC respectively, and the beginning of glucose infusion in all 3 glucose clamps 
(IGC, LIGC and AAIGC). In the LIGC, the end of lipid administration was defined as 
-15 minutes; BG was still measured every 5 minutes and time zero was still defined as 
the beginning of the IGC.  For glucose intravenous infusion, a 50% glucose solution was 
diluted with saline to a 20% solution. Infusion rate was set on a syringe pump. 
Serum samples for insulin, GIP and GLP-1 measurement were collected during the 
OGTT, LIGC and AAIGC at baseline (immediately prior to nutrient administration or at 
time zero in the IGC) and then at 15, 30, 45, 60, 75, 90 and 120 minutes and then every 
30 minutes thereafter until euglycemia was restored. In the IGC, insulin was measured 
similarly but GIP and GLP-1 were measured only at baseline and at 30 minutes and only 
in 5 cats. Blood was collected through indwelling jugular catheterse. The samples were 
collected into chilled glass tubes and then immediately centrifuged (at 4ºC and 4000 
RPM) and separated. Serum was stored at -20ºC until analysis. 
Catheters and nasoesophageal tube placement: On the morning before each part 
of the experiment, cats were sedated with intramuscular injections of dexmedetomidine 
(0.009 mg/kg) and butorphanol (0.22 mg/kg) to facilitate catheter placement. Atropine 
was given (0.022mg/kg intramuscularly) to prevent bradycardia.  Jugular catheterse were 
placed prior to the OGTT. These catheters were maintained by flushing heparinized 
saline daily until the end of the study. Cephalic cathetersf were placed prior to each IGC 
and were removed at the end of the IGC. These were used exclusively for glucose 
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infusion. The sedation was reversed with atipemazole (0.009 mg/kg) and the cats were 
monitored until full recovery. Food was given as usual at 3 pm, and one hour later the 
cats were lightly sedated with acepromazine (0.04 mg/kg) and butorphanol (0.22 mg/kg) 
and a 3.5F red rubber nasoesophageal feeding tube was placed. The tube was pre-
measured and marked to reach the ninth rib. Cats were conscious during the procedure 
and proper placing was verified by observing an intact swallowing reflex, and by 
checking the tube for negative pressure after placement. Elizabethan collars were used to 
prevent the cats from removing the nasoesophageal tubes.  Food and water were then 
withheld until after the experiment the next day. Nasoesophageal tubes were placed prior 
to OGTT, AAIGC and LIGC but not prior to IGC.  
Glucose and hormone measurements: Blood glucose concentrations were 
measured with a hand-held point-of-care glucose meterg that was validated for use in cats 
(Gilor et al., 2010). Insulin concentrations were measured with a feline ELISAh. Total 
GIP concentrations and total GLP-1 concentrations were measured with human ELISA 
kitsi, j that were validated for use in cats. Feline GIP and feline GLP-1 were not available 
and therefore spiking and recovery were not performed. In the GIP ELISA the intra-
assay CV was 4.9 ± 3.3% and the inter-assay CV was 6.2 ± 2.1%. Linear regression for 
expected vs. observed concentrations of GIP in serial dilutions are presented in figure 
5.1. The results of the regression were: R2 = 0.99 (P < 0.0001), Slope = 0.98 ± 0.02, Y 
intercept = 3.67± 2.25. In the GLP -1 ELISA the intra-assay CV was 7.3 ± 5.6%. Linear 
regression for expected vs. observed concentrations of GLP-1 in serial dilutions are 
presented in figure 5.2. The results of the regression were: R2 = 0.85 (P < 0.0001), slope 
= 0.60 ± 0.06, Y intercept = 0.58 ± 0.38 
 117 
Statistical analysis: Statistical analysis was performed using computer softwarek.  
The Shapiro-Wilk test was used to assess deviance from normal distribution of data. 
Data are reported as mean ± SE if normally distributed or as median (range). 
Comparisons between treatment groups were analyzed with paired or repeated measures 
tests. OGTT and IGC were performed in 10 cats. LIGC and AAIGC were performed in 
only 8 out of the 10 due to sampling catheter failure. In repeated measures tests that 
included OGTT and/or IGC, only cats with a full set of data were included. Paired t-tests 
or one-way repeated measures ANOVA were used for normally distributed data. The 
Wilcoxon signed-rank test and the Friedman’s test were used for data that were not 
normally distributed. Fold increase or fold difference were calculated as the deviation of 
a ratio from 1.0 using a one sample t test or the Wilcoxon signed-rank test. Comparisons 
between time points were analyzed with one-way repeated measures ANOVA. 
The area under the curve (AUC) was calculated using the trapezoidal method for 
the BG and for hormones concentrations. AUC was used to represent total hormone 
secretion.  




 Baseline BG’s in the IGC experiment were lower than in the other experiments 
but the differences were not significant (IGC: 81.8 ± 2.8 mg/dl vs. 87.5 ± 2.3 in the 
OGTT, 87.5 ± 3.4 in the LIGC and 84.8 ± 1.4 in the AAIGC).  
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Glucose-induced incretin effect: The AUC of blood glucose concentrations in the 
IGC was slightly higher (6.7 ± 2.8%) than the AUC in the OGTT (P = 0.038, Fig. 5.3). 
Compared to the 1 g/kg of glucose that was given orally for the OGTT, the total glucose 
infused during the IGC was significantly lower at 0.49 ± 0.06 g/kg (P < 0.0001, Fig. 5.4). 
Total insulin secretion was not significantly different (P = 0.19, Fig. 5.5) between the 
OGTT (46772 ng ·L-1 · min [19815 – 304406]) and the IGC (52168 ng · L-1 · min [19146 
– 79448]) with a median fold difference of 23% (-74 – 670). 
Median baseline GIP concentrations (of all experiments) were 11.4 pg/ml (3.5 – 
61.1). GIP concentration did not increase significantly during the OGTT. Median 
baseline GLP-1 concentrations (of all experiments) were 8.9 pmol/L (4.5 – 26.5). GLP-1 
concentrations peaked 30 minutes after glucose administration (fold increase 1.5 [0.9 – 
2.8]) and returned to baseline at 45 and 120 minutes (Fig. 5.6). It reached a maximum 
fold increase from baseline of 1.6 (1.2 – 2.9). Time to maximum was 75 minutes (30 – 
150).  
GIP and GLP-1 concentrations did not change significantly between time zero 
and 30 minutes of the IGC. 
 Lipid and amino acid stimulation: The AUC of blood glucose concentrations in 
the LIGC was lower than the AUC in the IGC (-9 ± 4%) but the difference was not 
significant (P = 0.15, Fig. 5.7). The AUC of blood glucose concentrations in the AAIGC 
was significantly lower than the AUC in the IGC (-10 ± 3 %, P = 0.002, Fig. 5.8). The 
AUC of blood glucose concentrations in the LIGC and AAIGC was not significantly 
different than the AUC in the OGTT (1 ± 5.5 %, P = 0.87 and 1 ± 6.4%, P = 0.89 
respectively) or from one to the other (2 ± 6%, P = 0.78). The total glucose infused 
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during the LIGC or AAIGC was not significantly different than 1 g/kg (LIGC: 0.91 ± 
0.14 g/kg, P = 0.53; AAIGC: 0.88 ± 0.09 g/kg, P = 0.25, Fig. 5.4). Insulin concentration 
increased within 15 minutes of lipid administration (at time zero of the isoglycemic 
clamp, while BG was still unchanged). Insulin AUC during AAIGC was significantly 
higher than in the LIGC (fold difference 120 ± 30%, P = 0.004). Insulin AUC during 
LIGC was significantly higher than in the OGTT (fold difference 160 ± 60%, P = 0.008), 
Fig. 5.9).  
GIP concentration peaked 15 minutes after lipid administration (24 fold increase 
[range 10 – 75 fold], Fig. 5.10) and remained elevated after 135 minutes (120 minutes of 
the glucose clamp). It reached a maximum fold increase of 32 (10 – 137) from baseline. 
Time to maximum was 52.5 minutes (15 – 105). GIP concentration peaked 15 minutes 
after amino acid administration (fold increase 11 [1 – 28]) and remained elevated after 
120 minutes. It reached a maximum fold increase of 12 (2 – 35) from baseline. Time to 
maximum was 52.5 minutes (15 – 90). Total GIP secretion (as measured by the area 
under the time-concentration curve) in response to lipids was 2.8 fold (1.5 – 9.0) greater 
than to amino acids (P = 0.008) but individual patterns of GIP serum concentration 
curves after lipids or amino acids stimulations were remarkably similar in 5 out of 8 cats 
(Figs 5.11a – h).  
GLP-1 concentrations during LIGC and AAIGC were measured in only 6 cats 
because of insufficient sample volume.  GLP-1 peaked 15 minutes after lipid 
administration (fold increase 1.5 [1.2 – 3.9], Fig. 5.12) and returned to baseline at 30 
minutes. Time to maximum was 30 minutes (15 – 75). GLP-1 concentration peaked 15 
minutes after amino acid administration (fold increase 1.7 [1.4 – 2.5]) and returned to 
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baseline at 45 minutes. It reached a maximum fold increase from baseline of 2.6 (1.5 – 
9.3). Time to maximum was 30 minutes (15 – 60). Total GLP-1 secretion (as measured 
by the area under the time-concentration curve) was not significantly different between 
glucose, lipids or amino acids oral stimulations (P = 0.56). 
 
Discussion 
In this study we examined the incretin effect in response to glucose stimulation in 
healthy cats. Consistent with the fact that the cat is an obligate carnivore, we found that 
the incretin effect in cats is minimal when compared to other species. The lack of 
significant difference between insulin AUC during the OGTT and IGC might suggest 
that in cats there is no incretin effect in response to glucose, however, our findings 
mostly suggest the opposite.  
First, it should be considered that the lack of difference in insulin AUC in itself 
signifies an incretin effect given the higher AUC of BG concentration during IGC 
compared with the OGTT, combined with the difference between the total amount of 
glucose infused vs. glucose administered orally. If there was no incretin effect, one 
would expect that the excess of oral glucose (twice as much as the IV glucose) would 
result in a higher BG concentration. The opposite occurred here. If there was no incretin 
effect, one would also expect a higher BG during the IGC to result in a higher AUC of 
insulin. The opposite occurred here. The combination of these 2 significant differences 
with the lack of difference in insulin AUC’s, supports the presence of an incretin effect, 
albeit small.  
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Second, it is possible that the incretin effect in cats is mostly mediated by a 
decrease in glucagon (resulting in a decrease in hepatic glucose output) and less by an 
increase in insulin itself. This is supported by the results of a recent study in which the 
effect of a DPP-4 inhibitor in cats on lowering BG were mostly mediated by a decrease 
in glucagon and less so by an increase in insulin (Furrer et al., 2010). This is also 
consistent with our finding that GLP-1 secretion was stimulated by oral glucose but GIP 
stimulation was not. In other species, both incretin hormones contribute an insulinotropic 
effect after glucose ingestion, but they have opposite effects on glucagon secretion: 
GLP-1 decreases glucagon secretion while GIP increases it (Kim and Egan, 2008; Carr et 
al., 2008). Lack of GIP secretion in response to oral glucose will lead to an overall 
decrease in insulinotropic effect but at the same time a net decrease in glucagon 
secretion. This should result in a decreased hepatic glucose output and a greater tolerance 
towards oral glucose. 
Third, it should be considered that the lack of a significant difference in insulin 
AUC was a result of lack of statistical power caused by the large variation in our insulin 
results. At the same time, it is possible that a lack of statistical power precluded us from 
finding the opposite result: That the insulin concentrations were in fact higher during the 
IGC, as expected if there is no incretin effect and the BG during the IGC is higher than 
the in the OGTT. In that case, the large difference in total glucose infused vs. oral 
glucose still requires an explanation. If there is no incretin effect, the similarity in BG in 
the OGTT and the IGC can only be explained by a lack of absorption of a significant 
fraction of the orally administered glucose. In a recent study, OGTT was performed in 
cats but with a dose of 2 g/kg of glucose (Hoenig et al., 2010). With that dose, 7/21 cats 
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developed signs of gastrointestinal upset (vomiting or diarrhea) that might be caused by 
the osmotic pool of unabsorbed glucose. Interestingly, the BG during OGTT in that 
study resulted in similar or lower BG than in our study giving twice the amount of 
glucose we gave. This difference is either a result of a more pronounced incretin effect 
(as seen in people with increasing doses of oral glucose; Nauck et al., 1986), a lack of 
complete glucose absorption in both studies, or simply due to differences in methods. In 
contrast to our study, Hoenig et al. (2010) administered glucose to cats under sedation. It 
is possible that the sedatives affected GI motility and thus changing the glucose 
excursion.  One limitation of our study was that glucose and other nutrients were 
administered via a nasoesophageal tube. The tube was placed the day before each 
experiment and by the time the experiment was started there was no apparent discomfort 
to the cats (except for occasional sneezing). Also, our cats were very well-acclimated to 
the conditions of the laboratory and had participated in previous studies. Although we 
did not perceive the cats to be stressed, it cannot be completely ruled out that some 
degree of stress was affecting them. In that case, a sympathetic response could inhibit 
insulin secretion, increase glucagon secretion and interfere with the incretin effect. The 
small difference in baseline BG between the OGTT and the IGC might be evidence of 
stress in these cats. Perhaps if stress had been completely avoided, a greater incretin 
effect would have been seen. A stress-free voluntary consumption of a glucose solution 
is not a viable option in cats, however, and we consider the method of glucose 
administration we chose to be the most practical. 
 If there is a glucose-induced incretin effect in cats, it might be mediated by GLP-
1 but it is clearly not mediated by GIP. GIP, however, may be responsible for an incretin 
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effect stimulated by other nutrients. Insulin concentration increased despite euglycemia 
15 minutes after lipid administration. This was accompanied by a significant and marked 
increase in GIP concentration. Interestingly, in people, oral triglycerides trigger GIP 
release, but this results in insulin secretion only during hyperglycemia (Ross and Dupre, 
1978). We did not measure triglyceride and fatty acid concentrations in the blood and it 
is possible that the increase in insulin concentration was a result of direct stimulation of 
pancreatic beta cells by triglycerides or fatty acids. It is unlikely, however, that within 15 
minutes of administration, lipids would be digested, absorbed into the lymphatic system, 
and enter the bloodstream in high enough concentrations to cause the stimulation of 
insulin secretion we observed. It is more likely that there was a direct stimulation of GIP 
and GLP-1 secretion which resulted in potentiation of insulin secretion.   
In dogs, secretion of GLP-1 is not directly stimulated by oral glucose. Rather, K 
cells are stimulated by glucose and L cells are stimulated by GIP, probably in a paracrine 
way (Damholt et al., 1999). Although dogs are the closest model to cats (at least among 
animal models in which the incretin effect has been reported), it seems that in 
stimulation of L cells by glucose, cats are more similar to other species. Stimulation of 
GLP-1 secretion was observed in our study with no appreciable increase in serum GIP 
concentrations. Although this does not rule out a paracrine effect of GIP on L cells, it 
makes it unlikely unless glucose stimulated GIP secretion very weakly or GIP did not 
enter the systemic circulation.  
In this study, caloric and volume equivalent stimulations with oral glucose, lipids 
or amino acids were followed by similar responses in GLP-1 secretion. In contrast, 
glucose did not stimulate GIP secretion, amino acids were associated with a strong 
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stimulation of GIP secretion, and lipids with an even stronger stimulation. AUC’s of BG 
after glucose, lipid and AA stimulations were not significantly different. Therefore, the 
difference in insulin secretion between the 3 stimulations cannot be accounted for by 
differences in blood glucose. Lipids and amino acids can directly stimulate insulin 
secretion and, therefore, the difference in insulin concentrations between the 3 
experiments cannot be assumed to be an incretin effect. The causal association with rapid 
and remarkable increase in GIP and GLP-1 concentrations and a similar increase in 
insulin concentrations, together with the known effect of GLP-1 and GIP in other 
species, support the notion that incretins have an insulinotropic effect in cats.  
As for the magnitude of stimulation by the 3 nutrients, it is important to note that 
the 3 solutions we administered were not equal in molar concentrations. We chose to 
equate the caloric content of the 3 solutions because that would give more clinically 
useful information regarding the relative benefit of a given nutrient. K and L cells are 
stimulated by fatty acids via specific G protein-coupled receptors (GPR). The 
mechanism of stimulation by amino acids and glucose are more controversial but it is 
either mediated by GPR’s, by sodium-coupled transporters, or by both. Regardless, 
stimulation of K and L cells by nutrients is proportional to the molar content of the 
nutrients. Notably, degradation of triglycerides to fatty acids is critical to stimulation of 
GLP-1 secretion (Beglinger et al., 2010) so that the final molar content of triglycerids 
affecting stimulation is 3 times the original molar content. In our study the molar content 
of amino acids and glucose were 5.6 and 3.8 times higher than the molar content of fatty 
acids (assuming all lipids were digested to fatty acids). We can therefore hypothesize 
that, on a molar basis, lipids are more potent stimulators of GLP-1 secretion in cats 
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compared to amino acids and glucose, even though on a caloric basis they resulted in 
similar responses. Moreover, degree of stimulation of K and L cells varies between 
saturated and unsaturated fatty acids and between different amino acids. For example, in 
people GLP-1 secretion is stimulated more by monounsaturated fatty acids than 
polyunsaturated fatty acids or saturated fatty acids (Beysen et al., 2002). In cell cultures, 
glutamine is a stronger stimulus of GLP-1 secretion than asparagine and alanine 
(Reimann et al., 2004). In fact, on a molar basis, glutamine and glucose stimulate GLP-1 
secretion to a similar degree (Greenfield et al., 2009). The lipid solution we used was 
composed mainly of unsaturated fatty acids. As obligate carnivores, the cat’s natural diet 
contains mostly saturated fat and it is plausible that their L and K cells respond to 
saturated fat more then to unsaturated fat. Further studies of the differential effect of 
specific fatty acids and amino acids should elucidate the potential of manipulating the 
composition of the diet to affect incretin secretion in cats. This might have implications 
to the treatment of diabetes and obesity.   
In people basal GIP concentrations in peripheral venous blood are typically 9-11 
pM and they increase 5-10 fold post-prandially. Basal GLP-1 concentrations in 
peripheral venous blood of people are typically 5-10 pM and increase 2-3 fold after a 
meal (Kim and Egan, 2008). In cats, we found baseline GIP concentrations that are about 
a fifth of the basal concentration in people, but there was much higher increase in 
response to lipids. Basal GLP-1 concentrations are similar in cats and people, with 
similar post-prandial fold increases. The differences in basal GIP between people and 
cats could be explained by a low cross reactivity of the anti-GIP antibody used in our 
assay. In contrast to GLP-1, the homology of GIP among mammals is not 100%. We 
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used a human GIP ELISA because feline GIP or feline specific GIP assays are not 
commercially available. If low cross reactivity was the issue, then post-stimulation 
concentrations of GIP were also underestimated. This would strengthen the finding that 
GIP is not stimulated by glucose in cats and that lipid- or amino acid-stimulated 
concentrations are much higher than in people. In people, GIP is crucial in maintaining 
glucose tolerance in the post-prandial phase. Lack of GIP response to glucose and an 
over all weak incretin effect could render the cat relatively glucose-intolerant, and might 
lead to inappropriate glycemic control in cats fed a diet high in carbohydrates. A recent 
study, however, showed no correlation between dietary carbohydrate content and 
development of diabetes in cats (Slingerland et al., 2009).  
Conclusion: In this study we found that the glucose-dependent insulinotropic 
effect of incretins in cats is minimal when compared to other species. We also explored 
the differential effects of glucose, lipids and amino acids on secretion of incretin 
hormones. In contrast to other species, glucose did not stimulate GIP secretion. Oral 
lipids and amino acids were followed by a fast and pronounced increase in serum GIP 
concentrations, with much greater fold increase than reported in other species. GLP-1 
responses were similar to previous reports from other species.  
Footnotes 
a Purina DM, Nestlé Purina PetCare Company  
b Dextrose 50% USP. Hospira Inc. Lakeforest, IL USA 
c
 Liposyn II 20% Hospira Inc. Lakeforest, IL USA 
d
 Aminosyn II 10% Hospira Inc. Lakeforest, IL USA 
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e BD Angiocath AutoGuard®, Becton Dickinson Infusion Therapy Systems, Inc., Sand, 
UT  USA 
f V-Cath®, 3.0F, NeoMedical, Inc, Fremont, CA  USA 
g
 OneTouch Ultra, LifeScan Inc., Milpitas CA USA 
h
 Feline Insulin ELISA, Mercodia AB, Uppsala, Sweden 
i
 Human GIP (total) ELISA, Millipore Inc., St. Charles, MO, USA 
j
 GLP-1 (7-36 and 9-36) ELISA , ALPCO Diagnostics, Salem, NH, USA 
k
 GraphPad Prism, GraphPad Software Inc., CA, USA  
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Figure 5.2 Expected vs. observed concentrations of GLP-1 in serial dilutions. R2 = 0.85 





Figure 5.3 Blood glucose concentrations during OGTT (solid line) and IGC (broken 





Figure 5.4 Box plot of the total glucose infused during OGTT, IGC, LIGC and AAIGC. 
The boxes represent the interquartile intervals from the 25th to the 75th percentiles. The 
solid horizontal bars through the boxes represent the medians, and the minimum and 
maximum are represented by the capped vertical bars. * indicates statistically significant 





Figure 5.5 Serum insulin concentrations (ng/L) during OGTT (solid line) and IGC 





Figure 5.6 Serum total GLP-1 concentrations (pmol/L) during OGTT. Error bars 






Figure 5.7 Blood glucose concentrations during LIGC (solid line) and IGC (broken 





Figure 5.8 Blood glucose concentrations during AAIGC (solid line) and IGC (broken 






Figure 5.9 Serum insulin concentrations (ng/L) during OGTT (solid line), LIGC (dashed 





Figure 5.10 Serum total GIP concentrations (pg/ml) during OGTT (solid line), LIGC 






Figure 5.11 A-H Serum total GIP concentrations (pg/ml) during LIGC (dashed line), 
and AAIGC (dotted line) in 8 individual cats. 

































Figure 5.11 (continued) 
 

































Figure 5.11 (continued) 

































Figure 5.11 (continued) 

































Figure 5.12 Serum total GLP-1 concentrations (pmol/L) during OGTT (solid line), 
LIGC (dashed line) and AAIGC (dotted line). Error bars represent the standard error of 
the mean. Letters indicate statistically significant difference from baseline of the 















Background: The GLP-1 mimetic exenatide has a glucose-dependent insulinotropic 
effect and it is effective in controlling blood glucose with minimal side effects in people 
with type 2 diabetes. Exenatide also delays gastric emptying, increases satiety and 
improves beta-cell function. 
Animals: Nine young, healthy, neutered, purpose-bred cats 
Objectives: To study the effect of exenatide on insulin secretion in cats, during 
euglycemia and hyperglycemia. 
Methods: Randomized, cross-over design. Blood glucose concentrations (BG) during an 
oral glucose tolerance test (OGTT) were determined in these cats previously. Two 
isoglycemic glucose clamps (mimicking the BG during the OGTT) were performed in 
each cat on separate days, one without prior treatment (IGC) and the second with 
exenatide (1 mcg/kg) injected subcutaneously 2 hours before (ExIGC). BG, insulin and 
exenatide were measured and glucose infusion rates were recorded and compared in 
paired-tests between the 2 experiments.  
Results: Following exenatide injection, insulin serum concentrations increased 
significantly (2.4 fold [range 1.0 – 9.2, P = 0.004]) within 15 minutes. This was followed 
by a mild decrease in BG and a return of insulin concentration to baseline despite a 
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continuous increase in serum exenatide concentrations. Insulin AUC
 
during ExIGC was 
significantly higher compared to insulin AUC during IGC (AUC ratio 2.0 ± 0.4, P=0.03). 
Total glucose infused was not significantly different between IGC and ExIGC. Exenatide 
was detectable in plasma at 15 minutes post-injection.  The mean exenatide 
concentration peaked at 45 minutes and then returned to baseline by 75 minutes. 
Exenatide was still detectable in the serum of 3 of 5 cats 8 hours post-injection. No 
adverse reactions to exenatide were observed.  
Conclusion and clinical importance: Exenatide affects insulin secretion in cats in a 
glucose-dependent manner, similar to its effect in other species. Although this effect was 
not accompanied by a greater ability to dispose of an IV glucose infusion, other 
potentially beneficial effects of exenatide on pancreatic beta cells, mainly increasing 
their proliferation and survival, should be investigated in cats. Exenatide may not be 
useful as a glucose-lowering drug in diabetic cats.  
 
Introduction 
Type 2 diabetes mellitus is common in cats. Although diet change and oral 
medications may help initially, most diabetic cats depend on insulin therapy to survive 
(Nelson, 2005). Insulin therapy does not halt the progression of the disease and it has 
potential side effects. Weight gain may indicate good response to therapy initially but 
can eventually become a problem. Hypoglycemia is a common complication of insulin 
therapy and can be life-threatening (Nelson, 2005).  
Glucagon-like polypeptide-1 (GLP-1) and glucose-dependent insulinotropic 
polypeptide (GIP) are incretin hormones. They are secreted from the gastrointestinal 
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tract into the circulation in response to ingestion of nutrients, and enhance glucose-
stimulated insulin secretion. These hormones are responsible for the incretin effect in 
which oral glucose administration is associated with a much greater increase in plasma 
insulin concentrations when compared to the same amount of glucose given 
intravenously (McIntyre et al., 1965; Holst et al., 2009). In diabetics, the secretion of 
GIP is normal or slightly reduced but its insulinotropic effect on the pancreas is 
markedly impaired. In contrast, GLP-1 retains its insulinotropic effects in type 2 DM (at 
least at supraphysiologic concentrations), but secretion of GLP-1 is decreased (Nauck et 
al., 1993; Toft-Nielsen et al., 2001a, Toft-Nielsen et al., 2001b; Holst et al., 2009). The 
effects of GLP-1 and GIP extend well beyond potentiating insulin secretion. GLP-1 
decreases glucagon secretion, increases satiety and slows gastric emptying. GIP increases 
glucagon secretion and enhances the action of insulin in adipose tissue. GLP-1 and GIP 
also increase proliferation of pancreatic beta-cells and decrease their apoptosis (Baggio 
and Drucker, 2007). Because of these beneficial effects, incretin-based drugs have been 
recently developed and successfully used as adjunctive treatments in human diabetic 
patients.  
The peptide exendin-4 is a 39-amino acid peptide that shares 53% homology with 
GLP-1. It was first isolated from the poisonous venom of the Gila Monster (Heloderma 
suspectum) (Baggio and Drucker, 2007). Exendin-4 is a potent GLP-1 receptor-agonist 
but unlike GLP-1 it is not a substrate for dipeptidyl peptidase 4 (DPP-4) and neutral 
endopeptidase (NEP). DPP4 and NEP are ubiquitous in tissues and in plasma of people 
and rodents (Deacon, 2005). They are responsible for the fast degradation and short half-
life of GLP-1 (a few minutes). Exenatide is a synthetic exendin-4. Resistant to 
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degradation, exenatide is eliminated by the kidneys and has a half-life of 3-4 hours in 
people. Its biological effect lasts about 8 hours after subcutaneous injection and it can be 
detected in the plasma for up to 15 hours (Kolterman et al., 2005). Exenatide has 
minimal side effects in people. It is sometimes associated with nausea and less frequently 
with vomiting. Infrequently, and especially when combined with other hypoglycemic 
drugs, it may cause hypoglycemia (Amori et al., 2007). Exenatide has been shown to be 
as effective as insulin glargine in the treatment of human type 2 DM but with less side 
effects such as weight gain and hypoglycemia (Heine et al., 2005; Barnett et al., 2007; 
Glass et al., 2008). In a 2-year follow-up of human patients receiving exenatide, patients 
achieved sustained and significant reductions in glycosylated hemoglobin, accompanied 
by significant weight loss and improvement in serum liver enzyme activity and blood 
pressure. Most importantly, treatment with exenatide improved beta cell function (as 
measured by HOMA-B) (Buse et al., 2007).  Exenatide has also been used recently to 
improve the survival and function of transplanted pancreatic islets in type 1 DM 
(Ghofaili et al., 2007). These effects of exenatide on the function and survival of 
pancreatic beta cells open the door for halting the progression of diabetes as opposed to 
merely managing it.  
Despite the crucial role incretins play in the pathogenesis and treatment of type 2 
DM in people, and despite the similarities between DM in people and in cats and the 
high prevalence of this disease in both species (Rand et al., 2004), very little is known 
regarding incretins in cats. Immunoreactivity of GLP-1 and GIP has been described in 
enteroendocrine cells in cats but data regarding the stimulus for secretion of these 
hormones or their effects are scarce (Larsson and Moody, 1980; Vaillant and Lund, 
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1986). Recently it has been shown that GLP-1 concentrations increase in cats after 
intragastric administration of glucose (Hoenig et al., 2010). In another study, a DPP-4 
inhibitor led to decrease in glucagon concentration and, to a lesser degree, to an increase 
in insulin concentrations after glucose challenge (Furrer et al., 2010). To the best of our 
knowledge, studies of incretin mimetics, such as exenatide, have not been reported in 
cats.  
Incretins have been described in people, rodents, dogs, and other species. Although 
the sequence of GLP-1 is highly conserved, there are some differences among species in 
the distribution of the intestinal L cells that secrete GLP-1 and the degree of their 
stimulation by different nutrients and hormones (Damholt et al., 1999, Deacon, 2005). 
We hypothesized that in cats exenatide can potentiate insulin secretion without causing 
hypoglycemia. We also hypothesized that exenatide can be detected in plasma of cats for 
at least 8 hours after subcutaneous injection.  
 
Materials and Methods 
Animals: Nine young, healthy, purpose-bred cats were used in this study. There 
were 4 spayed females and 5 neutered males with a median age 56 months (range 38 – 
58 months) and a mean body weight 4.8 ± 0.7 kg (range 3.8 – 6.1 kg). All cats were in 
normal body condition except one female that was slightly overweight. None of the cats 
were obese. Cats were group-housed in AAALAC-accredited facilities and all animal use 
was approved by the University of Illinois Institutional Animal Care and Use 
Committee. All cats were acclimatized and socialized for at least 4 weeks prior to the 
start of experiments, and extensive environmental enrichment was provided. Cats were 
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fed commercial cat fooda and monitored daily by physical exams. Body weight was 
measured weekly. Routine laboratory tests (including CBC, serum chemistry, serum total 
thyroxine, coagulation profile, and urinalysis) were performed at the time the cats were 
acquired and just prior to the first part of the experiment in each cat.  PCV, plasma total 
solids and CBC’s were repeated prior to the second part of the experiment and a CBC 
and a serum chemistry profile were repeated 2 weeks after exenatide injection in each 
cat.  
Study design: A repeated-measures study design was used. An intravenous 
glucose infusion administered at a variable rate was used to mimic hyperglycemia as 
recorded during an oral glucose tolerance test (described in chapter 5). For each cat, 
blood glucose concentrations were measured every five minutes and the rate of infusion 
was adjusted to match the blood glucose that was recorded for the specific cats in a 
previous experiment. This isoglycemic glucose clamp was performed twice: On the first 
day with no other treatment (IGC) and 2 weeks later, 2 hours after an injection of 
exenatideb (ExIGC). For glucose intravenous infusion, a 50% dextrose solutionc was 
diluted with saline to a 20% solution. Infusion rate was set on a syringe pump. Cats were 
fasted for 17 hours prior to each experiment (4:00 p.m. the afternoon before). Between 
8:00 and 9:00 a.m. two blood samples for BG measurement were obtained. On one 
occasion in which hyperglycemia was detected, the experiment was postponed until the 
next day. In the IGC, glucose infusion started at 9:00 a.m. During the IGC, BG was 
measured at time zero and then every 5 minutes until euglycemia was restored.  Blood 
samples for insulin, were collected at 0, 15, 30, 45, 60, 75, 90, 120, 150 and 180 minutes. 
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ExIGC: Performed 2 weeks after the IGC. At 9 a.m. (time zero of exenatide 
injection, -120 minutes from initiation of dextrose infusion) exenatide was injected using 
a 31g hypodermic needle that was attached to the pre-filled injection pen, as directed by 
the manufacturer. The pen delivers a fixed dose of 5 mcg (mean dose 1.04 ± 0.18 
mcg/kg). The injection was given subcutaneously, in a previously shaved area in the mid 
abdomen. Two hours after the exenatide injection (zero minutes of the IGC), an IV 
dextrose infusion was started and an isoglycemic clamp was performed with BG target 
concentrations of the previous IGC. Blood samples for measurements of insulin and 
exendin-4 concentrations were obtained at time zero (exenatide injection), 15, 30, 45, 60, 
75, 90, 120 (initiation of IGC), 135, 150, 165, 180, 195, 210, 240, 270 and 300 minutes. 
Samples were further obtained for exendin-4 measurements at 6, 8, 12 and 24 hours post 
injection. In one cat, the dextrose infusion was started at 60 minutes after injection 
because of hypoglycemia. In this cat, for statistical analysis, time 60 was considered time 
zero of the glucose infusion.  
Blood collection and storage: Blood was collected through indwelling jugular 
cathetersd. The samples were collected into chilled glass tubes and then immediately 
centrifuged (at 4ºC and 4000 RPM) and separated. Serum was stored at -20ºC until 
analysis. 
Catheter placement and maintenance: On the morning before each part of the 
experiment, cats were sedated with dexmedetomidine (0.009 mg/kg), butorphanol (0.22 
mg/kg), and atropine (0.022mg/kg) to facilitate catheter placement. Jugular catheters 
were placed prior to the oral glucose tolerance test. These catheters were maintained by 
flushing heparinized saline daily until the end of the study. Cephalic catheterse were 
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placed prior to IGC and ExIGC and were removed at the end of the dextrose infusion. 
These catheters were used exclusively for glucose infusion. A 1 sq inch area on the mid 
abdomen was shaved prior to the ExIGC to facilitate accuracy of subcutaneous injection 
and allow monitoring of the injection site. The sedation was reversed with atipemazole 
(0.009 mg/kg) and the cats were monitored until full recovery.  
Glucose and hormone measurements: Blood glucose concentrations were 
measured with a hand-held point-of-care glucose meterf that was validated for use in cats 
(Gilor et al., 2010). Insulin concentrations were measured with a feline ELISAg. 
Exendin-4 was measured with a specific EIA kith . This assay has a range of 0 – 25 ng/ml 
and a sensitivity of 0.01 ng/ml. It has 100% cross reactivity with active exendin-4 (3 – 
39) and its antagonist exendin (9 – 39) and 0% cross reactivity with GLP-1, GLP-2 and 
glucagon. The manufacturer of the assay reports an intra-assay CV of 5% and an inter-
assay CV of 14% but in our laboratory the intra-assay CV was 12% and the inter-assay 
CV was 25%.  Because this assay was not designed for use in cats we used pooled feline 
serum to replace the assay diluent in preparation of the standard curve so that potential 
matrix interference would be similar in the standard curve and in samples.  
Statistical analysis: Statistical analysis was performed using computer softwarei.  
The Shapiro-Wilk test was used to assess deviance from normal distribution of data. 
Grubbs' test was used to detect outliers. Data are reported as mean ± SE if normally 
distributed or as median (range). Comparisons between treatment groups were analyzed 
with paired t-tests.  Comparisons between time points were analyzed with one-way 
repeated measures ANOVA. Fold increase or fold difference were calculated as the 
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deviation of a ratio from 1.0 using a one sample t-test. The correlation between sets of 
abnormally distributed data was tested with Spearman’s rank correlation coefficient rho. 
The area under the curve (AUC) was calculated using the trapezoidal method for 
the BG and for insulin concentrations. AUC was used to represent total insulin secretion. 
All statistical tests were performed as two-tailed tests. A P value < 0.05 was 
considered significant for all tests except the Grubbs’ outlier test in which a P value < 
0.01 was considered significant. 
 
Results 
Results of the OGTT and the incretin effect are reported in chapter 5. 
In all cats, the injection of exenatide was not associated with any side effects and 
no local or systemic adverse reactions were observed. CBC’s and serum chemistry 
profiles performed 2 weeks after exenatide injection showed no significant abnormalities 
in any of the cats. 
Baseline BG did not differ significantly between the IGC and ExIGC (83.0 ± 2.9 
mg/dl vs. 82.3 ± 3.3 mg/dl respectively, P = 0.78). Baseline insulin concentrations also 
did not differ significantly between the IGC and ExIGC (313 ± 42 ng/L vs. 301 ± 47 
ng/L respectively, P = 0.84). Fifteen minutes after exenatide injection, insulin 
concentrations peaked at 724 ± 110 ng/L (an increase of 2.4 fold [1.0 – 9.2], P = 0.004, 
Figure 6.1). Insulin then returned to baseline at 30 minutes and decreased below baseline 
at 75 minutes (173 ± 48ng/L, P = 0.008). This was associated with a trend towards a 
decrease in BG below baseline at 45 minutes (-6.9 ± 3.2 mg/dL, P = 0.06, Figure 6.2).  
 155 
At 120 minutes (initiation of IV dextrose infusion), insulin concentrations and BG 
were not significantly different between the IGC and ExIGC (P = 0.25, P = 0.4 
respectively). Blood glucose concentrations during IV dextrose infusion did not differ 
significantly between the IGC and ExIGC (Mean AUC difference 0.02 ± 4%, P = 0.95, 
Figure 6.2). Total glucose infused also did not differ significantly between the IGC and 
ExIGC (0.49 ± 0.06 g/kg, 0.56 ± 0.09 g/kg respectively, P = 0.35, Figure 6.3). In only 6 
cats, more glucose was infused during the ExIGC. In one cat, the amount of glucose 
infused during the ExIGC was almost double than the amount infused during the IGC. In 
this cat, BG decreased to 54 mg/dl one hour after exenatide injection and the glucose 
infusion was started at that time. Insulin AUC
 
during IV dextrose infusion was 
significantly higher with exenatide injection compared to no treatment (AUC ratio 2.0 ± 
0.4, P=0.03, Figure 6.1). There was no correlation between the degree of stimulation at 
15 minutes (calculated as the ratio of insulin concentration at 15 vs. zero minutes) and 
the overall effect (represented by the ratio of AUC of insulin concentration during 
glucose infusion in the ExIGC and IGC). 
 Exenatide pharmacokinetics: Exenatide was measured in 6 cats. One cat was 
excluded from analysis. In this cat, serum concentrations of exenatide were consistently 
very high and were calculated as outliers for all but 2 time points. Importantly, pre-
injection concentrations were also very high, which suggested a matrix interference 
effect of this cat’s serum. The results for the 5 other cats are presented in figure 6.4. The 
mean exenatide concentration increased at the first measurement (15 minutes post-
injection) and reached a peak at 45 minutes post-injection (P = 0.016). By 90 minutes, 
the mean concentration was no longer significantly different from baseline. The mean 
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exenatide concentration from 120 to 240 minutes (during the isoglycemic clamp) was 0.4 
± 0.14 ng/ml. Exenatide was still detectable in the serum at 8 hours post injection in 3 
out of 5 cats. The 15 minute exenatide concentration tended to have positive correlation 
with the fold increase of insulin concentrations from 0 to 15 minutes (Spearman’s rho = 
0.9, P = 0.083).   
 
Discussion 
In this study we demonstrated that exenatide stimulates insulin secretion in a 
glucose-dependent manner in cats. A subcutaneous injection of exenatide caused a 
marked increase in serum insulin concentration within 15 minutes, followed by a small 
decrease in blood glucose concentrations and a return of insulin to baseline 
concentrations. The return of insulin to baseline concentrations occurred despite a 
continuous increase in exenatide concentrations in the serum. When exenatide 
concentrations peaked 45 minutes post-injection, BG was already below baseline and no 
further stimulation of insulin secretion occurred. When BG was elevated using a glucose 
infusion, the potentiating effect of exenatide was seen again. Serum insulin 
concentrations during the glucose infusion were significantly higher than serum insulin 
concentrations that were measured during an isoglycemic clamp.  
The marked effect on insulin secretion at euglycemia was not unexpected. In 
isolated rat pancreas, GLP-1 and exenatide caused similar increases in insulin secretion 
at an ambient blood glucose concentration of 54 mg/dl (Parks et al., 2001). In healthy 
fasted people, a subcutaneous injection of GLP-1 caused a 5-fold increase in plasma 
insulin concentrations within 10 minutes, followed by a decrease in BG (Edwards et al., 
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1998). Hypoglycemia developed in 3 of 10 subjects in that study with one of those 
becoming symptomatically hypoglycemic. Severe hypoglycemia is a rare side effect of 
exenatide in diabetic people and is always associated with concurrent treatment with 
sulfonylurea drugs (Amori et al., 2007). A single hypoglycemic event occurred in our 
study but glucose infusion was begun before clinical signs could have developed and its 
severity could not be assessed. Nausea, decreased appetite and less frequently, vomiting 
are observed in a subset of people with daily use of exenatide. No side effects were seen 
in our study despite giving approximately 10 times of the dose recommended in people.  
In clinical use, subcutaneous exenatide injections demonstrate glucoregulatory 
and weight loss effects with sustained plasma concentrations in the 0.2-0.4 ng/ml range 
(Gedulin et al., 2008). In our study, during the glucose infusion the mean exenatide 
concentration in the 5 cats was 0.4 ng/ml. This was associated with a mild but significant 
effect on insulin secretion when compared to an isoglycemic clamp with no prior 
treatment. Despite the difference in insulin concentrations, the total amount of glucose 
that needed to be infused to maintain an isoglycemic clamp was not significantly 
different between the isoglycemic clamps. The mundane reason for that could be a lack 
of sufficient statistical power, however, a physiologic explanation should be considered. 
In general, if exenatide caused an increase in insulin concentrations with no net effect on 
blood glucose, it should have either increased hepatic glucose output or decreased 
glucose disposal. Neither of these potential effects has been described with GLP-1. 
Multiple studies, both in vitro and in vivo, have shown that exenatide in general has the 
same physiologic effects as GLP-1(Kim and Egan, 2008). Recently, however, a study in 
rats revealed an unexpected consequence of acute exenatide
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et al., 2010). Exenatide, whether administered into the circulation or into the CNS, 
caused stimulation of the sympathetic nervous system, leading to hyperglycemia. This 
effect was independent of the glucose-dependent insulinotropic effect of exenatide and it 
waned with more chronic administration (after 6 days). A similar effect of exenatide in 
cats might cause an increase in hepatic glucose output and explain our results. 
Importantly, it would also justify examining the effect of chronic exenatide 
administration in healthy and diabetic cats.  
 Increased hepatic glucose output might also be mediated through a direct effect 
on the pancreas to increase glucagon secretion. In general, GLP-1 inhibits glucagon 
secretion in a glucose dependent manner, thus reducing hepatic glucose output especially 
in hyperglycemia. In contrast, GIP directly stimulates glucagon secretion but this effect 
is usually overcome by the insulinotropic effects of GIP with a net suppression of 
glucagon secretion and an overall glucose lowering action (Kim and Egan, 2008). It is 
widely accepted that the effect of GLP-1 to inhibit glucagon secretion is mostly indirect, 
mediated by the insulinotropic effect of GLP-1. A direct effect of GLP-1 on alpha cells is 
questionable and in a recent study, GLP-1 receptors were not demonstrated in alpha cells 
of rodents and people (Tornehave et al., 2008). When GLP-1 receptor was expressed in 
alpha cells, it had an unexpected effect: stimulation of glucagon secretion (Dillon et al., 
2005). Perhaps in cats, exenatide stimulates glucagon secretion (either via GLP-1 
receptor or via a different mechanism), similar to the effect of GIP in alpha cells. If that 
is the case, the direct stimulatory effect of GLP-1 was not overcome by the 
insulinotropic effect. Our results suggest that exenatide in cats has a smaller 
insulinotropic effect compared to other species which might contribute to this over all 
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lack of glucose lowering effect. The hypothesis that exenatide stimulates glucagon 
secretion is not supported by the results of a recent study that showed in cats a reduction 
in glucagon secretion after injection of DPP-4 (Furrer et al., 2010).  
Exenatide was detectable in plasma as early as 15 minutes post-injection (the 
earliest time point sampled), demonstrating its rapid absorption after a subcutaneous 
injection. The mean plasma exenatide concentration peaked 45 minutes post-injection 
and then sharply decreased, but exenatide was still detectable in the serum 8 hours post-
injection in 3 out of 5 cats. These results are consistent with a prolonged half-life in vivo 
and a resistance to degradation by DPP-4 as is seen in other species (Kolterman et al., 
2005). This is in sharp contrast to GLP-1, which is rapidly degraded after a subcutaneous 
injection with a half-life of 1–2 minutes (Baggio and Drucker, 2007). In this study we 
did not examine the biologic effect of exenatide throughout the duration of its presence 
in the serum, and, therefore, its duration of action could not be determined. Future 
studies should examine the duration of action of exenatide in cats as well as its effect on 
lowering blood glucose in diabetic cats. We have shown that exenatide has an 
insulinotropic effect in cats.  Even if this effect is not translated into a glucose-lowering 
effect, as might be suggested from our isoglycemic clamp results, other biological effects 
of exenatide might be useful in the treatment of diabetes in cats and should be explored.  
In conclusion, exenatide has a glucose-dependent insulinotropic effect in cats. 
Our study justifies the use of exenatide in a clinical trial in diabetic cats as well as further 
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Figure 6.1 Serum insulin concentrations (ng/L) after exenatide injection (solid line) and 
during an isoglycemic clamp (broken line). Exenatide was injected at zero minutes. IV 






Figure 6.2 Blood glucose concentrations after exenatide injection (solid line) and during 
an isoglycemic clamp (broken line). Exenatide was injected at zero minutes. IV dextrose 











Figure 6.4 Exenatide concentrations (ng/ml) after a subcutaneous injection at zero 

















Diabetes is a common disease in middle-aged and older cats. With a prevalence of 
0.5 - 2% (Panciera et al., 1990; Rand et al., 2004) and an estimated population of 90 
million cats in American households alone, there are approximately 1 million diabetic 
cats in the United States. Recent evidence suggests that the prevalence of diabetes in cats 
is increasing because of an increase in the frequency of predisposing factors such as 
obesity and physical inactivity (Prahl et al., 2007). Diabetes is also a common reason for 
euthanasia of feline patients. This is partly because of the low compliance of owners to 
twice-a-day injections of insulin, and partly because of the complications that are 
associated with the disease and its treatment. In people, novel treatments for diabetes 
have proven useful in improving beta cell function and glycemic control, and, at the 
same time, reducing the rate of side effects of treatment. We studied some of these 
treatments in healthy cats. The data presented here justify clinical trials of these drugs in 
diabetic cats. Our data also give insights into the unique physiology of the domestic cat 
and can serve as a basis for new avenues of research in treatment of diabetes and obesity 
by diet manipulation. 
Type 2 diabetes mellitus is characterized by an insufficient secretion of insulin in 
response to hyperglycemia. Although diet change and oral medications may help 
initially, most diabetic cats depend on insulin therapy to survive (Nelson, 2005; Marshall 
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et al., 2008). Hypoglycemia is a common complication of insulin therapy and can be life-
threatening (Nelson, 2005). The occurrence of hypoglycemia has been reduced 
significantly in human medicine with the introduction of the synthetic insulin analogs 
insulin detemir and insulin glargine (Danne et al., 2008; Fakhoury et al., 2008; Monami 
et al., 2008). These insulin analogs have long durations of action with a relatively flat 
time-action profiles, and, thus, are used as once-a-day drugs to replace basal secretion of 
insulin. We compared the pharmacodynamics of insulin detemir and insulin glargine in 
healthy cats using the isoglycemic clamp method. We also studied the pharmacokinetics 
of these insulin analogs in cats. We found that the duration of action of both analogs is 
shorter than is reported in people. With a mean duration of action of about 12 and 10 
hours, respectively, insulin detemir and insulin glargine should probably be used as 
twice-a-day drugs in cats. It has been shown in people, however, that in patients with 
type 2 diabetes a basal insulin that does not last 24 hours can sometimes be sufficient 
because of residual endogenous insulin secretion (Swinnen et al., 2008). A small clinical 
trial in cats has shown that clinical signs of diabetes can be controlled with once-a-day 
insulin glargine (Weaver et al., 2006). Therefore, the efficacy of insulin detemir and 
insulin glargine should be compared in a clinical trial in diabetic cats. In people, 
prolongation of the duration of action of peakless insulin analogs can be achieved by 
increasing doses (Plank et al., 2005; Klein et al., 2007). We showed that the 
pharmacodynamic profiles of insulin detemir and insulin glargine are variable, and 
“peakless” time-action profiles cannot be safely assumed. Thus, increasing the dose to 
achieve longer duration of action might result in an unwanted higher peak of action and a 
hypoglycemic crisis. 
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Traditionally, duration of action and potency of an insulin formulation are assessed 
with blood glucose curves. These require frequent blood sampling and they rely on the 
unfounded assumption that day-to-day variability of the insulin formulation is minimal.  
Of commercially available insulin formulations, insulin detemir has the lowest day-to-
day variability in people (Klein et al., 2007). Future studies should investigate this in cats 
and may prove the usefulness of glucose curves in monitoring diabetic patients.  In our 
comparison of the pharmacodynamics and pharmacokinetics of insulin detemir, we 
found that a glucose-lowering effect can no longer be observed after the measured 
insulin concentration (unadjusted for insulin cross reactivity) decreased below 25 mU/L 
in the Iso-Insulin ELISA. This information might be clinically useful. If measured after 
an overnight fast, one single measurement of serum insulin concentration in the Iso-
Insulin ELISA could indicate whether insulin detemir is still present in concentrations 
that should have a glucose-lowering effect, and could give an indication of its duration of 
action. This might replace the cumbersome and inaccurate blood glucose curve method, 
especially if insulin detemir proves to have a low day-to-day variability in diabetic cats.  
Insulin therapy, despite the side effects associated with it, is necessary for survival in 
insulin-deficient patients.  Most type 2 diabetic people and many type 2 diabetic cats 
retain some residual capacity to secrete insulin, albeit in insufficient amounts. Incretin-
based therapies take advantage of this phenomenon. The incretin hormones GIP and 
GLP-1 stimulate insulin secretion in a glucose-dependent manner. Thus, they are less 
likely to cause hypoglycemia than exogenous insulin. Incretin hormones also stimulate 
insulin biosynthesis and beta cell proliferation and improve beta cell survival.  Incretin-
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based therapies are as effective as insulin therapy in treating diabetes in people but they 
are associated with fewer side effects.  
We studied the synthetic GLP-1-mimetic exenatide in healthy cats. We used the only 
commercially available formulation of exenatide (at present) which is supplied as a pre-
filled injection pen. The pen delivers a fixed dose of 5 mcg so that the final dose 
administered in this study was about 10 times higher than the recommended dose in 
people. We found that exenatide stimulates insulin secretion in cats in a glucose-
dependent manner, but it did not increase glucose tolerability. It is plausible that, as in 
rats, exenatide also has stimulating effects in the sympathetic nervous system, thus 
increasing hepatic glucose production (Perez-Tilve et al., 2010). In rats the acute effect 
on the sympathetic nervous system wanes off after a few days but the insulinotropic 
effect remains.  If this is also the case in cats, exenatide might still be effective in 
lowering blood glucose concentrations in diabetic patients. We also found that exenatide 
is rapidly absorbed after a subcutaneous injection and it is rapidly cleared from the 
blood. Finally, one out of nine cats in this study developed hypoglycemia. The lack of 
apparent glucose-lowering effect, the rapid clearance from the blood and the potential 
safety concern, make this formulation of exenatide of questionable advantage in the 
treatment of feline diabetes. Our data do show, however, that this incretin-mimetic has 
insulinotropic effects in cats, which means that, in principal, incretin-mimetics should be 
studied further in cats. A different formulation, one that is longer-acting and with more 
flexibility in dosing, might prove beneficial.  
Finally, we studied some physiologic aspects of the incretin effect in cats. By 
definition, the incretin effect is the secretion of an excess amount of insulin after oral 
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ingestion of glucose when compared to intravenously administered glucose. Incretin 
hormones, however, are secreted in response to ingestion of other nutrients as well and 
they have a multitude of other effects. We asked two questions in this study: First, is 
there an incretin effect, as defined above, in cats?, and second, what is the differential 
effect of oral glucose, lipids, or amino acids on secretion of GIP, GLP-1 and insulin?  To 
answer the first question, we performed an oral glucose tolerance test and compared the 
results to an isoglycemic clamp in each cat. To the best of our knowledge, this is the first 
report of an oral glucose tolerance testing in awake cats. Because stress has an effect on 
blood glucose and insulin secretion, nasoesophageal tubes, placed on the day before each 
experiment under light sedation, were used for oral administration of glucose. We also 
report here, for the first time, the fasting and stimulated serum concentration of GIP in 
cats.  
We found that a glucose-stimulated incretin effect does occur in cats, it is probably 
mediated by GLP-1, and its magnitude is lower than what has been reported in other 
species (Nauck et al., 1986).  This small incretin effect is probably related to the fact that 
GIP secretion was not stimulated by glucose. This is a unique finding that contrasts with 
reports from other species, but it is not surprising given the fact that cats are obligate 
carnivores and do not feed on carbohydrates in the wild.  In concordance, GIP was 
strongly stimulated by amino acids and even more so by lipids. GLP-1 secretion was 
stimulated to a similar degree by all three nutrients. It is plausible that insufficient 
activity of GIP after a meal rich in carbohydrates might contribute to prolonged 
postprandial hyperglycemia and the development of diabetes. Interestingly, insulin 
secretion was stimulated in this study after fat ingestion when blood glucose 
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concentrations were normal.  This was probably the result of stimulation by GLP-1 
and/or GIP.  We also demonstrated stimulation of insulin secretion at euglycemia by 
exenatide as described in chapter 6. The stimulation of insulin secretion by exenatide 
ceased when blood glucose decreased about 10% below baseline, despite a continuous 
rise in exenatide concentrations. This stimulation of insulin secretion at euglycemia 
might explain the observation that in cats fed a diet rich in protein and fat (and low in 
carbohydrates) post-prandial blood glucose decreases (Mori et al., 2009). 
Our data support further studies of the use of insulin detemir and insulin glargine in 
diabetic cats, and further investigation of the plausibility of monitoring insulin detemir 
treatment by measuring insulin concentration in the blood. Our data do not support the 
clinical use of the GLP-1-mimetic exenatide in its currently available formulation, but 
our data do support further investigation of similar drugs with longer durations of action. 
Finally, we report new findings on the incretin effect in cats. GIP secretion is not 
stimulated by oral glucose in cats but it is strongly stimulated by amino acids and lipids. 
GLP-1 mediates a glucose-stimulated incretin effect in cats, and its secretion is similarly 
stimulated by glucose, amino acids, and lipids. 
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